CN112119065B - 苯并二氮杂环类化合物、其制备方法及用途 - Google Patents
苯并二氮杂环类化合物、其制备方法及用途 Download PDFInfo
- Publication number
- CN112119065B CN112119065B CN201980032188.9A CN201980032188A CN112119065B CN 112119065 B CN112119065 B CN 112119065B CN 201980032188 A CN201980032188 A CN 201980032188A CN 112119065 B CN112119065 B CN 112119065B
- Authority
- CN
- China
- Prior art keywords
- compound
- alkylene
- alkyl
- cancer
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- -1 Benzodiazepine compound Chemical class 0.000 title claims abstract description 103
- 238000002360 preparation method Methods 0.000 title abstract description 98
- 229940049706 benzodiazepine Drugs 0.000 title abstract description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 264
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 19
- 201000010099 disease Diseases 0.000 claims abstract description 17
- 238000011282 treatment Methods 0.000 claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 10
- 230000008569 process Effects 0.000 claims abstract description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 118
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 60
- 229910052736 halogen Inorganic materials 0.000 claims description 39
- 150000002367 halogens Chemical class 0.000 claims description 39
- 150000003839 salts Chemical class 0.000 claims description 39
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 33
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 30
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 30
- 206010028980 Neoplasm Diseases 0.000 claims description 27
- 125000004076 pyridyl group Chemical group 0.000 claims description 27
- 125000003545 alkoxy group Chemical group 0.000 claims description 22
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 20
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims description 19
- 125000000623 heterocyclic group Chemical group 0.000 claims description 18
- 125000001424 substituent group Chemical group 0.000 claims description 18
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 17
- 229910052739 hydrogen Inorganic materials 0.000 claims description 17
- 239000001257 hydrogen Substances 0.000 claims description 17
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 16
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 15
- 201000011510 cancer Diseases 0.000 claims description 11
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 8
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims description 8
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 6
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 229910052731 fluorine Inorganic materials 0.000 claims description 5
- 239000011737 fluorine Substances 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 239000000460 chlorine Substances 0.000 claims description 4
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- 238000007363 ring formation reaction Methods 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- YOWQWFMSQCOSBA-UHFFFAOYSA-N 2-methoxypropene Chemical compound COC(C)=C YOWQWFMSQCOSBA-UHFFFAOYSA-N 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 125000001153 fluoro group Chemical group F* 0.000 claims description 3
- 125000005842 heteroatom Chemical group 0.000 claims description 3
- 125000005948 methanesulfonyloxy group Chemical group 0.000 claims description 3
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 3
- 125000003566 oxetanyl group Chemical group 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010005949 Bone cancer Diseases 0.000 claims description 2
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000013452 Fallopian tube neoplasm Diseases 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 201000003444 follicular lymphoma Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 125000002883 imidazolyl group Chemical group 0.000 claims description 2
- 238000001361 intraarterial administration Methods 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000007912 intraperitoneal administration Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 230000036210 malignancy Effects 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 210000001595 mastoid Anatomy 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 2
- 206010038038 rectal cancer Diseases 0.000 claims description 2
- 201000001275 rectum cancer Diseases 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 206010042863 synovial sarcoma Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 208000025440 neoplasm of neck Diseases 0.000 claims 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 abstract description 2
- 238000001819 mass spectrum Methods 0.000 description 86
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 78
- 238000006243 chemical reaction Methods 0.000 description 76
- 238000005160 1H NMR spectroscopy Methods 0.000 description 65
- 239000007858 starting material Substances 0.000 description 56
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 39
- 239000000243 solution Substances 0.000 description 33
- FRYRJNHMRVINIZ-UHFFFAOYSA-N B1CCOO1 Chemical compound B1CCOO1 FRYRJNHMRVINIZ-UHFFFAOYSA-N 0.000 description 30
- ASUDFOJKTJLAIK-UHFFFAOYSA-N 2-methoxyethanamine Chemical compound COCCN ASUDFOJKTJLAIK-UHFFFAOYSA-N 0.000 description 29
- 239000000203 mixture Substances 0.000 description 29
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
- 239000000706 filtrate Substances 0.000 description 23
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 22
- 239000012074 organic phase Substances 0.000 description 22
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 21
- 239000000651 prodrug Substances 0.000 description 21
- 229940002612 prodrug Drugs 0.000 description 21
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 20
- 239000003960 organic solvent Substances 0.000 description 20
- 239000012453 solvate Substances 0.000 description 20
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 150000001204 N-oxides Chemical class 0.000 description 18
- 239000002207 metabolite Substances 0.000 description 18
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 229910052757 nitrogen Inorganic materials 0.000 description 15
- 125000000842 isoxazolyl group Chemical group 0.000 description 14
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 14
- 239000012141 concentrate Substances 0.000 description 13
- 239000007788 liquid Substances 0.000 description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 12
- 230000004913 activation Effects 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 239000012046 mixed solvent Substances 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 12
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 11
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 10
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 238000000605 extraction Methods 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- 238000001816 cooling Methods 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- ONCAZCNPWWQQMW-UHFFFAOYSA-N 3-(trifluoromethyl)benzenesulfonyl chloride Chemical compound FC(F)(F)C1=CC=CC(S(Cl)(=O)=O)=C1 ONCAZCNPWWQQMW-UHFFFAOYSA-N 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 8
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 229910000027 potassium carbonate Inorganic materials 0.000 description 7
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 7
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 6
- 108091008680 RAR-related orphan receptors Proteins 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 125000002947 alkylene group Chemical group 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 6
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- JKMSICMLBQRLLY-UHFFFAOYSA-N 3-[7-[3-(difluoromethoxy)-5-fluorophenyl]-4-oxo-1-[3-(trifluoromethyl)phenyl]sulfonyl-2H-quinazolin-3-yl]-2,2-dimethylpropanoic acid Chemical compound FC(OC=1C=C(C=C(C1)F)C1=CC=C2C(N(CN(C2=C1)S(=O)(=O)C1=CC(=CC=C1)C(F)(F)F)CC(C(=O)O)(C)C)=O)F JKMSICMLBQRLLY-UHFFFAOYSA-N 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 5
- 239000007821 HATU Substances 0.000 description 5
- 230000001270 agonistic effect Effects 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 125000001188 haloalkyl group Chemical group 0.000 description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 238000004809 thin layer chromatography Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 229960001727 tretinoin Drugs 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 3
- BNNICQAVXPXQAH-UHFFFAOYSA-N 2-amino-4-bromobenzoic acid Chemical compound NC1=CC(Br)=CC=C1C(O)=O BNNICQAVXPXQAH-UHFFFAOYSA-N 0.000 description 3
- PVBYSPDFVLPOFQ-UHFFFAOYSA-N 3-[7-[2-(difluoromethoxy)phenyl]-4-oxo-1-[3-(trifluoromethyl)phenyl]sulfonyl-2H-quinazolin-3-yl]-2,2-dimethylpropanoic acid Chemical compound FC(OC1=C(C=CC=C1)C1=CC=C2C(N(CN(C2=C1)S(=O)(=O)C1=CC(=CC=C1)C(F)(F)F)CC(C(=O)O)(C)C)=O)F PVBYSPDFVLPOFQ-UHFFFAOYSA-N 0.000 description 3
- QLEUUZSASAVZLO-UHFFFAOYSA-N 7-[3-(difluoromethoxy)-5-fluorophenyl]-3-(2-ethoxyethyl)-1-[3-(trifluoromethyl)phenyl]sulfonyl-2H-quinazolin-4-one Chemical compound FC(OC=1C=C(C=C(C1)F)C1=CC=C2C(N(CN(C2=C1)S(=O)(=O)C1=CC(=CC=C1)C(F)(F)F)CCOCC)=O)F QLEUUZSASAVZLO-UHFFFAOYSA-N 0.000 description 3
- XPVMVXMLZKYYOD-UHFFFAOYSA-N 7-[3-(difluoromethoxy)-5-fluorophenyl]-3-(3-methoxypropyl)-1-[3-(trifluoromethyl)phenyl]sulfonyl-2H-quinazolin-4-one Chemical compound FC(OC=1C=C(C=C(C1)F)C1=CC=C2C(N(CN(C2=C1)S(=O)(=O)C1=CC(=CC=C1)C(F)(F)F)CCCOC)=O)F XPVMVXMLZKYYOD-UHFFFAOYSA-N 0.000 description 3
- PBTHVSWGEHGXIJ-OAHLLOKOSA-N 7-[3-(difluoromethoxy)-5-fluorophenyl]-3-[(2R)-2-methoxypropyl]-1-[3-(trifluoromethyl)phenyl]sulfonyl-2H-quinazolin-4-one Chemical compound FC(OC=1C=C(C=C(C1)F)C1=CC=C2C(N(CN(C2=C1)S(=O)(=O)C1=CC(=CC=C1)C(F)(F)F)C[C@@H](C)OC)=O)F PBTHVSWGEHGXIJ-OAHLLOKOSA-N 0.000 description 3
- PBTHVSWGEHGXIJ-HNNXBMFYSA-N 7-[3-(difluoromethoxy)-5-fluorophenyl]-3-[(2S)-2-methoxypropyl]-1-[3-(trifluoromethyl)phenyl]sulfonyl-2H-quinazolin-4-one Chemical compound FC(OC=1C=C(C=C(C1)F)C1=CC=C2C(N(CN(C2=C1)S(=O)(=O)C1=CC(=CC=C1)C(F)(F)F)C[C@H](C)OC)=O)F PBTHVSWGEHGXIJ-HNNXBMFYSA-N 0.000 description 3
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- GPAYUJZHTULNBE-UHFFFAOYSA-N diphenylphosphine Chemical compound C=1C=CC=CC=1PC1=CC=CC=C1 GPAYUJZHTULNBE-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- TYPZYEGTMBBMCF-UHFFFAOYSA-N ethyl 3-(7-bromo-4-oxo-1,2-dihydroquinazolin-3-yl)-2,2-dimethylpropanoate Chemical compound BrC1=CC=C2C(N(CNC2=C1)CC(C(=O)OCC)(C)C)=O TYPZYEGTMBBMCF-UHFFFAOYSA-N 0.000 description 3
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- 125000001072 heteroaryl group Chemical group 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 238000004020 luminiscence type Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000002808 molecular sieve Substances 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 150000007530 organic bases Chemical class 0.000 description 3
- 108090000629 orphan nuclear receptors Proteins 0.000 description 3
- 102000004164 orphan nuclear receptors Human genes 0.000 description 3
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 3
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 229940096998 ursolic acid Drugs 0.000 description 3
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 3
- VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 description 2
- KNXQDJCZSVHEIW-UHFFFAOYSA-N (3-fluorophenyl)boronic acid Chemical group OB(O)C1=CC=CC(F)=C1 KNXQDJCZSVHEIW-UHFFFAOYSA-N 0.000 description 2
- NLLGFYPSWCMUIV-UHFFFAOYSA-N (3-methoxyphenyl)boronic acid Chemical group COC1=CC=CC(B(O)O)=C1 NLLGFYPSWCMUIV-UHFFFAOYSA-N 0.000 description 2
- LXQMHOKEXZETKB-UHFFFAOYSA-N 1-amino-2-methylpropan-2-ol Chemical group CC(C)(O)CN LXQMHOKEXZETKB-UHFFFAOYSA-N 0.000 description 2
- GNDMQJAVYMDFJS-UHFFFAOYSA-N 3-(7-bromo-4-oxo-1,2-dihydroquinazolin-3-yl)propanoic acid Chemical compound BrC1=CC=C2C(N(CNC2=C1)CCC(=O)O)=O GNDMQJAVYMDFJS-UHFFFAOYSA-N 0.000 description 2
- OLKGWYNIHQJLON-UHFFFAOYSA-N 3-[7-(3-chloro-5-methoxyphenyl)-4-oxo-1-[3-(trifluoromethyl)phenyl]sulfonyl-2H-quinazolin-3-yl]-2,2-dimethylpropanoic acid Chemical compound ClC=1C=C(C=C(C1)OC)C1=CC=C2C(N(CN(C2=C1)S(=O)(=O)C1=CC(=CC=C1)C(F)(F)F)CC(C(=O)O)(C)C)=O OLKGWYNIHQJLON-UHFFFAOYSA-N 0.000 description 2
- HEUMGRMWYNEHLC-UHFFFAOYSA-N 3-[7-[3-(difluoromethoxy)-5-fluorophenyl]-4-oxo-1,2-dihydroquinazolin-3-yl]propanoic acid Chemical compound FC(OC=1C=C(C=C(C1)F)C1=CC=C2C(N(CNC2=C1)CCC(=O)O)=O)F HEUMGRMWYNEHLC-UHFFFAOYSA-N 0.000 description 2
- NBQLIDWFLFTAMW-UHFFFAOYSA-N 7-[3-(difluoromethoxy)-5-fluorophenyl]-3-(2-methoxyethyl)-1,2-dihydroquinazolin-4-one Chemical compound FC(OC=1C=C(C=C(C1)F)C1=CC=C2C(N(CNC2=C1)CCOC)=O)F NBQLIDWFLFTAMW-UHFFFAOYSA-N 0.000 description 2
- FPOBQATUZYESEJ-UHFFFAOYSA-N 7-[3-(difluoromethoxy)-5-fluorophenyl]-3-(2-methoxyethyl)-1-[3-(trifluoromethyl)phenyl]sulfonyl-2H-quinazolin-4-one Chemical compound FC(OC=1C=C(C=C(C1)F)C1=CC=C2C(N(CN(C2=C1)S(=O)(=O)C1=CC(=CC=C1)C(F)(F)F)CCOC)=O)F FPOBQATUZYESEJ-UHFFFAOYSA-N 0.000 description 2
- QUPVXRMJSYWPBP-UHFFFAOYSA-N 7-[3-(difluoromethoxy)-5-fluorophenyl]-3-(2-methoxyethyl)-2,2-dimethyl-1-[3-(trifluoromethyl)phenyl]sulfonylquinazolin-4-one Chemical compound FC(OC=1C=C(C=C(C1)F)C1=CC=C2C(N(C(N(C2=C1)S(=O)(=O)C1=CC(=CC=C1)C(F)(F)F)(C)C)CCOC)=O)F QUPVXRMJSYWPBP-UHFFFAOYSA-N 0.000 description 2
- QRLJNHGRKRBWIE-UHFFFAOYSA-N 7-[3-(difluoromethoxy)-5-fluorophenyl]-3-(2-methoxyethyl)-2,2-dimethyl-1H-quinazolin-4-one Chemical compound FC(OC=1C=C(C=C(C1)F)C1=CC=C2C(N(C(NC2=C1)(C)C)CCOC)=O)F QRLJNHGRKRBWIE-UHFFFAOYSA-N 0.000 description 2
- FIUVMTCCUAHSAD-UHFFFAOYSA-N 7-bromo-3-(2-methoxyethyl)-1,2-dihydroquinazolin-4-one Chemical compound BrC1=CC=C2C(N(CNC2=C1)CCOC)=O FIUVMTCCUAHSAD-UHFFFAOYSA-N 0.000 description 2
- UBUPZZFOFDZPMR-UHFFFAOYSA-N 7-bromo-3-(2-methoxyethyl)-2,2-dimethyl-1H-quinazolin-4-one Chemical compound BrC1=CC=C2C(N(C(NC2=C1)(C)C)CCOC)=O UBUPZZFOFDZPMR-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical group CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- QOVYHDHLFPKQQG-NDEPHWFRSA-N N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O Chemical compound N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O QOVYHDHLFPKQQG-NDEPHWFRSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical group [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 2
- HTVPSERVQUKECA-UHFFFAOYSA-N [2-(difluoromethoxy)phenyl]boronic acid Chemical group OB(O)C1=CC=CC=C1OC(F)F HTVPSERVQUKECA-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- KEHCUGCFFZEXGC-UHFFFAOYSA-N ethyl 3-[7-(3-chloro-5-methoxyphenyl)-4-oxo-1,2-dihydroquinazolin-3-yl]-2,2-dimethylpropanoate Chemical compound CCOC(=O)C(C)(C)CN1CNC2=C(C1=O)C=CC(=C2)C3=CC(=CC(=C3)Cl)OC KEHCUGCFFZEXGC-UHFFFAOYSA-N 0.000 description 2
- QMKABRUOBBOCLB-UHFFFAOYSA-N ethyl 3-[7-(3-chloro-5-methoxyphenyl)-4-oxo-1-[3-(trifluoromethyl)phenyl]sulfonyl-2H-quinazolin-3-yl]-2,2-dimethylpropanoate Chemical compound CCOC(=O)C(C)(C)CN1CN(C2=C(C1=O)C=CC(=C2)C3=CC(=CC(=C3)Cl)OC)S(=O)(=O)C4=CC=CC(=C4)C(F)(F)F QMKABRUOBBOCLB-UHFFFAOYSA-N 0.000 description 2
- NPWARBZPNBSZPT-UHFFFAOYSA-N ethyl 3-[7-[3-(difluoromethoxy)-5-fluorophenyl]-4-oxo-1,2-dihydroquinazolin-3-yl]-2,2-dimethylpropanoate Chemical compound CCOC(=O)C(C)(C)CN1CNC2=C(C1=O)C=CC(=C2)C3=CC(=CC(=C3)F)OC(F)F NPWARBZPNBSZPT-UHFFFAOYSA-N 0.000 description 2
- CWHSPDYTQIFGRT-UHFFFAOYSA-N ethyl 3-[7-[3-(difluoromethoxy)-5-fluorophenyl]-4-oxo-1-[3-(trifluoromethyl)phenyl]sulfonyl-2H-quinazolin-3-yl]-2,2-dimethylpropanoate Chemical compound CCOC(=O)C(C)(C)CN1CN(C2=C(C1=O)C=CC(=C2)C3=CC(=CC(=C3)F)OC(F)F)S(=O)(=O)C4=CC=CC(=C4)C(F)(F)F CWHSPDYTQIFGRT-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000008098 formaldehyde solution Substances 0.000 description 2
- 125000005946 imidazo[1,2-a]pyridyl group Chemical group 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 235000011056 potassium acetate Nutrition 0.000 description 2
- 235000011181 potassium carbonates Nutrition 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 235000011009 potassium phosphates Nutrition 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 239000011535 reaction buffer Substances 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- 235000017550 sodium carbonate Nutrition 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 229910052722 tritium Inorganic materials 0.000 description 2
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 1
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- SZYXKFKWFYUOGZ-UHFFFAOYSA-N (2,3-difluorophenyl)boronic acid Chemical group OB(O)C1=CC=CC(F)=C1F SZYXKFKWFYUOGZ-UHFFFAOYSA-N 0.000 description 1
- KTOJGSDLJNUAEP-UHFFFAOYSA-N (2,5-difluorophenyl)boronic acid Chemical group OB(O)C1=CC(F)=CC=C1F KTOJGSDLJNUAEP-UHFFFAOYSA-N 0.000 description 1
- DBZAICSEFBVFHL-UHFFFAOYSA-N (2,6-difluorophenyl)boronic acid Chemical group OB(O)C1=C(F)C=CC=C1F DBZAICSEFBVFHL-UHFFFAOYSA-N 0.000 description 1
- TYOGIUGNZOBBHE-UHFFFAOYSA-N (2-chloro-3-fluorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC(F)=C1Cl TYOGIUGNZOBBHE-UHFFFAOYSA-N 0.000 description 1
- OVTZJDSREVDCTJ-UHFFFAOYSA-N (2-chloro-5-fluorophenyl)boronic acid Chemical compound OB(O)C1=CC(F)=CC=C1Cl OVTZJDSREVDCTJ-UHFFFAOYSA-N 0.000 description 1
- NXSZSZJWZVLHAY-UHFFFAOYSA-N (2-chloro-6-fluorophenyl)boronic acid Chemical compound OB(O)C1=C(F)C=CC=C1Cl NXSZSZJWZVLHAY-UHFFFAOYSA-N 0.000 description 1
- NPLZNDDFVCGRAG-UHFFFAOYSA-N (2-cyanophenyl)boronic acid Chemical group OB(O)C1=CC=CC=C1C#N NPLZNDDFVCGRAG-UHFFFAOYSA-N 0.000 description 1
- VEHQHYJZLSODOU-UHFFFAOYSA-N (2-fluoro-3-methylphenyl)boronic acid Chemical compound CC1=CC=CC(B(O)O)=C1F VEHQHYJZLSODOU-UHFFFAOYSA-N 0.000 description 1
- QCSLIRFWJPOENV-UHFFFAOYSA-N (2-fluorophenyl)boronic acid Chemical group OB(O)C1=CC=CC=C1F QCSLIRFWJPOENV-UHFFFAOYSA-N 0.000 description 1
- ROEQGIFOWRQYHD-UHFFFAOYSA-N (2-methoxyphenyl)boronic acid Chemical group COC1=CC=CC=C1B(O)O ROEQGIFOWRQYHD-UHFFFAOYSA-N 0.000 description 1
- NVOLYUXUHWBCRJ-UHFFFAOYSA-N (2-methoxypyridin-3-yl)boronic acid Chemical group COC1=NC=CC=C1B(O)O NVOLYUXUHWBCRJ-UHFFFAOYSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- RVDUOVVHQKMQLM-PGMHMLKASA-N (2r)-1-methoxypropan-2-amine;hydrochloride Chemical group Cl.COC[C@@H](C)N RVDUOVVHQKMQLM-PGMHMLKASA-N 0.000 description 1
- HDXPVDSGCDOOFU-PGMHMLKASA-N (2r)-2-methoxypropan-1-amine;hydrochloride Chemical group Cl.CO[C@H](C)CN HDXPVDSGCDOOFU-PGMHMLKASA-N 0.000 description 1
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 1
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- HDXPVDSGCDOOFU-WCCKRBBISA-N (2s)-2-methoxypropan-1-amine;hydrochloride Chemical group Cl.CO[C@@H](C)CN HDXPVDSGCDOOFU-WCCKRBBISA-N 0.000 description 1
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 1
- QWQBQRYFWNIDOC-UHFFFAOYSA-N (3,5-difluorophenyl)boronic acid Chemical group OB(O)C1=CC(F)=CC(F)=C1 QWQBQRYFWNIDOC-UHFFFAOYSA-N 0.000 description 1
- VHQABGUEHFRBRI-UHFFFAOYSA-N (3-chloro-2-methoxyphenyl)boronic acid Chemical compound COC1=C(Cl)C=CC=C1B(O)O VHQABGUEHFRBRI-UHFFFAOYSA-N 0.000 description 1
- WAVZSRUGKKOQRB-UHFFFAOYSA-N (3-chloro-5-methoxyphenyl)boronic acid Chemical compound COC1=CC(Cl)=CC(B(O)O)=C1 WAVZSRUGKKOQRB-UHFFFAOYSA-N 0.000 description 1
- XDBHWPLGGBLUHH-UHFFFAOYSA-N (3-cyanophenyl)boronic acid Chemical group OB(O)C1=CC=CC(C#N)=C1 XDBHWPLGGBLUHH-UHFFFAOYSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 1
- MIPHRQMEIYLZFZ-SCSAIBSYSA-N (3r)-oxolan-3-amine Chemical group N[C@@H]1CCOC1 MIPHRQMEIYLZFZ-SCSAIBSYSA-N 0.000 description 1
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 1
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
- OMBVEVHRIQULKW-DNQXCXABSA-M (3r,5r)-7-[3-(4-fluorophenyl)-8-oxo-7-phenyl-1-propan-2-yl-5,6-dihydro-4h-pyrrolo[2,3-c]azepin-2-yl]-3,5-dihydroxyheptanoate Chemical compound O=C1C=2N(C(C)C)C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C(C=3C=CC(F)=CC=3)C=2CCCN1C1=CC=CC=C1 OMBVEVHRIQULKW-DNQXCXABSA-M 0.000 description 1
- MIPHRQMEIYLZFZ-BYPYZUCNSA-N (3s)-oxolan-3-amine Chemical group N[C@H]1CCOC1 MIPHRQMEIYLZFZ-BYPYZUCNSA-N 0.000 description 1
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 1
- GQWZKBTZAFEQJZ-UHFFFAOYSA-N (6-methoxypyridin-2-yl)boronic acid Chemical group COC1=CC=CC(B(O)O)=N1 GQWZKBTZAFEQJZ-UHFFFAOYSA-N 0.000 description 1
- XHSGIZRXEBIOFC-UHFFFAOYSA-N (6-methylpyridin-2-yl)boronic acid Chemical compound CC1=CC=CC(B(O)O)=N1 XHSGIZRXEBIOFC-UHFFFAOYSA-N 0.000 description 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
- 125000004529 1,2,3-triazinyl group Chemical group N1=NN=C(C=C1)* 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 description 1
- DJMOXMNDXFFONV-UHFFFAOYSA-N 1,3-dimethyl-7-[2-(n-methylanilino)ethyl]purine-2,6-dione Chemical compound C1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CCN(C)C1=CC=CC=C1 DJMOXMNDXFFONV-UHFFFAOYSA-N 0.000 description 1
- KKHFRAFPESRGGD-UHFFFAOYSA-N 1,3-dimethyl-7-[3-(n-methylanilino)propyl]purine-2,6-dione Chemical compound C1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CCCN(C)C1=CC=CC=C1 KKHFRAFPESRGGD-UHFFFAOYSA-N 0.000 description 1
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- RVDUOVVHQKMQLM-UHFFFAOYSA-N 1-methoxypropan-2-amine;hydrochloride Chemical group Cl.COCC(C)N RVDUOVVHQKMQLM-UHFFFAOYSA-N 0.000 description 1
- RFYOJSXODKQELG-UHFFFAOYSA-N 2,2-dimethyl-3-[4-oxo-7-phenyl-1-[3-(trifluoromethyl)phenyl]sulfonyl-2H-quinazolin-3-yl]propanoic acid Chemical compound O=C1N(CN(C2=CC(=CC=C12)C1=CC=CC=C1)S(=O)(=O)C1=CC(=CC=C1)C(F)(F)F)CC(C(=O)O)(C)C RFYOJSXODKQELG-UHFFFAOYSA-N 0.000 description 1
- ODVFBSIDMIDQIH-UHFFFAOYSA-N 2,2-dimethyl-3-[7-(6-methylpyridin-2-yl)-4-oxo-1-[3-(trifluoromethyl)phenyl]sulfonyl-2H-quinazolin-3-yl]propanoic acid Chemical compound CC1=CC=CC(=N1)C1=CC=C2C(N(CN(C2=C1)S(=O)(=O)C1=CC(=CC=C1)C(F)(F)F)CC(C(=O)O)(C)C)=O ODVFBSIDMIDQIH-UHFFFAOYSA-N 0.000 description 1
- FQMZXMVHHKXGTM-UHFFFAOYSA-N 2-(1-adamantyl)-n-[2-[2-(2-hydroxyethylamino)ethylamino]quinolin-5-yl]acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=CC=CC2=NC(NCCNCCO)=CC=C21 FQMZXMVHHKXGTM-UHFFFAOYSA-N 0.000 description 1
- CZONOKUCSJKJBV-UHFFFAOYSA-N 2-[3-(2-methoxyethyl)-4-oxo-1-[3-(trifluoromethyl)phenyl]sulfonyl-2H-quinazolin-7-yl]benzonitrile Chemical compound C(#N)C1=C(C=CC=C1)C1=CC=C2C(N(CN(C2=C1)S(=O)(=O)C1=CC(=CC=C1)C(F)(F)F)CCOC)=O CZONOKUCSJKJBV-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 1
- CBTNQRKDUUTJFQ-UHFFFAOYSA-N 2-[7-[3-(difluoromethoxy)-5-fluorophenyl]-4-oxo-1-[3-(trifluoromethyl)phenyl]sulfonyl-2H-quinazolin-3-yl]-N,N-dimethylacetamide Chemical compound FC(OC=1C=C(C=C(C1)F)C1=CC=C2C(N(CN(C2=C1)S(=O)(=O)C1=CC(=CC=C1)C(F)(F)F)CC(=O)N(C)C)=O)F CBTNQRKDUUTJFQ-UHFFFAOYSA-N 0.000 description 1
- RNSROUMWRORABM-UHFFFAOYSA-N 2-[7-[3-(difluoromethoxy)-5-fluorophenyl]-4-oxo-1-[3-(trifluoromethyl)phenyl]sulfonyl-2H-quinazolin-3-yl]-N,N-dimethylethanesulfonamide Chemical compound FC(OC=1C=C(C=C(C1)F)C1=CC=C2C(N(CN(C2=C1)S(=O)(=O)C1=CC(=CC=C1)C(F)(F)F)CCS(=O)(=O)N(C)C)=O)F RNSROUMWRORABM-UHFFFAOYSA-N 0.000 description 1
- UIGVNALTEIMHQH-UHFFFAOYSA-N 2-[7-[3-(difluoromethoxy)-5-fluorophenyl]-4-oxo-1-[3-(trifluoromethyl)phenyl]sulfonyl-2H-quinazolin-3-yl]-N-methylethanesulfonamide Chemical compound FC(OC=1C=C(C=C(C1)F)C1=CC=C2C(N(CN(C2=C1)S(=O)(=O)C1=CC(=CC=C1)C(F)(F)F)CCS(=O)(=O)NC)=O)F UIGVNALTEIMHQH-UHFFFAOYSA-N 0.000 description 1
- FMKGJQHNYMWDFJ-CVEARBPZSA-N 2-[[4-(2,2-difluoropropoxy)pyrimidin-5-yl]methylamino]-4-[[(1R,4S)-4-hydroxy-3,3-dimethylcyclohexyl]amino]pyrimidine-5-carbonitrile Chemical compound FC(COC1=NC=NC=C1CNC1=NC=C(C(=N1)N[C@H]1CC([C@H](CC1)O)(C)C)C#N)(C)F FMKGJQHNYMWDFJ-CVEARBPZSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
- KNVRBEGQERGQRP-UHFFFAOYSA-N 2-amino-n,n-dimethylacetamide Chemical group CN(C)C(=O)CN KNVRBEGQERGQRP-UHFFFAOYSA-N 0.000 description 1
- RTVWJWNJHGNHTD-UHFFFAOYSA-N 2-amino-n,n-dimethylethanesulfonamide Chemical group CN(C)S(=O)(=O)CCN RTVWJWNJHGNHTD-UHFFFAOYSA-N 0.000 description 1
- IMDTYQHPAJZVOB-UHFFFAOYSA-N 2-amino-n-methylethanesulfonamide;hydrochloride Chemical group Cl.CNS(=O)(=O)CCN IMDTYQHPAJZVOB-UHFFFAOYSA-N 0.000 description 1
- BPGIOCZAQDIBPI-UHFFFAOYSA-N 2-ethoxyethanamine Chemical group CCOCCN BPGIOCZAQDIBPI-UHFFFAOYSA-N 0.000 description 1
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 1
- SDNXQWUJWNTDCC-UHFFFAOYSA-N 2-methylsulfonylethanamine Chemical group CS(=O)(=O)CCN SDNXQWUJWNTDCC-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- VQIIVEKFIGPFER-UHFFFAOYSA-N 3-(2-methoxyethyl)-7-(2-methoxyphenyl)-1-[3-(trifluoromethyl)phenyl]sulfonyl-2H-quinazolin-4-one Chemical compound COC1=C(C=CC=C1)C1=CC=C2C(N(CN(C2=C1)S(=O)(=O)C1=CC(=CC=C1)C(F)(F)F)CCOC)=O VQIIVEKFIGPFER-UHFFFAOYSA-N 0.000 description 1
- ULGZDVUCSMIVMC-UHFFFAOYSA-N 3-(2-methoxyethyl)-7-(3-methoxyphenyl)-1-[3-(trifluoromethyl)phenyl]sulfonyl-2H-quinazolin-4-one Chemical compound COC=1C=C(C=CC1)C1=CC=C2C(N(CN(C2=C1)S(=O)(=O)C1=CC(=CC=C1)C(F)(F)F)CCOC)=O ULGZDVUCSMIVMC-UHFFFAOYSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- STCMKVBFGNBBPC-UHFFFAOYSA-N 3-[3-(2-methoxyethyl)-4-oxo-1-[3-(trifluoromethyl)phenyl]sulfonyl-2H-quinazolin-7-yl]benzonitrile Chemical compound C(#N)C=1C=C(C=CC1)C1=CC=C2C(N(CN(C2=C1)S(=O)(=O)C1=CC(=CC=C1)C(F)(F)F)CCOC)=O STCMKVBFGNBBPC-UHFFFAOYSA-N 0.000 description 1
- VGUYQWQJMWGYMS-UHFFFAOYSA-N 3-[7-(2-chloro-3-fluorophenyl)-4-oxo-1-[3-(trifluoromethyl)phenyl]sulfonyl-2H-quinazolin-3-yl]-2,2-dimethylpropanoic acid Chemical compound ClC1=C(C=CC=C1F)C1=CC=C2C(N(CN(C2=C1)S(=O)(=O)C1=CC(=CC=C1)C(F)(F)F)CC(C(=O)O)(C)C)=O VGUYQWQJMWGYMS-UHFFFAOYSA-N 0.000 description 1
- BIFGZTYOABAIHM-UHFFFAOYSA-N 3-[7-(2-chloro-5-fluorophenyl)-4-oxo-1-[3-(trifluoromethyl)phenyl]sulfonyl-2H-quinazolin-3-yl]-2,2-dimethylpropanoic acid Chemical compound ClC1=C(C=C(C=C1)F)C1=CC=C2C(N(CN(C2=C1)S(=O)(=O)C1=CC(=CC=C1)C(F)(F)F)CC(C(=O)O)(C)C)=O BIFGZTYOABAIHM-UHFFFAOYSA-N 0.000 description 1
- NDTJQBIZUJQXNV-UHFFFAOYSA-N 3-[7-(2-chloro-6-fluorophenyl)-4-oxo-1-[3-(trifluoromethyl)phenyl]sulfonyl-2H-quinazolin-3-yl]-2,2-dimethylpropanoic acid Chemical compound ClC1=C(C(=CC=C1)F)C1=CC=C2C(N(CN(C2=C1)S(=O)(=O)C1=CC(=CC=C1)C(F)(F)F)CC(C(=O)O)(C)C)=O NDTJQBIZUJQXNV-UHFFFAOYSA-N 0.000 description 1
- ZSVCFVMEMCJVKW-UHFFFAOYSA-N 3-[7-(2-fluoro-3-methylphenyl)-4-oxo-1-[3-(trifluoromethyl)phenyl]sulfonyl-2H-quinazolin-3-yl]-2,2-dimethylpropanoic acid Chemical compound FC1=C(C=CC=C1C)C1=CC=C2C(N(CN(C2=C1)S(=O)(=O)C1=CC(=CC=C1)C(F)(F)F)CC(C(=O)O)(C)C)=O ZSVCFVMEMCJVKW-UHFFFAOYSA-N 0.000 description 1
- NQQKYSFHGFDVDC-UHFFFAOYSA-N 3-[7-(3-chloro-2-methoxyphenyl)-4-oxo-1-[3-(trifluoromethyl)phenyl]sulfonyl-2H-quinazolin-3-yl]-2,2-dimethylpropanoic acid Chemical compound ClC=1C(=C(C=CC1)C1=CC=C2C(N(CN(C2=C1)S(=O)(=O)C1=CC(=CC=C1)C(F)(F)F)CC(C(=O)O)(C)C)=O)OC NQQKYSFHGFDVDC-UHFFFAOYSA-N 0.000 description 1
- ILJPMHZYPCCJGM-UHFFFAOYSA-N 3-[7-(3-fluorophenyl)-4-oxo-1-[3-(trifluoromethyl)phenyl]sulfonyl-2H-quinazolin-3-yl]-2,2-dimethylpropanoic acid Chemical compound FC=1C=C(C=CC1)C1=CC=C2C(N(CN(C2=C1)S(=O)(=O)C1=CC(=CC=C1)C(F)(F)F)CC(C(=O)O)(C)C)=O ILJPMHZYPCCJGM-UHFFFAOYSA-N 0.000 description 1
- MOJZCGXDYBQBJR-UHFFFAOYSA-N 3-[7-(3-methoxyphenyl)-4-oxo-1-[3-(trifluoromethyl)phenyl]sulfonyl-2H-quinazolin-3-yl]-2,2-dimethylpropanoic acid Chemical compound COC=1C=C(C=CC1)C1=CC=C2C(N(CN(C2=C1)S(=O)(=O)C1=CC(=CC=C1)C(F)(F)F)CC(C(=O)O)(C)C)=O MOJZCGXDYBQBJR-UHFFFAOYSA-N 0.000 description 1
- GEYGYEGFHROHPN-UHFFFAOYSA-N 3-[7-[3-(difluoromethoxy)-5-fluorophenyl]-4-oxo-1-[3-(trifluoromethyl)phenyl]sulfonyl-2H-quinazolin-3-yl]-N,N-dimethylpropanamide Chemical compound FC(OC=1C=C(C=C(C1)F)C1=CC=C2C(N(CN(C2=C1)S(=O)(=O)C1=CC(=CC=C1)C(F)(F)F)CCC(=O)N(C)C)=O)F GEYGYEGFHROHPN-UHFFFAOYSA-N 0.000 description 1
- WIQGALOJDSWMPC-UHFFFAOYSA-N 3-[7-[3-(difluoromethoxy)-5-fluorophenyl]-4-oxo-1-[3-(trifluoromethyl)phenyl]sulfonyl-2H-quinazolin-3-yl]propanenitrile Chemical compound FC(OC=1C=C(C=C(C1)F)C1=CC=C2C(N(CN(C2=C1)S(=O)(=O)C1=CC(=CC=C1)C(F)(F)F)CCC#N)=O)F WIQGALOJDSWMPC-UHFFFAOYSA-N 0.000 description 1
- BXOSCIPOLJNLJL-UHFFFAOYSA-N 3-[7-[3-(difluoromethoxy)-5-fluorophenyl]-4-oxo-1-[3-(trifluoromethyl)phenyl]sulfonyl-2H-quinazolin-3-yl]propanoic acid Chemical compound FC(OC=1C=C(C=C(C1)F)C1=CC=C2C(N(CN(C2=C1)S(=O)(=O)C1=CC(=CC=C1)C(F)(F)F)CCC(=O)O)=O)F BXOSCIPOLJNLJL-UHFFFAOYSA-N 0.000 description 1
- VSCZZBUCNIUATP-UHFFFAOYSA-N 3-[[7-[3-(difluoromethoxy)-5-fluorophenyl]-3-(2-methoxyethyl)-4-oxo-2H-quinazolin-1-yl]sulfonyl]benzonitrile Chemical compound FC(OC=1C=C(C=C(C1)F)C1=CC=C2C(N(CN(C2=C1)S(=O)(=O)C1=CC(=CC=C1)C#N)CCOC)=O)F VSCZZBUCNIUATP-UHFFFAOYSA-N 0.000 description 1
- JNDIDJUNNCBHTI-UHFFFAOYSA-N 3-amino-n,n-dimethylpropanamide Chemical group CN(C)C(=O)CCN JNDIDJUNNCBHTI-UHFFFAOYSA-N 0.000 description 1
- DPLJNTWBXCKJOL-UHFFFAOYSA-N 3-bromo-4,5-diethoxybenzonitrile Chemical compound CCOC1=CC(C#N)=CC(Br)=C1OCC DPLJNTWBXCKJOL-UHFFFAOYSA-N 0.000 description 1
- BHNRGBRMCNHNQD-UHFFFAOYSA-N 3-cyanobenzenesulfonyl chloride Chemical group ClS(=O)(=O)C1=CC=CC(C#N)=C1 BHNRGBRMCNHNQD-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- JHJKSEKUZNJKGO-UHFFFAOYSA-N 3-methoxybenzenesulfonyl chloride Chemical group COC1=CC=CC(S(Cl)(=O)=O)=C1 JHJKSEKUZNJKGO-UHFFFAOYSA-N 0.000 description 1
- FAXDZWQIWUSWJH-UHFFFAOYSA-N 3-methoxypropan-1-amine Chemical group COCCCN FAXDZWQIWUSWJH-UHFFFAOYSA-N 0.000 description 1
- ROADCYAOHVSOLQ-UHFFFAOYSA-N 3-oxetanone Chemical group O=C1COC1 ROADCYAOHVSOLQ-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- FTRYJCQXHSBHHI-UHFFFAOYSA-N 4-[7-[3-(difluoromethoxy)-5-fluorophenyl]-4-oxo-1-[3-(trifluoromethyl)phenyl]sulfonyl-2H-quinazolin-3-yl]-N,N-dimethylbutanamide Chemical compound FC(OC=1C=C(C=C(C1)F)C1=CC=C2C(N(CN(C2=C1)S(=O)(=O)C1=CC(=CC=C1)C(F)(F)F)CCCC(=O)N(C)C)=O)F FTRYJCQXHSBHHI-UHFFFAOYSA-N 0.000 description 1
- WYFCZWSWFGJODV-MIANJLSGSA-N 4-[[(1s)-2-[(e)-3-[3-chloro-2-fluoro-6-(tetrazol-1-yl)phenyl]prop-2-enoyl]-5-(4-methyl-2-oxopiperazin-1-yl)-3,4-dihydro-1h-isoquinoline-1-carbonyl]amino]benzoic acid Chemical compound O=C1CN(C)CCN1C1=CC=CC2=C1CCN(C(=O)\C=C\C=1C(=CC=C(Cl)C=1F)N1N=NN=C1)[C@@H]2C(=O)NC1=CC=C(C(O)=O)C=C1 WYFCZWSWFGJODV-MIANJLSGSA-N 0.000 description 1
- AZRRZGIBBLWSSQ-UHFFFAOYSA-N 4-ethyl-7-phenyl-3,5-diazabicyclo[2.2.2]octane-2,6-dione Chemical compound N1C(=O)C2C(=O)NC1(CC)CC2C1=CC=CC=C1 AZRRZGIBBLWSSQ-UHFFFAOYSA-N 0.000 description 1
- XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 description 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 1
- MZYCBSCICKHIPV-UHFFFAOYSA-N 7-(2,3-difluorophenyl)-3-(2-methoxyethyl)-1-[3-(trifluoromethyl)phenyl]sulfonyl-2H-quinazolin-4-one Chemical compound FC1=C(C=CC=C1F)C1=CC=C2C(N(CN(C2=C1)S(=O)(=O)C1=CC(=CC=C1)C(F)(F)F)CCOC)=O MZYCBSCICKHIPV-UHFFFAOYSA-N 0.000 description 1
- CDEXQUSVNRLLLF-UHFFFAOYSA-N 7-(2,5-difluorophenyl)-3-(2-methoxyethyl)-1-[3-(trifluoromethyl)phenyl]sulfonyl-2H-quinazolin-4-one Chemical compound FC1=C(C=C(C=C1)F)C1=CC=C2C(N(CN(C2=C1)S(=O)(=O)C1=CC(=CC=C1)C(F)(F)F)CCOC)=O CDEXQUSVNRLLLF-UHFFFAOYSA-N 0.000 description 1
- OHWAHYMEZYONRX-UHFFFAOYSA-N 7-(2,6-difluorophenyl)-3-(2-methoxyethyl)-1-[3-(trifluoromethyl)phenyl]sulfonyl-2H-quinazolin-4-one Chemical compound FC1=C(C(=CC=C1)F)C1=CC=C2C(N(CN(C2=C1)S(=O)(=O)C1=CC(=CC=C1)C(F)(F)F)CCOC)=O OHWAHYMEZYONRX-UHFFFAOYSA-N 0.000 description 1
- GXEIPGUMZFUBLW-UHFFFAOYSA-N 7-(2-fluorophenyl)-3-(2-methoxyethyl)-1-[3-(trifluoromethyl)phenyl]sulfonyl-2H-quinazolin-4-one Chemical compound FC1=C(C=CC=C1)C1=CC=C2C(N(CN(C2=C1)S(=O)(=O)C1=CC(=CC=C1)C(F)(F)F)CCOC)=O GXEIPGUMZFUBLW-UHFFFAOYSA-N 0.000 description 1
- LFQHMQZNQUXINA-UHFFFAOYSA-N 7-(3,5-difluorophenyl)-3-(2-methoxyethyl)-1-[3-(trifluoromethyl)phenyl]sulfonyl-2H-quinazolin-4-one Chemical compound FC=1C=C(C=C(C1)F)C1=CC=C2C(N(CN(C2=C1)S(=O)(=O)C1=CC(=CC=C1)C(F)(F)F)CCOC)=O LFQHMQZNQUXINA-UHFFFAOYSA-N 0.000 description 1
- PZGQAKBHCJZIAJ-UHFFFAOYSA-N 7-(3-fluorophenyl)-3-(2-methoxyethyl)-1-[3-(trifluoromethyl)phenyl]sulfonyl-2H-quinazolin-4-one Chemical compound FC=1C=C(C=CC1)C1=CC=C2C(N(CN(C2=C1)S(=O)(=O)C1=CC(=CC=C1)C(F)(F)F)CCOC)=O PZGQAKBHCJZIAJ-UHFFFAOYSA-N 0.000 description 1
- KFZOYJWFPAAUQL-UHFFFAOYSA-N 7-[2-(difluoromethoxy)phenyl]-3-(2-methoxyethyl)-1-[3-(trifluoromethyl)phenyl]sulfonyl-2H-quinazolin-4-one Chemical compound FC(OC1=C(C=CC=C1)C1=CC=C2C(N(CN(C2=C1)S(=O)(=O)C1=CC(=CC=C1)C(F)(F)F)CCOC)=O)F KFZOYJWFPAAUQL-UHFFFAOYSA-N 0.000 description 1
- NDCSKJIFBCEUDL-UHFFFAOYSA-N 7-[3-(difluoromethoxy)-5-fluorophenyl]-3-(1-methoxypropan-2-yl)-1-[3-(trifluoromethyl)phenyl]sulfonyl-2H-quinazolin-4-one Chemical compound FC(OC=1C=C(C=C(C1)F)C1=CC=C2C(N(CN(C2=C1)S(=O)(=O)C1=CC(=CC=C1)C(F)(F)F)C(COC)C)=O)F NDCSKJIFBCEUDL-UHFFFAOYSA-N 0.000 description 1
- JZRRBUGMJWQPSV-UHFFFAOYSA-N 7-[3-(difluoromethoxy)-5-fluorophenyl]-3-(2-hydroxy-2-methylpropyl)-1-[3-(trifluoromethyl)phenyl]sulfonyl-2H-quinazolin-4-one Chemical compound FC(OC=1C=C(C=C(C1)F)C1=CC=C2C(N(CN(C2=C1)S(=O)(=O)C1=CC(=CC=C1)C(F)(F)F)CC(C)(C)O)=O)F JZRRBUGMJWQPSV-UHFFFAOYSA-N 0.000 description 1
- XWEPNSIGATWMNB-UHFFFAOYSA-N 7-[3-(difluoromethoxy)-5-fluorophenyl]-3-(2-methoxyethyl)-1-(3-methoxyphenyl)sulfonyl-2H-quinazolin-4-one Chemical compound FC(OC=1C=C(C=C(C1)F)C1=CC=C2C(N(CN(C2=C1)S(=O)(=O)C1=CC(=CC=C1)OC)CCOC)=O)F XWEPNSIGATWMNB-UHFFFAOYSA-N 0.000 description 1
- IMMOJQCPQAXGJF-UHFFFAOYSA-N 7-[3-(difluoromethoxy)-5-fluorophenyl]-3-(2-methylsulfonylethyl)-1-[3-(trifluoromethyl)phenyl]sulfonyl-2H-quinazolin-4-one Chemical compound FC(OC=1C=C(C=C(C1)F)C1=CC=C2C(N(CN(C2=C1)S(=O)(=O)C1=CC(=CC=C1)C(F)(F)F)CCS(=O)(=O)C)=O)F IMMOJQCPQAXGJF-UHFFFAOYSA-N 0.000 description 1
- PXQJLQGHRDKFIX-UHFFFAOYSA-N 7-[3-(difluoromethoxy)-5-fluorophenyl]-3-(2-morpholin-4-ylethyl)-1-[3-(trifluoromethyl)phenyl]sulfonyl-2H-quinazolin-4-one Chemical compound FC(OC=1C=C(C=C(C1)F)C1=CC=C2C(N(CN(C2=C1)S(=O)(=O)C1=CC(=CC=C1)C(F)(F)F)CCN1CCOCC1)=O)F PXQJLQGHRDKFIX-UHFFFAOYSA-N 0.000 description 1
- JKUJURXLYIPSFC-UHFFFAOYSA-N 7-[3-(difluoromethoxy)-5-fluorophenyl]-3-(oxan-2-ylmethyl)-1-[3-(trifluoromethyl)phenyl]sulfonyl-2H-quinazolin-4-one Chemical compound FC(OC=1C=C(C=C(C1)F)C1=CC=C2C(N(CN(C2=C1)S(=O)(=O)C1=CC(=CC=C1)C(F)(F)F)CC1OCCCC1)=O)F JKUJURXLYIPSFC-UHFFFAOYSA-N 0.000 description 1
- SYDYJDJTBOGJIM-UHFFFAOYSA-N 7-[3-(difluoromethoxy)-5-fluorophenyl]-3-(oxan-4-yl)-1-[3-(trifluoromethyl)phenyl]sulfonyl-2H-quinazolin-4-one Chemical compound FC(OC=1C=C(C=C(C1)F)C1=CC=C2C(N(CN(C2=C1)S(=O)(=O)C1=CC(=CC=C1)C(F)(F)F)C1CCOCC1)=O)F SYDYJDJTBOGJIM-UHFFFAOYSA-N 0.000 description 1
- WBGGCJCGKYROLG-UHFFFAOYSA-N 7-[3-(difluoromethoxy)-5-fluorophenyl]-3-(oxetan-2-ylmethyl)-1-[3-(trifluoromethyl)phenyl]sulfonyl-2H-quinazolin-4-one Chemical compound FC(OC=1C=C(C=C(C1)F)C1=CC=C2C(N(CN(C2=C1)S(=O)(=O)C1=CC(=CC=C1)C(F)(F)F)CC1OCC1)=O)F WBGGCJCGKYROLG-UHFFFAOYSA-N 0.000 description 1
- KVLYRZSFHGAHJW-UHFFFAOYSA-N 7-[3-(difluoromethoxy)-5-fluorophenyl]-3-(oxetan-3-yl)-1-[3-(trifluoromethyl)phenyl]sulfonyl-2H-quinazolin-4-one Chemical compound FC(OC=1C=C(C=C(C1)F)C1=CC=C2C(N(CN(C2=C1)S(=O)(=O)C1=CC(=CC=C1)C(F)(F)F)C1COC1)=O)F KVLYRZSFHGAHJW-UHFFFAOYSA-N 0.000 description 1
- NDCSKJIFBCEUDL-OAHLLOKOSA-N 7-[3-(difluoromethoxy)-5-fluorophenyl]-3-[(2R)-1-methoxypropan-2-yl]-1-[3-(trifluoromethyl)phenyl]sulfonyl-2H-quinazolin-4-one Chemical compound FC(OC=1C=C(C=C(C1)F)C1=CC=C2C(N(CN(C2=C1)S(=O)(=O)C1=CC(=CC=C1)C(F)(F)F)[C@@H](COC)C)=O)F NDCSKJIFBCEUDL-OAHLLOKOSA-N 0.000 description 1
- GQZZECYNTJDASF-IBGZPJMESA-N 7-[3-(difluoromethoxy)-5-fluorophenyl]-3-[(3S)-oxolan-3-yl]-1-[3-(trifluoromethyl)phenyl]sulfonyl-2H-quinazolin-4-one Chemical compound FC(OC=1C=C(C=C(C1)F)C1=CC=C2C(N(CN(C2=C1)S(=O)(=O)C1=CC(=CC=C1)C(F)(F)F)[C@@H]1COCC1)=O)F GQZZECYNTJDASF-IBGZPJMESA-N 0.000 description 1
- ICAZKTQCWSMCPS-HXUWFJFHSA-N 7-[3-(difluoromethoxy)-5-fluorophenyl]-3-[[(2R)-oxolan-2-yl]methyl]-1-[3-(trifluoromethyl)phenyl]sulfonyl-2H-quinazolin-4-one Chemical compound FC(OC=1C=C(C=C(C1)F)C1=CC=C2C(N(CN(C2=C1)S(=O)(=O)C1=CC(=CC=C1)C(F)(F)F)C[C@@H]1OCCC1)=O)F ICAZKTQCWSMCPS-HXUWFJFHSA-N 0.000 description 1
- ICAZKTQCWSMCPS-FQEVSTJZSA-N 7-[3-(difluoromethoxy)-5-fluorophenyl]-3-[[(2S)-oxolan-2-yl]methyl]-1-[3-(trifluoromethyl)phenyl]sulfonyl-2H-quinazolin-4-one Chemical compound FC(OC=1C=C(C=C(C1)F)C1=CC=C2C(N(CN(C2=C1)S(=O)(=O)C1=CC(=CC=C1)C(F)(F)F)C[C@H]1OCCC1)=O)F ICAZKTQCWSMCPS-FQEVSTJZSA-N 0.000 description 1
- OTYYJQCIVVSYGJ-UHFFFAOYSA-N 7-[3-(difluoromethoxy)-5-fluorophenyl]-3-ethyl-1-[3-(trifluoromethyl)phenyl]sulfonyl-2H-quinazolin-4-one Chemical compound FC(OC=1C=C(C=C(C1)F)C1=CC=C2C(N(CN(C2=C1)S(=O)(=O)C1=CC(=CC=C1)C(F)(F)F)CC)=O)F OTYYJQCIVVSYGJ-UHFFFAOYSA-N 0.000 description 1
- NCMJINNOYLDZHZ-UHFFFAOYSA-N 7-[3-(difluoromethoxy)-5-fluorophenyl]-3-methyl-1-[3-(trifluoromethyl)phenyl]sulfonyl-2H-quinazolin-4-one Chemical compound FC(OC=1C=C(C=C(C1)F)C1=CC=C2C(N(CN(C2=C1)S(=O)(=O)C1=CC(=CC=C1)C(F)(F)F)C)=O)F NCMJINNOYLDZHZ-UHFFFAOYSA-N 0.000 description 1
- LIQVPUOPGWTGAF-UHFFFAOYSA-N 7-[3-(difluoromethoxy)-5-fluorophenyl]-3-propan-2-yl-1-[3-(trifluoromethyl)phenyl]sulfonyl-2H-quinazolin-4-one Chemical compound FC(OC=1C=C(C=C(C1)F)C1=CC=C2C(N(CN(C2=C1)S(=O)(=O)C1=CC(=CC=C1)C(F)(F)F)C(C)C)=O)F LIQVPUOPGWTGAF-UHFFFAOYSA-N 0.000 description 1
- BTYDWEFALGDEAB-UHFFFAOYSA-N 7-[3-(difluoromethoxy)phenyl]-3-(2-methoxyethyl)-1-[3-(trifluoromethyl)phenyl]sulfonyl-2H-quinazolin-4-one Chemical compound FC(OC=1C=C(C=CC1)C1=CC=C2C(N(CN(C2=C1)S(=O)(=O)C1=CC(=CC=C1)C(F)(F)F)CCOC)=O)F BTYDWEFALGDEAB-UHFFFAOYSA-N 0.000 description 1
- NWJXAYWCZYETMD-UHFFFAOYSA-N 7-[4-(difluoromethoxy)phenyl]-3-(2-methoxyethyl)-1-[3-(trifluoromethyl)phenyl]sulfonyl-2H-quinazolin-4-one Chemical compound FC(OC1=CC=C(C=C1)C1=CC=C2C(N(CN(C2=C1)S(=O)(=O)C1=CC(=CC=C1)C(F)(F)F)CCOC)=O)F NWJXAYWCZYETMD-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- JQUCWIWWWKZNCS-LESHARBVSA-N C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F Chemical compound C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F JQUCWIWWWKZNCS-LESHARBVSA-N 0.000 description 1
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 229940126639 Compound 33 Drugs 0.000 description 1
- 229940127007 Compound 39 Drugs 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010001515 Galectin 4 Proteins 0.000 description 1
- 102100039556 Galectin-4 Human genes 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- PBJLKPFJCLOLDM-UHFFFAOYSA-N N',N'-dimethylbutane-1,4-diamine hydrochloride Chemical group Cl.CN(C)CCCCN PBJLKPFJCLOLDM-UHFFFAOYSA-N 0.000 description 1
- LVDRREOUMKACNJ-BKMJKUGQSA-N N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)N[C@H]1CCC(=O)N([C@@H]1c1ccc(Cl)cc1)c1ccc2c(C)cc(=O)n(C)c2c1 LVDRREOUMKACNJ-BKMJKUGQSA-N 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 1
- 241000720974 Protium Species 0.000 description 1
- 108091008773 RAR-related orphan receptors γ Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 210000000068 Th17 cell Anatomy 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 1
- IOSLINNLJFQMFF-XMMPIXPASA-N [(2R)-1-[[4-[[3-[(4-fluorophenyl)methylsulfanyl]phenoxy]methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound FC1=CC=C(CSC=2C=C(OCC3=CC=C(CN4[C@H](CCC4)CO)C=C3)C=CC=2)C=C1 IOSLINNLJFQMFF-XMMPIXPASA-N 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- YNOGYQAEJGADFJ-YFKPBYRVSA-N [(2s)-oxolan-2-yl]methanamine Chemical group NC[C@@H]1CCCO1 YNOGYQAEJGADFJ-YFKPBYRVSA-N 0.000 description 1
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 1
- FGQKXEUNYFZVMW-UHFFFAOYSA-N [3-(difluoromethoxy)phenyl]boronic acid Chemical group OB(O)C1=CC=CC(OC(F)F)=C1 FGQKXEUNYFZVMW-UHFFFAOYSA-N 0.000 description 1
- MFZNJRNTHPKCFY-UHFFFAOYSA-N [4-(difluoromethoxy)phenyl]boronic acid Chemical group OB(O)C1=CC=C(OC(F)F)C=C1 MFZNJRNTHPKCFY-UHFFFAOYSA-N 0.000 description 1
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 1
- WREOTYWODABZMH-DTZQCDIJSA-N [[(2r,3s,4r,5r)-3,4-dihydroxy-5-[2-oxo-4-(2-phenylethoxyamino)pyrimidin-1-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N(C=C\1)C(=O)NC/1=N\OCCC1=CC=CC=C1 WREOTYWODABZMH-DTZQCDIJSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Substances CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 1
- AGSPXMVUFBBBMO-UHFFFAOYSA-N beta-aminopropionitrile Chemical group NCCC#N AGSPXMVUFBBBMO-UHFFFAOYSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000017712 cerebellum development Effects 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000002925 chemical effect Effects 0.000 description 1
- 230000001767 chemoprotection Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 229940125851 compound 27 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940125877 compound 31 Drugs 0.000 description 1
- 229940125878 compound 36 Drugs 0.000 description 1
- 229940125807 compound 37 Drugs 0.000 description 1
- 229940127573 compound 38 Drugs 0.000 description 1
- 229940126540 compound 41 Drugs 0.000 description 1
- 229940125936 compound 42 Drugs 0.000 description 1
- 229940125844 compound 46 Drugs 0.000 description 1
- 229940127271 compound 49 Drugs 0.000 description 1
- 229940126545 compound 53 Drugs 0.000 description 1
- 229940127113 compound 57 Drugs 0.000 description 1
- 229940125900 compound 59 Drugs 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- SNRCKKQHDUIRIY-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloromethane;dichloropalladium;iron(2+) Chemical compound [Fe+2].ClCCl.Cl[Pd]Cl.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 SNRCKKQHDUIRIY-UHFFFAOYSA-L 0.000 description 1
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000013506 data mapping Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- HFKSPHRKTPGEKT-UHFFFAOYSA-N ethyl 3-[(2-amino-4-bromobenzoyl)amino]-2,2-dimethylpropanoate Chemical compound NC1=C(C=CC(=C1)Br)C(=O)NCC(C(=O)OCC)(C)C HFKSPHRKTPGEKT-UHFFFAOYSA-N 0.000 description 1
- HAWROYHPFXYIGS-UHFFFAOYSA-N ethyl 3-amino-2,2-dimethylpropanoate;hydrochloride Chemical compound Cl.CCOC(=O)C(C)(C)CN HAWROYHPFXYIGS-UHFFFAOYSA-N 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- COQRGFWWJBEXRC-UHFFFAOYSA-N hydron;methyl 2-aminoacetate;chloride Chemical group Cl.COC(=O)CN COQRGFWWJBEXRC-UHFFFAOYSA-N 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical group CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004066 metabolic change Effects 0.000 description 1
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 1
- KQEVIFKPZOGBMZ-UHFFFAOYSA-N methyl 3-bromopropanoate Chemical compound COC(=O)CCBr KQEVIFKPZOGBMZ-UHFFFAOYSA-N 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N mono-methylamine Natural products NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
- YESJKZGCXPCJMF-UHFFFAOYSA-N n-(2-aminoethyl)methanesulfonamide;hydrochloride Chemical group Cl.CS(=O)(=O)NCCN YESJKZGCXPCJMF-UHFFFAOYSA-N 0.000 description 1
- RWIVICVCHVMHMU-UHFFFAOYSA-N n-aminoethylmorpholine Chemical compound NCCN1CCOCC1 RWIVICVCHVMHMU-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 229940039748 oxalate Drugs 0.000 description 1
- NYGCBQKDTGBHSC-UHFFFAOYSA-N oxan-2-ylmethanamine Chemical group NCC1CCCCO1 NYGCBQKDTGBHSC-UHFFFAOYSA-N 0.000 description 1
- AHVQYHFYQWKUKB-UHFFFAOYSA-N oxan-4-amine Chemical group NC1CCOCC1 AHVQYHFYQWKUKB-UHFFFAOYSA-N 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- QDEFNAHLCTUWAH-UHFFFAOYSA-N oxetan-2-ylmethanamine Chemical group NCC1CCO1 QDEFNAHLCTUWAH-UHFFFAOYSA-N 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- FDBYIYFVSAHJLY-UHFFFAOYSA-N resmetirom Chemical compound N1C(=O)C(C(C)C)=CC(OC=2C(=CC(=CC=2Cl)N2C(NC(=O)C(C#N)=N2)=O)Cl)=N1 FDBYIYFVSAHJLY-UHFFFAOYSA-N 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- RSIJVJUOQBWMIM-UHFFFAOYSA-L sodium sulfate decahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].[O-]S([O-])(=O)=O RSIJVJUOQBWMIM-UHFFFAOYSA-L 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 238000002877 time resolved fluorescence resonance energy transfer Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/92—Oxygen atoms with hetero atoms directly attached to nitrogen atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Abstract
本发明涉及一类苯并二氮杂环类化合物、其制备方法及用途以及含有所述化合物的药物组合物。特别是,本发明涉及式I化合物、其制备方法,式I化合物作为RORγ调节剂用于预防和/或治疗疾病的用途,以及含有式I化合物的药物组合物。
Description
发明领域
本发明属于医药领域,具体涉及一类苯并二氮杂环类化合物、其制备方法及用途以及含有所述化合物的药物组合物。特别是,本发明涉及式I化合物、其制备方法,式I化合物作为RORγ调节剂用于预防和/或治疗疾病的用途,以及含有式I化合物的药物组合物。
发明背景
维A酸受体相关孤儿核受体(ROR)在多种生理过程中起调控作用,包括RORα,RORβ和RORγ三种亚型。近年的研究发现,相较于维A酸,RORs与氧化类固醇衍生物的亲和力更高,并为其所调控。RORs广泛分布于机体的各个组织中,能够直接进入细胞核调节靶基因的转录,进而参与不同生理过程,表现出不同的组织特异性。其中,RORα在各种组织中均有表达,但在大脑中高表达,在小脑发展和骨形成中起重要作用。RORβ作用范围较小,主要在大脑中表达,在视网膜、大脑皮层发展中起作用。RORγ可以在许多组织中表达,包括胸腺、肝脏和骨骼肌,在次级淋巴组织发展中起关键作用。
RORγ有RORγ1和RORγ2(RORγt)两种亚型。RORγ1在多种组织中表达,而RORγ2是特异性表达在免疫细胞上的亚型。RORγ2是Th17和Tc17效应T细胞分化与维持的关键转录因子,调节Th17细胞分泌效应因子IL-17,并在NK细胞、γδT细胞以及iNK T细胞的分化中起重要作用,这些细胞可介导免疫系统对抗癌细胞以及细菌、真菌等病原微生物。在肿瘤微环境中,Thl7细胞和IL-17可招募自然杀伤细胞和细胞毒性CD8+T细胞对肿瘤细胞进行攻击和杀伤。一些研究显示,卵巢癌病人肿瘤部位浸润Thl7细胞水平和IL-17表达水平与良好的预后呈正相关关系。
针对癌症的治疗,尽管已进行了大量的研究,付出了巨大的努力,其仍然是人类健康的一大威胁。无论在发达国家还是在发展中国家,癌症都是死亡率最高的疾病,并且发病率和死亡率仍不断增高。目前,针对肿瘤的治疗药物,并非对所有的肿瘤病人均有效。因此,开发具有调节RORγ活性的化合物可能对肿瘤的治疗将有助益,为肿瘤病人的治疗提供更多选择。目前,RORγ调节剂的开发在医药工业界已逐渐得到重视,已公开的专利申请包括WO2017157332A1、WO2011115892A1等。
然而,当前仍迫切需要研究和开发高活性、副作用少、抗耐药性、具有改善的药代动力学等性质的新的调节RORγ活性的化合物。
发明内容
本发明的一个方面提供式I化合物或其药学上可接受的盐、立体异构体、互变异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药,其中:
环A1选自苯基和5-10元杂芳基;
环A2选自苯基、5-6元杂芳基和3-6元杂环基;
L为共价键或选自-C(Ra)(Rb)-和-C(Ra)(Rb)-C(Ra)(Rb)-;
R1选自C1-6烷基和4-10元杂环基;且可任选地被0、1、2或3个独立的选自下组的取代基所取代,该组取代基选自:卤素、-CN、-OH、-CO2R5a、-OR6、-S(O)2-R6、-C(O)-N(R5a)(R5b)、-N(R5a)C(O)R6、-S(O)2-N(R5a)(R5b)、-N(R5a)S(O)2R6、4-10元杂环基、6-10元芳基和5-10元杂芳基;
每个R2各自独立地选自卤素、氰基、羟基、C1-6烷基、C3-6环烷基、C1-6卤代烷基、C1-6烷氧基、C1-6卤代烷氧基和-O-C3-6环烷基;
每个R3各自独立地选自卤素、氰基、羟基、C1-6烷基、C1-6卤代烷基、C3-6环烷基、C1-6烷氧基、C1-6卤代烷氧基和-S(O)2-R6;
每个R4各自独立地选自卤素、氰基、C1-6烷基和C1-6烷氧基;
R5a和R5b各自独立地选自氢和C1-6烷基;
或者R5a、R5b连同其相连的氮原子共同形成3-7元杂环基;
R6选自C1-6烷基和C3-6环烷基;
每个Ra和Rb各自独立地选自氢和C1-6烷基;
m为0、1、2或3;
n为0、1、2或3;
p为0、1或2。
在一些实施方案中,本发明提供了式I化合物或其药学上可接受的盐、立体异构体、互变异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药,其中所述式I化合物具有式II-A或II-B的结构,
其中:
每个Ra和Rb各自独立地选自氢和C1-4烷基;
环A1、环A2、R1、R2、R3、m和n定义如式I中所定义。
在一些实施方案中,本发明提供了式I、式II-A或式II-B化合物或其药学上可接受的盐、立体异构体、互变异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药,其中:R1选自C1-4烷基和4-6元杂环基;且可任选地被0、1或2个独立的选自下组的取代基所取代,该组取代基包括:卤素、-CN、-OH、-CO2R5a、-OR6、-S(O)2-R6、-C(O)-N(R5a)(R5b)、-N(R5a)C(O)R6、-S(O)2-N(R5a)(R5b)、-N(R5a)S(O)2R6、4-6元杂环基、6-10元芳基和5-10元杂芳基;更优选R1选自C1-4烷基、C1-4卤代烷基、-C1-4亚烷基-CN、-C1-4亚烷基-OH、-C1-4亚烷基-CO2R5a、-C1-4亚烷基-O-R6、-C1-4亚烷基-S(O)2-R6、-C1-4亚烷基-C(O)-N(R5a)(R5b)、-C1-4亚烷基-N(R5a)C(O)R6、-C1-4亚烷基-S(O)2-N(R5a)(R5b)和-C1-4亚烷基-N(R5a)S(O)2R6、氧杂环丁烷基、四氢呋喃基、四氢-2H-吡喃基、-C1-4亚烷基-氧杂环丁烷、-C1-4亚烷基-四氢呋喃、-C1-4亚烷基-四氢吡喃和-C1-4亚烷基-吗啉;进一步优选R1选自C1-4烷基、C1-4卤代烷基、-C1-4亚烷基-CN、-C1-4亚烷基-OH、-C1-4亚烷基-CO2R5a、-C1-4亚烷基-O-R6、-C1-4亚烷基-S(O)2-R6、-C1-4亚烷基-C(O)-N(R5a)(R5b)、-C1-4亚烷基-N(R5a)C(O)R6、-C1-4亚烷基-S(O)2-N(R5a)(R5b)和-C1-4亚烷基-N(R5a)S(O)2R6、氧杂环丁烷基、四氢呋喃基、四氢-2H-吡喃基、-C1-4亚烷基-氧杂环丁烷、-C1-4亚烷基-四氢呋喃、和-C1-4亚烷基-四氢吡喃;
R5a和R5b各自独立地选自氢和C1-4烷基;
或者R5a、R5b连同其相连的氮原子共同形成4-6元杂环基;
R6选自C1-4烷基和C3-6环烷基;
优选地,R1选自C1-4烷基、C1-4卤代烷基、-C1-4亚烷基-CN、-C1-4亚烷基-OH、-C1-4亚烷基-C(O)OH、-C1-4亚烷基-C(O)O-C1-4烷基、-C1-4亚烷基-O-C1-4烷基、-C1-4亚烷基-O-C3-6环烷基、-C1-4亚烷基-S(O)2-C1-4烷基、-C1-4亚烷基-C(O)-NH-C1-4烷基、-C1-4亚烷基-C(O)-N(C1-4烷基)(C1-4烷基)、-C1-4亚烷基-NH-C(O)-C1-4烷基、-C1-4亚烷基-S(O)2-N(C1-4烷基)(C1-4烷基)、-C1-4亚烷基-S(O)2-NH-(C1-4烷基)、-C1-4亚烷基-S(O)2-NH2、-C1-4亚烷基-NH-S(O)2-C1-4烷基、氧杂环丁烷基、四氢呋喃基、四氢-2H-吡喃基、-C1-3亚烷基-氧杂环丁烷、-C1-3亚烷基-四氢呋喃、-C1-3亚烷基-四氢吡喃和-C1-3亚烷基-吗啉;
优选地,R1选自C1-4烷基、C1-4卤代烷基、-C1-4亚烷基-CN、-C1-4亚烷基-OH、-C1-4亚烷基-C(O)OH、-C1-4亚烷基-C(O)O-C1-4烷基、-C1-4亚烷基-O-C1-4烷基、-C1-4亚烷基-O-C3-6环烷基、-C1-4亚烷基-S(O)2-C1-4烷基、-C1-4亚烷基-C(O)-NH-C1-4烷基、-C1-4亚烷基-C(O)-N(C1-4烷基)(C1-4烷基)、-C1-4亚烷基-NH-C(O)-C1-4烷基、-C1-4亚烷基-S(O)2-N(C1-4烷基)(C1-4烷基)、-C1-4亚烷基-S(O)2-NH-(C1-4烷基)、-C1-4亚烷基-S(O)2-NH2、-C1-4亚烷基-NH-S(O)2-C1-4烷基、氧杂环丁烷基、四氢呋喃基、四氢-2H-吡喃基、-C1-3亚烷基-氧杂环丁烷、-C1-3亚烷基-四氢呋喃、和-C1-3亚烷基-四氢吡喃;
更优选地,R1选自-CH3、-CH2CH3、-CH(CH3)2、-CH2CH2CH2F、-CH2CH2-CN、-CH2CH2CH2-CN、-CH2CH2C(CH3)2-CN、-CH2C(CH3)2-OH、-CH2CH2C(CH3)2-OH、-CH2C(O)OH、-CH2CH2C(O)OH、-CH2C(CH3)2C(O)OH、-CH2C(O)O-CH3、-CH2CH2C(O)O-CH3、-CH2C(CH3)2C(O)O-CH3、-CH2CH2-O-CH3、-CH2CH(CH3)-O-CH3、-CH2CH2CH2-O-CH3、-CH2CH2-O-CH2CH3、-CH(CH3)CH2-O-CH3、-CH2CH2-S(O)2-CH3、-CH2CH2-C(O)-NH-CH3、-CH2CH2CH2-C(O)-N(CH3)2、-CH2CH2-C(O)-N(CH3)2、-CH2-C(O)-N(CH3)2、-CH2CH2-NH-C(O)-CH3、-CH2CH2-S(O)2-N(CH3)2、-CH2CH2-S(O)2-NHCH3、-CH2CH2-S(O)2-NH2、-CH2CH2-NH-S(O)2-CH3、
更优选地,R1选自-CH3、-CH2CH3、-CH(CH3)2、-CH2CH2CH2F、-CH2CH2-CN、-CH2CH2CH2-CN、-CH2CH2C(CH3)2-CN、-CH2C(CH3)2-OH、-CH2CH2C(CH3)2-OH、-CH2C(O)OH、-CH2CH2C(O)OH、-CH2C(CH3)2C(O)OH、-CH2C(O)O-CH3、-CH2CH2C(O)O-CH3、-CH2C(CH3)2C(O)O-CH3、-CH2CH2-O-CH3、-CH2CH(CH3)-O-CH3、-CH2CH2CH2-O-CH3、-CH2CH2-O-CH2CH3、-CH(CH3)CH2-O-CH3、-CH2CH2-S(O)2-CH3、-CH2CH2-C(O)-NH-CH3、-CH2CH2CH2-C(O)-N(CH3)2、-CH2CH2-C(O)-N(CH3)2、-CH2-C(O)-N(CH3)2、-CH2CH2-NH-C(O)-CH3、-CH2CH2-S(O)2-N(CH3)2、-CH2CH2-S(O)2-NHCH3、-CH2CH2-S(O)2-NH2、-CH2CH2-NH-S(O)2-CH3、
在一些实施方案中,本发明提供式I、式II-A或式II-B化合物或其药学上可接受的盐、立体异构体、互变异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药,其中:环A1选自苯基和5-10元杂芳基;优选地,环A1选自苯基、吡啶基、异噁唑基、吡唑基和咪唑并[1,2-a]吡啶基;更优选地,环A1选自苯基和吡啶基。
在一些实施方案中,本发明提供式I、式II-A或式II-B化合物或其药学上可接受的盐、立体异构体、互变异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药,其中:R2选自卤素、氰基、羟基、C1-4烷基、C3-6环烷基、C1-4卤代烷基、C1-4烷氧基、C1-4卤代烷氧基和-O-C3-6环烷基;优选地,R2选自卤素、氰基、C3-6环烷基、C1-4卤代烷基和C1-4卤代烷氧基;更优选地,R2选自氟、氯、氰基、甲基、甲氧基和二氟甲氧基。
在一些实施方案中,本发明提供式I、式II-A或式II-B化合物或其药学上可接受的盐、立体异构体、互变异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药,其中:环A1选自苯基和5-10元杂芳基;R2选自卤素、氰基、羟基、C1-4烷基、C3-6环烷基、C1-4卤代烷基、C1-4烷氧基、C1-4卤代烷氧基和-O-C3-6环烷基;
优选地,环A1选自苯基、吡啶基、异噁唑基、吡唑基和咪唑并[1,2-a]吡啶基;R2选自卤素、氰基、C3-6环烷基、C1-4卤代烷基和C1-4卤代烷氧基;
更优选地,环A1选自苯基和吡啶基;R2选自卤素、氰基、C1-4烷基、C3-6环烷基、C1-4烷氧基、C1-4卤代烷基和C1-4卤代烷氧基;
特别优选地,环A1选自苯基和吡啶基;R2选自氟、氯、氰基、甲基、甲氧基和二氟甲氧基。
在一些实施方案中,本发明提供式I、式II-A或式II-B化合物或其药学上可接受的盐、立体异构体、互变异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药,其中:环A2选自苯基和5-6元杂芳基;优选地,环A2选自苯基、吡啶基、异噁唑基和吡唑基;更优选地,环A2选自苯基、吡啶基、异噁唑基和吡唑基。
在一些实施方案中,本发明提供式I、式II-A或式II-B化合物或其药学上可接受的盐、立体异构体、互变异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药,其中:R3选自卤素、氰基、C1-4烷基、C1-4卤代烷基、C3-6环烷基、C1-4烷氧基、C1-4卤代烷氧基和-S(O)2-C1-4烷基;
优选地,在一些实施方案中,本发明提供式I、式II-A或式II-B化合物或其药学上可接受的盐、立体异构体、互变异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药,其中:环A2选自苯基和5-6元杂芳基;R3选自卤素、氰基、C1-4烷基、C1-4卤代烷基、C3-6环烷基、C1-4烷氧基、C1-4卤代烷氧基和-S(O)2-C1-4烷基;
优选地,环A2选自苯基、吡啶基、异噁唑基和吡唑基;R3选自卤素、氰基、C1-4烷基、C1-4卤代烷基、C1-4卤代烷氧基和-S(O)2-C1-4烷基。
特别优选地,环A2选自苯基、吡啶基、异噁唑基和吡唑基;R3选自三氟甲基、甲基、氰基、氟和甲磺酰基。
在一些实施方案中,本发明提供式II-A或II-B化合物或其药学上可接受的盐、立体异构体、互变异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药,其中:
环A1选自苯基、吡啶基、异噁唑基、吡唑基和咪唑并[1,2-a]吡啶基;
环A2选自苯基、吡啶基、异噁唑基和吡唑基;
Ra和Rb都是氢;
R1选自-CH3、-CH2CH3、-CH(CH3)2、-CH2CH2CH2F、-CH2CH2-CN、-CH2CH2CH2-CN、-CH2CH2C(CH3)2-CN、-CH2C(CH3)2-OH、-CH2CH2C(CH3)2-OH、-CH2C(O)OH、-CH2CH2C(O)OH、-CH2C(CH3)2C(O)OH、-CH2C(O)O-CH3、-CH2CH2C(O)O-CH3、-CH2C(CH3)2C(O)O-CH3、-CH2CH2-O-CH3、-CH2CH(CH3)-O-CH3、-CH2CH2CH2-O-CH3、-CH2CH2-O-CH2CH3、-CH(CH3)CH2-O-CH3、-CH2CH2-S(O)2-CH3、-CH2CH2-C(O)-NH-CH3、-CH2CH2CH2-C(O)-N(CH3)2、-CH2CH2-C(O)-N(CH3)2、-CH2-C(O)-N(CH3)2、-CH2CH2-NH-C(O)-CH3、-CH2CH2-S(O)2-N(CH3)2、-CH2CH2-S(O)2-NHCH3、-CH2CH2-S(O)2-NH2、-CH2CH2-NH-S(O)2-CH3、 优选地,R1选自-CH3、-CH2CH3、-CH(CH3)2、-CH2CH2CH2F、-CH2CH2-CN、-CH2CH2CH2-CN、-CH2CH2C(CH3)2-CN、-CH2C(CH3)2-OH、-CH2CH2C(CH3)2-OH、-CH2C(O)OH、-CH2CH2C(O)OH、-CH2C(CH3)2C(O)OH、-CH2C(O)O-CH3、-CH2CH2C(O)O-CH3、-CH2C(CH3)2C(O)O-CH3、-CH2CH2-O-CH3、-CH2CH(CH3)-O-CH3、-CH2CH2CH2-O-CH3、-CH2CH2-O-CH2CH3、-CH(CH3)CH2-O-CH3、-CH2CH2-S(O)2-CH3、-CH2CH2-C(O)-NH-CH3、-CH2CH2CH2-C(O)-N(CH3)2、-CH2CH2-C(O)-N(CH3)2、-CH2-C(O)-N(CH3)2、-CH2CH2-NH-C(O)-CH3、-CH2CH2-S(O)2-N(CH3)2、-CH2CH2-S(O)2-NHCH3、-CH2CH2-S(O)2-NH2、-CH2CH2-NH-S(O)2-CH3、/>
每个R2各自独立地选自卤素、氰基、C1-4烷基、C1-4卤代烷基、C1-4烷氧基、C1-4卤代烷氧基;
每个R3各自独立地选自卤素、氰基、C1-4烷基、C1-4卤代烷基和-S(O)2-C1-4烷基;
m为0、1、2或3;
n为0、1、2或3。
本发明的另一个方面提供式I化合物或其药学上可接受的盐、立体异构体、互变异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药,其中:
环A1选自苯基和5-10元杂芳基;
环A2选自苯基、5-6元杂芳基和3-6元杂环基;
L为共价键或选自-C(Ra)(Rb)-和-C(Ra)(Rb)-C(Ra)(Rb)-;
R1选自-C1-6烷基;且可任选地被0、1、2或3个独立的选自下组的取代基所取代,该组取代基选自:卤素、-CN、-OH、-CO2R5a、-OR6、-S(O)2-R6、-C(O)-N(R5a)(R5b)、-N(R5a)C(O)R6、-S(O)2-N(R5a)(R5b)、-N(R5a)S(O)2R6、6-10元芳基和5-10元杂芳基;
每个R2各自独立地选自卤素、氰基、羟基、C1-6烷基、C3-6环烷基、C1-6卤代烷基、C1-6烷氧基、C1-6卤代烷氧基和-O-C3-6环烷基;
每个R3各自独立地选自卤素、氰基、羟基、C1-6烷基、C1-6卤代烷基、C3-6环烷基、C1-6烷氧基、C1-6卤代烷氧基和-S(O)2-R6;
每个R4各自独立地选自卤素、氰基、C1-6烷基和C1-6烷氧基;
R5a和R5b各自独立地选自氢和C1-6烷基;
或者R5a、R5b连同其相连的氮原子共同形成3-7元杂环基;
R6选自C1-6烷基和C3-6环烷基;
每个Ra和Rb各自独立地选自氢和C1-6烷基;
m为0、1、2或3;
n为0、1、2或3;
p为0、1或2。
在一些实施方案中,本发明提供了式I化合物或其药学上可接受的盐、立体异构体、互变异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药,其中所述式I化合物具有式II-A或II’-B的结构,
其中:
每个Ra和Rb各自独立地选自氢和C1-4烷基;
环A1、环A2、R1、R2、R3、m和n定义如式I中所定义。
在一些实施方案中,本发明提供了式I、式II-A或式II’-B化合物或其药学上可接受的盐、立体异构体、互变异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药,其中:R1选自-C1-4烷基;且可任选地被0、1或2个独立的选自下组的取代基所取代,该组取代基包括:卤素、-CN、-OH、-CO2R5a、-OR6、-S(O)2-R6、-C(O)-N(R5a)(R5b)、-N(R5a)C(O)R6、-S(O)2-N(R5a)(R5b)、-N(R5a)S(O)2R6、6-10元芳基和5-10元杂芳基;更优选R1选自-C1-4烷基、-C1-4卤代烷基、-C1-4亚烷基-CN、-C1-4亚烷基-OH、-C1-4亚烷基-CO2R5a、-C1-4亚烷基-O-R6、-C1-4亚烷基-S(O)2-R6、-C1-4亚烷基-C(O)-N(R5a)(R5b)、-C1-4亚烷基-N(R5a)C(O)R6、-C1-4亚烷基-S(O)2-N(R5a)(R5b)和-C1-4亚烷基-N(R5a)S(O)2R6;
R5a和R5b各自独立地选自氢和C1-4烷基;
或者R5a、R5b连同其相连的氮原子共同形成4-6元杂环基;
R6选自C1-4烷基和C3-6环烷基;
优选地,R1选自-C1-4烷基、-C1-4卤代烷基、-C1-4亚烷基-CN、-C1-4亚烷基-OH、-C1-4亚烷基-C(O)OH、-C1-4亚烷基-C(O)O-C1-4烷基、-C1-4亚烷基-O-C1-4烷基、-C1-4亚烷基-O-C3-6环烷基、-C1-4亚烷基-S(O)2-C1-4烷基、-C1-4亚烷基-C(O)-NH-C1-4烷基、-C1-4亚烷基-C(O)-N(C1-4烷基)(C1-4烷基)、-C1-4亚烷基-NH-C(O)-C1-4烷基、-C1-4亚烷基-S(O)2-N(C1-4烷基)(C1-4烷基)、-C1-4亚烷基-S(O)2-NH-(C1-4烷基)、-C1-4亚烷基-S(O)2-NH2和-C1-4亚烷基-NH-S(O)2-C1-4烷基;
更优选地,R1选自-CH3、-CH2CH3、-CH(CH3)2、-CH2CH2CH2F、-CH2CH2CH2-CN、-CH2CH2C(CH3)2-CN、-CH2C(CH3)2-OH、-CH2CH2C(CH3)2-OH、-CH2CH2C(O)OH、-CH2CH2C(O)O-CH3、-CH2CH-O-CH3、-CH2CH2-S(O)2-CH3、-CH2CH2-C(O)-NH-CH3、-CH2CH2CH2-C(O)-N(CH3)2、-CH2CH2-C(O)-N(CH3)2、-CH2-C(O)-N(CH3)2、-CH2CH2-NH-C(O)-CH3、-CH2CH2-S(O)2-N(CH3)2、-CH2CH2-S(O)2-NHCH3、-CH2CH2-S(O)2-NH2和-CH2CH2-NH-S(O)2-CH3。
在一些实施方案中,本发明提供式I、式II-A或式II’-B化合物或其药学上可接受的盐、立体异构体、互变异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药,其中:环A1选自苯基和5-10元杂芳基;R2选自卤素、氰基、羟基、C1-4烷基、C3-6环烷基、C1-4卤代烷基、C1-4烷氧基、C1-4卤代烷氧基和-O-C3-6环烷基;
优选地,环A1选自苯基、吡啶基、异噁唑基、吡唑基和咪唑并[1,2-a]吡啶基;R2选自卤素、氰基、C3-6环烷基、C1-4卤代烷基、和C1-4卤代烷氧基;
更优选地,环A1选自苯基和吡啶基;R2选自卤素、氰基、C3-6环烷基、C1-4卤代烷基、和C1-4卤代烷氧基;
特别优选地,R2选自氟、氰基、甲基、甲氧基和二氟甲氧基。
在一些实施方案中,本发明提供式I、式II-A或式II’-B化合物或其药学上可接受的盐、立体异构体、互变异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药,其中:环A2选自苯基和5-6元杂芳基;R3选自卤素、氰基、C1-4烷基、C1-4卤代烷基、C3-6环烷基、C1-4烷氧基、C1-4卤代烷氧基和-S(O)2-C1-4烷基;
优选地,环A2选自苯基、吡啶基、异噁唑基和吡唑基;R3选自卤素、氰基、C1-4烷基、C1-4卤代烷基和C1-4卤代烷氧基。
特别优选地,R3选自三氟甲基、甲基、氰基、氟和甲磺酰基。
在一些实施方案中,本发明提供式II-A或II’-B化合物或其药学上可接受的盐、立体异构体、互变异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药,其中:
环A1选自苯基、吡啶基、异噁唑基、吡唑基和咪唑并[1,2-a]吡啶基;
环A2选自苯基、吡啶基、异噁唑基和吡唑基;
Ra和Rb都是氢;
R1选自-CH3、-CH2CH3、-CH(CH3)2、-CH2CH2CH2F、-CH2CH2CH2-CN、-CH2CH2C(CH3)2-CN、-CH2C(CH3)2-OH、-CH2CH2C(CH3)2-OH、-CH2CH2C(O)OH、-CH2CH2C(O)O-CH3、-CH2CH-O-CH3、-CH2CH2-S(O)2-CH3、-CH2CH2-C(O)-NH-CH3、-CH2CH2CH2-C(O)-N(CH3)2、-CH2CH2-C(O)-N(CH3)2、-CH2CH2-NH-C(O)-CH3、-CH2CH2-S(O)2-N(CH3)2、-CH2CH2-S(O)2-NHCH3、-CH2CH2-S(O)2-NH2和-CH2CH2-NH-S(O)2-CH3;
每个R2各自独立地选自卤素、氰基、C1-4烷基、C1-4卤代烷基、C1-4烷氧基、C1-4卤代烷氧基;
每个R3各自独立地选自卤素、氰基、C1-4烷基、C1-4卤代烷基和-S(O)2-C1-4烷基;
m为0、1、2或3;
n为0、1、2或3。
在一些实施方案中,本发明提供选自以下的化合物:
/>
或其药学上可接受的盐、立体异构体、互变异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药。
本发明所述化合物中的原子可以被其同位素替代。例如12C可被其同位素13C或14C替代;1H可被2H(D,氘)或3H(T,氚)替代等。本发明包括式I、式II-A、式II-B或式II’-B所述化合物以及I、式II-A、式II-B或式II’-B化合物中的任意原子经其同位素替换后得到的同位素标记的化合物。
在本发明中,上面所定义的式I、式II-A、式II-B或式II’-B化合物或其药学上可接受的盐、立体异构体、互变异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药也称为本发明化合物。
在另一方面,本发明还涉及制备式II-A的化合物的方法,所述方法包括以下步骤:
其中,X表示离去基团,所述的离去基团包括但不限于卤素原子、甲磺酰基氧基、对甲基苯磺酰基氧基等。R1、R2、R3、Ra、Rb、环A1、环A2、m、n如上面对式II-A化合物所定义;
(1)使化合物IN-A-1与化合物IN-A-2反应以得到化合物IN-A-3;
所述反应优选在适合的有机溶剂中进行。所述有机溶剂可选自四氢呋喃、N,N-二甲基甲酰胺、N,N-二甲基乙酰胺、1,4-二氧六环及其任意组合,优选四氢呋喃。所述反应优选在适合的缩合剂存在下进行。所述缩合剂可选自二环己基碳二亚胺、1-(3-二甲基氨基丙基)-3-乙基碳二亚胺、HATU、苯并三氮唑-N,N,N',N'-四甲基脲六氟磷酸酯、1H-苯并三唑-1-基氧三吡咯烷基六氟磷酸盐,优选HATU。所述反应优选在适合的有机碱存在下进行。所述有机碱可选自三乙胺、吡啶、4-二甲基氨基吡啶、二异丙基乙胺,优选二异丙基乙胺。所述反应优选在适合的温度下进行,所述温度优选为20-50℃。所述反应优选进行合适的时间,例如2-8小时。
(2)使化合物IN-A-3与化合物IN-A-4进行关环反应以得到化合物IN-A-5;
所述反应优选在适合的有机溶剂中进行。所述有机溶剂可选自醇类质子溶剂、N,N-二甲基甲酰胺、N,N-二甲基乙酰胺、1,4-二氧六环、乙腈及其任意组合。所述反应优选在适合的碱存在下进行。所述碱可选自氢氧化钠、氢氧化锂、氢氧化钾、甲醇钠、叔丁醇钠,优选氢氧化钠。所述反应优选在适合的温度下进行,所述温度优选为25-80℃。所述反应优选进行合适的时间,例如2-8小时。
特别地,当化合物IN-A-5中的Ra与Rb均为甲基时,也可以使化合物IN-A-3与2-甲氧基丙烯进行关环反应以得到化合物IN-A-5。所述反应优选在适合的有机溶剂中进行。所述有机溶剂可选自-丙酮、乙腈、丙腈、四氢呋喃、1,4-二氧六环及其任意组合,优选乙腈。所述反应优选在适合的酸存在下进行。所述酸可选自对甲苯磺酸、苯磺酸、樟脑磺酸、盐酸、硫酸,优选对甲苯磺酸。所述反应优选在适合的温度下进行,所述温度优选为25-80℃。所述反应优选进行合适的时间,例如2-8小时。
(3)使化合物IN-A-5与化合物IN-A-6反应以得到化合物IN-A-7;
所述反应优选在适合的有机溶剂中进行。所述有机溶剂可选自N,N-二甲基甲酰胺、N-甲基吡咯烷酮、甲苯、乙醇、乙二醇二甲醚、水、1,4-二氧六环及其任意组合,优选甲苯、乙醇、水的混合溶剂。所述反应优选在适合的缩合剂存在下进行。所述催化剂可选自各种钯催化剂,优选四(三苯基膦)钯。所述反应优选在适合的碱存在下进行。所述碱可选自磷酸钾、醋酸钾、碳酸氢钠、碳酸钠、碳酸钾等,优选碳酸钠。所述反应优选在适合的温度下进行,所述温度优选为60-120℃。所述反应优选进行合适的时间,例如2-8小时。
(4)使化合物IN-A-7与化合物IN-A-8反应以得到式(II-A)的化合物;
所述反应优选在适合的有机溶剂中进行。所述有机溶剂可选自三乙胺、N,N-二异丙基乙基胺、吡啶及其任意组合,优选吡啶。所述反应优选在适合的温度下进行,所述温度优选为40-80℃。所述反应优选进行合适的时间,例如2-8小时。
本发明还涉及制备式II-B的化合物的方法,所述方法包括以下步骤:
其中,X表示离去基团,所述的离去基团包括但不限于卤素原子、甲磺酰基氧基、对甲基苯磺酰基氧基等。R1、R2、R3、Ra、Rb、环A1、环A2、m、n如上面对式II-B化合物所定义;
(1)使化合物IN-B-1与化合物IN-B-2反应以得到化合物IN-B-3;
所述反应优选在适合的有机溶剂中进行。所述有机溶剂可选自甲酸、冰醋酸等酸性溶剂及其任意组合,优选冰醋酸。所述反应优选在适合的温度下进行,所述温度优选为80-150℃。所述反应优选进行合适的时间,例如2-8小时。
(2)使化合物IN-B-3还原反应以得到化合物IN-B-4;
所述反应优选在适合的有机溶剂中进行。所述有机溶剂可选自乙醚、四氢呋喃、乙二醇二甲醚等惰性溶剂及其任意组合,优选四氢呋喃。所述反应优选在适合的还原试剂存在下进行。所述还原试剂可选自四氢铝锂、硼烷、红铝等,优选四氢铝锂。所述反应优选在适合的温度下进行,所述温度优选为20-50℃。所述反应优选进行合适的时间,例如2-8小时。
(3)使化合物IN-B-4与化合物IN-A-8反应以得到化合物IN-B-5;
所述反应优选在适合的有机溶剂中进行。所述有机溶剂可选自三乙胺、N,N-二异丙基乙胺、吡啶及其任意组合,优选吡啶。所述反应优选在适合的温度下进行,所述温度优选为40-80℃。所述反应优选进行合适的时间,例如2-8小时。
(4)使化合物IN-B-5与化合物IN-A-6反应以得到化合物IN-B-6;
所述反应优选在适合的有机溶剂中进行。所述有机溶剂可选自N,N-二甲基甲酰胺、N-甲基吡咯烷酮、甲苯、乙醇、乙二醇二甲醚、水、1,4-二氧六环及其任意组合,优选甲苯、乙醇、水的混合溶剂。所述反应优选在适合的缩合剂存在下进行。所述催化剂可选自各种钯催化剂,优选四(三苯基膦)钯。所述反应优选在适合的碱存在下进行。所述碱可选自磷酸钾、醋酸钾、碳酸氢钠、碳酸钠、碳酸钾等,优选碳酸钠。所述反应优选在适合的温度下进行,所述温度优选为60-120℃。所述反应优选进行合适的时间,例如2-8小时。
(5)使化合物IN-B-6与化合物IN-B-7反应以得到式(II-B)的化合物。
所述反应优选在适合的有机溶剂中进行。所述有机溶剂可选自N,N-二甲基甲酰胺、N-甲基吡咯烷酮、四氢呋喃等及其任意组合,优选N,N-二甲基甲酰胺。所述反应优选在适合的碱存在下进行。所述碱可选自氢化钠,叔丁醇钾、叔丁醇钠,甲醇钠等,优选叔丁醇钾。所述反应优选在适合的温度下进行,所述温度优选为10-40℃。所述反应优选进行合适的时间,例如2-8小时。
上述各反应步骤的具体条件为本领域公知,对此本发明不作具体限定。根据本发明的教导结合本领域公知常识,本领域技术人员可以对通式中的各取代基进行选择替换以制备得到不同的化合物,这些选择和替换均在本发明的保护范围之内。
本发明还涉及药物组合物,其包含本发明化合物,以及任选地,一种或多种药学上可接受的载体或赋形剂。
本发明还涉及药物制剂,其包含本发明化合物,或其药物组合物。
本发明还涉及本发明化合物、其药物组合物、或其药物制剂在制备作为维A酸受体相关孤儿核受体γ(RORγ)调节剂的药物中的用途。
本发明还涉及本发明化合物或其药物组合物、或其药物制剂在制备用于预防和/或治疗RORγ介导的疾病或病症的药物中的用途。在一实施方案中,所述药物还包含其他抗肿瘤剂。
本发明还涉及一种预防和/或治疗RORγ介导的疾病或病症的方法,其包括向有需要的受试者施用有效量的本发明化合物、其药物组合物、或其药物制剂。
本发明还涉及本发明化合物、其药物组合物、或其药物制剂,其用于预防和/或治疗RORγ介导的疾病或病症。
本发明还涉及本发明化合物、其药物组合物、或其药物制剂,其用于调节维A酸受体相关孤儿核受体γ(RORγ)。
在一些实施方案中,所述RORγ介导的疾病或病症选自肿瘤或癌症,例如非霍奇金淋巴瘤、弥漫大B细胞淋巴瘤、滤泡性淋巴瘤、滑膜肉瘤、乳腺癌、宫颈癌、结肠癌、肺癌、口腔癌、脑癌、胃癌、肝癌、直肠癌、胰腺癌、皮肤癌、前列腺癌、骨癌、肾癌、卵巢癌、膀胱癌、输卵管肿瘤、腹膜肿瘤、黑色素瘤、实体瘤、神经胶质瘤、神经胶母细胞瘤、乳突状恶性瘤、头颈部肿瘤、白血病、淋巴瘤或骨髓瘤。
本发明中,将活性成分制备成药物组合物的目的是便于或有利于生物体的给药,利于活性成分的吸收进而发挥生物活性。
所述赋形剂是指在药物制剂中除主药以外的附加物。其性质稳定,与主药无配伍禁忌,不产生副作用,不影响疗效,在常温下不易变形、干裂、霉变、虫蛀、对人体无害、无生理作用,不与主药产生化学或物理作用,不影响主药的含量测定等。
本发明的化合物可以通过以下途径给药:胃肠外、局部、静脉内、口服、皮下、动脉内、真皮内、经皮、直肠、颅内、腹膜内、鼻内、肌内途径或作为吸入剂。本发明的化合物可以任选地与在治疗本发明所述的各种疾病中至少有一定效果的其它活性成分联合给药。
本发明的化合物可根据给药途径配成各种适宜的剂型。
本发明所述的药物组合物或适宜的剂型可以含有0.01mg至1000mg的本发明化合物。
当口服用药时,本发明的化合物可制成任意口服可接受的制剂形式,包括但不限于片剂、胶囊、水溶液或水悬浮液。
当皮肤局部施用时,本发明的化合物可制成适当的软膏、洗剂或霜剂制剂形式,其中将活性成分悬浮或溶解于一种或多种载体中。
本发明的化合物还可以无菌注射制剂形式用药,包括无菌注射水或油悬浮液或无菌注射溶液。
在本发明的实施方案中,进行合适的体外或体内测定来确定本发明药物组合物的效果以及给药是否适用于治疗个体所患疾病或医学疾病状态。这些测定的实例在下文非限制性实施例结合具体疾病或医学治疗进行了描述。通常,足以实现预防或治疗效果的本发明组合物的有效量为约0.001mg/千克体重/天至约10,000mg/千克体重/天。剂量和频率根据制剂在受试者中的半衰期而不同。也可以根据是预防性处理还是治疗性处理而不同。在预防性应用中,以相对低频率的间隔长期给予相对低的剂量。在治疗性应用中,有时需要以相对短的间隔给予相对高的剂量,直至疾病的进展被延缓或停止,并优选地直至个体表现出疾病症状的部分或完全改善,在此之后,可以给予患者预防方案。
定义
以下对本发明的术语进行解释,对于特定的术语,如果本发明中的含义与本领域技术人员通常理解的含义不一致,以本发明中的含义为准;如果在本发明中没有定义,则其具有本领域技术人员通常理解的含义。除非有相反陈述,本发明中使用的术语具有下述含义:
本发明所用术语“包括”、“包含”、“具有”、“含有”或“涉及”及其在本文中的其它变体形式为开放式的,且不排除其它未列举的元素或方法步骤。
本发明所用术语“氢”及所述的各基团中的氢,是指氕(H),氘(D)或氚(T)。
本发明所用术语“卤素”是指氟、氯、溴或碘。
本发明所用术语“共价键”是指两个原子共同使用它们的外层电子,在理想情况下达到电子饱和的状态,由此组成比较稳定的化学结构。基于价键理论,式(I)的L中的共价键是指L相邻的两个N原子间共用一对电子而构成的单键。
本发明所用术语“C1-6烷基”是指具有1-6个碳原子的直链或支链烷基,例如C1-4烷基、C1-2烷基、C1烷基、C2烷基、C3烷基、C4烷基、C5烷基或C6烷基。具体的实例包括但不限于甲基、乙基、丙基、异丙基、正丁基、异丁基、仲丁基、叔丁基、正戊基、正己基等。
本发明所用术语“C1-6卤代烷基”是指被一个或多个卤素原子取代的具有1-6个碳原子的直链或支链烷基,例如C1-4卤代烷基、C1-2卤代烷基、C1卤代烷基、C2卤代烷基、C3卤代烷基、C4卤代烷基、C5卤代烷基或C6卤代烷基。具体的实例包括但不限于三氟甲基、二氟甲基、三氟乙基、单氟甲基等。
本发明所用术语“C1-6烷氧基”是指C1-6烷基-O-基团,其中C1-6烷基具有上面所定义的含义。
本发明所用术语“C1-6卤代烷氧基”是指C1-6卤代烷基-O-基团,其中C1-6卤代烷基具有上面所定义的含义。
本发明所用术语“C1-6亚烷基”是指本文中定义的C1-6烷基去除一个氢后形成的直链或支链二价烷基,例如C1-4亚烷基、C1-2亚烷基、C1亚烷基、C2亚烷基、C3亚烷基、C4亚烷基、C5亚烷基或C6亚烷基。具体的实例包括但不限于-CH2-、-CH(CH3)-、-CH2CH2-、-CH2CH(CH3)-、-CH(CH3)CH2-、-CH2CH2CH2-、-CH2CH2CH2CH2-、-CH2C(CH3)2-、-CH2CH2CH2CH2CH2-、-CH2CH2CH2CH(CH3)-、-CH2CH2C(CH3)2-、-CH2CH2CH2CH2CH2CH2-等。
本发明所用术语“C3-6环烷基”是指含有3-6个碳原子的饱和或部分饱和的单环烷基,例如3元、4元、5元或6元环烷基。具体的实例包括但不限于环丙基、环丁基、环戊基、环己基等。
本发明所用术语“6-10元芳基”是指在环部分具有6-10个碳原子的单环或二环芳香烃基团,例如苯基。
本发明所用术语“5-10元杂芳基”是指含有5-10个环成员的单环或多环芳香族基团,且所述环成员中至少1个至多4个(例如1、2、3或4个)为选自N、O和S的杂原子。本发明所用术语“5-6元杂芳基”是指含有5-6个环成员的单环芳香族基团,且所述环成员中至少1个至多4个(例如1、2、3或4个)为选自N、O和S的杂原子,例如5元杂芳基、6元杂芳基等。杂芳基的具体的实例包括但不限于呋喃基、噻吩基、吡咯基、噻唑基、异噻唑基、噻二唑基、噁唑基、异噁唑基、咪唑基、吡唑基、1,2,3-三唑基、1,2,4-三唑基、1,2,3-噁二唑基、1,2,4-噁二唑基、1,2,5-噁二唑基、1,3,4-噁二唑基、吡啶基、2-吡啶酮基、4-吡啶酮基、嘧啶基、2H-1,2-噁嗪基、4H-1,2-噁嗪基、6H-1,2-噁嗪基、4H-1,3-噁嗪基、6H-1,3-噁嗪基、4H-1,4-噁嗪基、哒嗪基、吡嗪基、1,2,3-三嗪基、1,3,5-三嗪基、1,2,4,5-四嗪基、咪唑并[1,2-a]吡啶基等。特别地,杂芳基的具体的实例包括但不限于吡啶基、异噁唑基、吡唑基和咪唑并[1,2-a]吡啶基。
本发明所用术语“4-10元杂环基”是指含有4-10个环成员的完全饱和的或部分饱和的环状基团,例如3-7个环成员、或4-6个环成员,所述环成员中至少1个例如1、2或3个选自N、C(=O)、O、S、S(=O)、和S(=O)2,其余的环成员为C原子。例如,杂环基为包含1或2个选自N、O和S的4-6元杂环基,如
如果取代基被描述为“任选地被…取代”,则取代基可(1)未被取代或(2)被取代。如果取代基的碳被描述为任选地被取代基列表中的一个或多个取代,则碳上的一个或多个氢(至存在的任何氢的程度)可单独和/或一起被独立地选择的任选的取代基替代。如果取代基的氮被描述为任选地被取代基列表中的一个或多个取代,则氮上的一个或多个氢(至存在的任何氢的程度)可各自被独立地选择的任选的取代基替代。所述取代基包括但不限于卤素、氰基、羟基、C1-6烷基、C3-6环烷基、C1-6卤代烷基、C1-6烷氧基、C1-6卤代烷氧基、-O-C3-6环烷基、芳基例如苯基、5-6元杂芳基和5-6杂环基等。
本发明所用术语“一个或多个”是指在合理条件下的1个或超过1个,例如2个、3个、4个、5个或10个。
除非指明,否则如本文中所使用,取代基的连接点可来自取代基的任意适宜位置。
本发明所用术语“立体异构体”表示由于至少一个不对称中心形成的异构体。在具有一个或多个(例如1个、2个、3个或4个)不对称中心的化合物中,其可产生外消旋混合物、单一对映异构体、非对映异构体混合物和单独的非对映异构体。特定个别分子也可以几何异构体(顺式/反式)存在。本发明的化合物可以两种或更多种处于快速平衡的结构不同的形式的混合物(通常称作互变异构体)存在。互变异构体的代表性实例包括酮-烯醇互变异构体、苯酚-酮互变异构体、亚硝基-肟互变异构体、亚胺-烯胺互变异构体等。要理解,本申请的范围涵盖所有这样的以任意比例(例如60%、65%、70%、75%、80%、85%、90%、95%、96%、97%、98%、99%)的异构体或其混合物。
除非另外指明,否则本发明的化合物意欲可以立体异构体(其包括顺式及反式异构体、光学异构体(例如R及S对映异构体)、非对映异构体、几何异构体、旋转异构体、构象异构体、阻转异构体及其混合物)的形式存在。本发明的化合物可表现一种以上类型的异构现象,且由其混合物(例如外消旋混合物及非对映异构体对)组成。
本发明涵盖本发明的化合物的所有可能的结晶形式或多晶型物,其可为单一多晶型物或多于一种多晶型物的任意比例的混合物。
本发明的化合物可以溶剂合物(如水合物)的形式存在,其中本发明的化合物包含作为所述化合物晶格的结构要素的极性溶剂,特别是例如水、甲醇或乙醇。极性溶剂特别是水的量可以化学计量比或非化学计量比存在。
本发明的化合物或其药学上可接受的盐还可以形成溶剂合物,例如醇合物等。
本发明的化合物还可以是前药或以或可在体内代谢变化后释放出所述活性成分的形式。如本所用,“前药”是指被化学修饰的活性或非活性的化合物,给药至受试者后,其经过体内的生理作用(例如水解、新成代谢等)变为本发明化合物。选择和制备适当的前药衍生物是本领域技术人员公知技术。
本发明的化合物还可以是化学保护的形式,所述保护基可保护在化合物的活性基团(如氨基)上,所述保护基可在体内代谢释放出活性成分。选择和制备适当的化学保护的形式是本领域技术人员公知技术。
本发明所用术语“药学上可接受的”是指物质或组合物必须与构成制剂的其他组分和/或用其治疗的受试者在化学和/或毒理学上相容。
本发明所用术语“药学上可接受的盐”包括与药学上可以接受的无机酸或者有机酸、或者无机碱或有机碱形成的常规盐。示例性的酸加成盐包括,例如,无机酸盐如盐酸盐、氢溴酸盐、氢碘酸盐、硫酸盐、硝酸盐、磷酸盐(如,例如,磷酸盐、磷酸氢盐或磷酸二氢盐)、碳酸盐、碳酸氢盐或高氯酸盐;有机酸盐如乙酸盐、丙酸盐、丁酸盐、戊酸盐、己酸盐、庚酸盐、辛酸盐、环戊烷丙酸盐、十一酸盐、乳酸盐、苹果酸盐、草酸盐、富马酸盐、酒石酸盐、马来酸盐、柠檬酸盐、烟酸盐、苯甲酸盐、水杨酸盐或抗坏血酸盐;磺酸盐如甲磺酸盐、乙磺酸盐、2-羟基乙磺酸盐、苯磺酸盐、对甲苯磺酸盐、2-萘磺酸盐、3-苯基磺酸盐或樟脑磺酸盐;酸性氨基酸盐如天冬氨酸盐或谷氨酸盐。本发明所用术语“药物组合物”包括包含治疗有效量的本发明式I的化合物的产品,以及直接地或间接地由本发明式I化合物的组合产生的任何产品。
本发明所用术语“有效量”是指足以实现所需治疗效果的量,例如,实现减轻与待治疗疾病相关的症状的量。
本发明所用的术语“治疗”目的是减轻或消除所针对的疾病状态或病症。如果受试者按照本文所述方法接受了治疗量的化合物、其光学异构体或其药学上可接受的盐或其药物组合物,该受试者一种或多种指征和症状表现出可观察到的和/或可检测出的降低或改善,则受试者被成功地“治疗”了。还应当理解,所述的疾病状态或病症的治疗的不仅包括完全地治疗,还包括未达到完全地治疗,但实现了一些生物学或医学相关的结果。
如本文所用,术语“受试者”指动物,例如哺乳动物。受试者还指例如灵长类(例如人类)、牛、绵羊、山羊、马、狗、猫、兔、大鼠、小鼠、鱼、鸟等。
具体实施方式
为了使本发明的目的和技术方案更加清楚,以下结合具体实施例进一步阐述本发明。应理解,这些实施例仅用于说明本发明而不用于限制本发明的范围。并且,下列实施例中未提及的具体实验方法,均按照常规实验方法进行。
在本申请中,当化学名称和结构式不一致时,应当以结构式所示为准,除非根据上下文可以推断化学名称而非结构式是正确的。
本文中的缩写具有以下含义:
以下实施例中记载的化合物的结构通过1H-NMR或MS来确证。1H-NMR的测定仪器使用Bruker 400MHz核磁共振仪,测定溶剂为CD3OD、CDCl3或DMSO-d6,内标物质为TMS,全部δ值用ppm值表示。质谱(MS)的测定仪器使用Agilent(ESI)质谱仪,型号为Agilent 6120B。
薄层色谱硅胶板(TLC)使用Merck产的铝板(20×20cm),薄层层析分离纯化采用的是GF 254(0.4~0.5mm)。
反应的监测采用薄层色谱法(TLC)或LC-MS,使用的展开剂体系有:二氯甲烷和甲醇体系,正己烷和乙酸乙酯体系,石油醚和乙酸乙酯体系,溶剂的体积比根据化合物的极性不同而进行调节或者加入三乙胺等进行调节。
柱层析一般使用200~300目硅胶为载体。洗脱剂的体系包括:二氯甲烷和甲醇体系,石油醚和乙酸乙酯体系,溶剂的体积比根据化合物的极性不同而进行调节,也可以加入少量的三乙胺进行调节。
制备高效液相色谱仪,仪器型号:Agilent 1260,色谱柱:Waters XBridge PrepC18 OBD(19mm×150mm×5.0μm);色谱柱温:25℃;流速:20.0mL/min;检测波长:214nm;洗脱梯度:(0min:10%A,90%B;16.0min:90%A,10%B);流动相A:100%乙腈;流动相B:0.05%碳酸氢铵水溶液。
除非特别指出,实施例的反应温度为室温(20℃~30℃)。
本发明所使用的试剂购自Acros Organics、Aldrich Chemical Company、上海特伯化学科技有限公司等。
实施例
实施例1:3-(7-(3-(二氟甲氧基)-5-氟苯基)-4-氧代-1-((3-(三氟甲基)苯基)磺酰基)-1,2-二氢喹唑啉-3(4H)-基)丙酸甲酯(化合物1)的制备
第一步:3-(2-氨基-4-溴苯基甲酰基氨基)丙酸甲酯的制备
将2-氨基-4-溴苯甲酸(1.0g,4.63mmol)、3-氨基丙酸甲酯盐酸盐(0.72g,6.94mmol)和HATU(2.64g,6.94mmol)加入四氢呋喃(10mL)中,室温搅拌下缓慢加入DIPEA(1.79g,13.9mmol)后维持室温反应4小时。将反应液倾入水(100mL)中,乙酸乙酯萃取三次,合并有机相,无水硫酸钠干燥,过滤并将滤液减压浓缩,得到本步的标题化合物(1.1g,收率:78.9%)。
MS m/z(ESI):301.0[M+H]+。
第二步:3-(7-溴-4-氧代-1,2-二氢喹唑啉-3(4H)-基)丙酸的制备
将3-(2-氨基-4-溴苯基甲酰基氨基)丙酸甲酯(1.0g,3.32mmol)、氢氧化钠(146.3mg,3.66mmol)混溶于乙醇(50mL)中,加入37%甲醛水溶液(3.32mmol,2.91mL)后,加热至60℃反应3小时。将反应液减压浓缩后加入水(100mL),2N稀盐酸调节pH=7左右,乙酸乙酯萃取三次,合并有机相,无水硫酸钠干燥,过滤并将滤液减压浓缩,浓缩物经制备高效液相色谱仪纯化得到本步的标题化合物(0.9g,收率:90.6%)。
MS m/z(ESI):299.0[M+H]+。
第三步:3-(7-(3-(二氟甲氧基)-5-氟苯基)-4-氧代-1,2-二氢喹唑啉-3(4H)-基)丙酸的制备
将3-(7-溴-4-氧代-1,2-二氢喹唑啉-3(4H)-基)丙酸(200mg,668.6μmol)和2-(3-(二氟甲氧基)-5-氟苯基)-4,4,5,5-四甲基-1,3,2-二氧杂硼杂环戊烷(289mg,1.0mmol)溶于甲苯(6mL)、水(2mL)和乙醇(2mL)的混合溶剂中,加入四(三苯基膦)钯(38.6mg,33.4μmol)和碳酸钠(141.8mg,1.34mmol)后,氮气置换后加热至90℃反应4小时。将反应液倾入水(100mL)中,乙酸乙酯萃取三次,合并有机相,无水硫酸钠干燥,过滤并将滤液减压浓缩,得到本步的标题化合物(0.21g,收率:83.6%)。
MS m/z(ESI):381.1[M+H]+。
第四步:3-(7-(3-(二氟甲氧基)-5-氟苯基)-4-氧代-1,2-二氢喹唑啉-3(4H)-基)丙酸甲酯的制备
将3-(7-(3-(二氟甲氧基)-5-氟苯基)-4-氧代-1,2-二氢喹唑啉-3(4H)-基)丙酸(50mg,0.13mmol)溶于甲醇(2mL)中,冰浴下加入二氯亚砜(16mg,0.13mmol),加热至70℃反应2小时。将反应液浓缩后倾入水(50mL)中,乙酸乙酯萃取三次,合并有机相,无水硫酸钠干燥,过滤并将滤液减压浓缩,得到本步的标题化合物(50mg,收率:96.4%)。
MS m/z(ESI):395.1[M+H]+。
第五步:3-(7-(3-(二氟甲氧基)-5-氟苯基)-4-氧代-1-((3-(三氟甲基)苯基)磺酰基)-1,2-二氢喹唑啉-3(4H)-基)丙酸甲酯(化合物1)的制备
将3-(7-(3-(二氟甲氧基)-5-氟苯基)-4-氧代-1,2-二氢喹唑啉-3(4H)-基)丙酸甲酯(60.0mg,152.2μmol)完全溶于吡啶(5mL)中,加热至60℃,加入分子筛(120.0mg),搅拌约30分钟后,加入3-三氟甲基苯磺酰氯(38.0mg,152.2μmol),维持60℃反应4小时。冷却至室温后,减压浓缩,浓缩物经制备高效液相色谱仪纯化得到标题化合物(23.0mg,收率:25.1%)。
MS m/z(ESI):603.1[M+H]+
1H-NMR(400MHz,DMSO-d6)δ:8.09-8.07(m,1H),7.99-7.98(m,1H),7.90-7.87(m,1H),7.84-7.82(m,1H),7.78-7.70(m,3H),7.48(t,J=72.8Hz,1H),7.60-7.57(m,1H),7.48-7.46(m,1H),7.29-7.27(m,1H),5.33(s,2H),3.59(s,3H),3.40-3.38(m,2H),2.49-2.46(m,2H)。
实施例2:3-(7-(3-(二氟甲氧基)-5-氟苯基)-4-氧代-1-((3-(三氟甲基)苯基)磺酰基)-1,2-二氢喹唑啉-3(4H)-基)丙酸(化合物2)的制备
将3-(7-(3-(二氟甲氧基)-5-氟苯基)-4-氧代-1-((3-(三氟甲基)苯基)磺酰基)-1,2-二氢喹唑啉-3(4H)-基)丙酸甲酯(170.0mg,282.2μmol)溶于甲醇(2mL)、四氢呋喃(2mL)和水(2mL)的混合溶剂中,加入氢氧化钠(12.0mg,282.2μmol),继续于25℃搅拌反应4小时。将反应液倾倒入水(100mL)中,2N稀盐酸调节pH=2,乙酸乙酯萃取三次,合并有机相,无水硫酸钠干燥,过滤并将滤液减压浓缩,浓缩物经制备高效液相色谱仪纯化得到标题化合物(50.0mg,收率:30.1%)。
MS m/z(ESI):589.1[M+H]+
1H-NMR(400MHz,CDCl3)δ:7.96-7.93(m,2H),7.81-7.76(m,2H),7.61-7.50(m,3H),7.28-7.24(m,2H),6.98-6.96(m,1H),6.61(t,J=72.8Hz,1H),5.29-5.26(m,2H),5.43-5.40(m,2H),2.68-2.65(m,2H)。
实施例3:3-(8-(3-(二氟甲氧基)-5-氟苯基)-5-氧代-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢-1H-苯并[e][1,4]二氮杂-4(5H)-基)丙酸甲酯(化合物3)的制备
第一步:8-溴-3,4-二氢-1H-苯并[e][1,4]二氮杂-2,5-二酮的制备
4-溴靛红酸酐(1.0g,4.1mmol)和甘氨酸(465.2mg,6.2mmol)完全溶解于冰乙酸(10mL),加热至120℃反应4小时。冷却至室温后,将反应液倾入水(100mL)中,抽滤并用水(100mL)洗涤固体,得到本步的标题化合物(1.0g,收率:91.09%)。
MS m/z(ESI):255.0[M+H]+。
第二步:8-溴-3,4-二氢-1H-苯并[e][1,4]二氮杂-5(2H)-酮的制备
将四氢铝锂(149.0mg,3.9mmol)分散至无水四氢呋喃(10mL)中,加入8-溴-3,4-二氢-1H-苯并[e][1,4]二氮杂-2,5-二酮(500.0mg,2.0mmol)后,于25℃反应4小时。向反应液中缓慢加入十水硫酸钠淬灭反应,抽滤并用乙酸乙酯(100mL)洗涤固体,浓缩滤液得到本步的标题化合物(150.0mg,收率:31.7%)。
MS m/z(ESI):241.0[M+H]+。
第三步:8-溴-1-((3-(三氟甲基)苯基)磺酰基)-3,4-二氢-1H-苯并[e][1,4]二氮杂-5(2H)-酮的制备
将8-溴-3,4-二氢-1H-苯并[e][1,4]二氮杂-5(2H)-酮(150.0mg,622.2μmol)完全溶解于吡啶(5mL)中,加热至60℃,加入分子筛(250.0mg)搅拌约30分钟后,加入3-三氟甲基苯磺酰氯(228.3mg,933.3μmol)和4-二甲氨基吡啶(5.0mg,40.1μmol),维持60℃反应4小时。冷却至室温后,减压浓缩,浓缩物经制备高效液相色谱仪纯化得到本步的标题化合物(72.0mg,收率:25.7%)。
MS m/z(ESI):449.0[M+H]+。
第四步:8-(3-(二氟甲氧基)-5-氟苯基)-1-((3-(三氟甲基)苯基)磺酰基)-3,4-二氢-1H-苯并[e][1,4]二氮杂-5(2H)-酮的制备
将8-溴-1-((3-(三氟甲基)苯基)磺酰基)-3,4-二氢-1H-苯并[e][1,4]二氮杂-5(2H)-酮(70.0mg,155.8μmol)、2-(3-(二氟甲氧基)-5-氟苯基)-4,4,5,5-四甲基-1,3,2-二氧杂硼杂环戊烷(90.0mg,0.3mmol)、[1,1'-双(二苯基膦基)二茂铁]二氯化钯(6.0mg,7.8μmol)和碳酸钾(64.5mg,0.5mmol)溶于1,4-二氧六环(4mL)和水(2mL)混合溶剂中,氮气置换后加热至80℃反应4小时。将反应液倾入水(100mL)中,乙酸乙酯萃取三次,合并有机相,无水硫酸钠干燥,过滤并将滤液减压浓缩,得到本步的标题化合物(71.0mg,收率:86.0%)。
MS m/z(ESI):531.1[M+H]+。
第五步:3-(8-(3-(二氟甲氧基)-5-氟苯基)-5-氧代-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢-1H-苯并[e][1,4]二氮杂-4(5H)-基)丙酸甲酯(化合物3)的制备
将8-(3-(二氟甲氧基)-5-氟苯基)-1-((3-(三氟甲基)苯基)磺酰基)-3,4-二氢-1H-苯并[e][1,4]二氮杂-5(2H)-酮(70.0mg,132.0μmol)溶于DMF(5mL)中,加入叔丁醇钾(14.8mg,132.0μmol),于25℃搅拌10分钟后,加入3-溴丙酸甲酯(22.1mg,132.0μmol),继续于25℃搅拌反应4小时。将反应液倾入水(100mL)中,乙酸乙酯萃取三次,合并有机相,无水硫酸钠干燥,过滤并将滤液减压浓缩,浓缩物经制备高效液相色谱仪纯化得到标题化合物(42.0mg,收率:51.6%)。
MS m/z(ESI):617.1[M+H]+
1H-NMR(400MHz,DMSO-d6)δ:8.09-8.07(m,1H),7.94-7.91(m,1H),7.80-7.76(m,4H),7.60-7.54(m,2H),7.47(t,J=72.8Hz,1H),7.45-7.42(m,1H),7.26-7.23(m,1H),4.06-4.03(m,2H),3.58(s,3H),3.33-3.30(m,2H),3.12(t,J=7.2Hz,2H),2.33(t,J=7.2Hz,2H)。
实施例4:3-(8-(3-(二氟甲氧基)-5-氟苯基)-5-氧代-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢-1H-苯并[e][1,4]二氮杂-4(5H)-基)丙酸(化合物4)的制备
将3-(8-(3-(二氟甲氧基)-5-氟苯基)-5-氧代-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢-1H-苯并[e][1,4]二氮杂-4(5H)-基)丙酸甲酯(100.0mg,162.2μmol)溶于甲醇(2mL)、四氢呋喃(2mL)和水(2mL)的混合溶剂中,加入氢氧化钠(13.0mg,324.4μmol),继续于25℃搅拌反应4小时。将反应液倾倒入水(100mL)中,2N稀盐酸调节pH=2,乙酸乙酯萃取三次,合并有机相,无水硫酸钠干燥,过滤并将滤液减压浓缩,浓缩物经制备高效液相色谱仪纯化得到标题化合物(60.0mg,收率:58.3%)。/>
MS m/z(ESI):603.1[M+H]+
1H-NMR(400MHz,DMSO-d6)δ:12.32(br,1H),8.09-8.07(m,1H),7.94-7.91(m,1H),7.84-7.76(m,4H),7.60-7.54(m,2H),7.47(t,J=72.8Hz,1H),7.44-7.42(m,1H),7.26-7.23(m,1H),4.06-4.03(m,2H),3.33-3.31(m,2H),3.09(t,J=7.2Hz,2H),2.24(t,J=7.2Hz,2H)。
实施例5:7-(3-(二氟甲氧基)-5-氟苯基)-3-(2-甲氧基乙基)-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物5)的制备
第一步:2-氨基-4-溴-N-(2-甲氧乙基)苯甲酰胺的制备
将2-氨基-4-溴苯甲酸(500mg,2.3mmol)、2-甲氧基乙胺(261mg,3.5mmol)和HATU(1.8g,4.6mmol)加入四氢呋喃(10mL)中,室温搅拌下缓慢加入DIPEA(0.9g,6.9mmol)后维持室温反应4小时。将反应液倾入水(100mL)中,乙酸乙酯萃取三次,合并有机相,无水硫酸钠干燥,过滤并将滤液减压浓缩,得到本步的标题化合物(600mg,收率:94.9%)。
MS m/z(ESI):273.0[M+H]+。
第二步:7-溴-3-(2-甲氧基乙基)-2,3-二氢喹唑啉-4(1H)-酮的制备
将2-氨基-4-溴-N-(2-甲氧乙基)苯甲酰胺(500mg,1.8mmol)和氢氧化钠(81mg,2.0mmol)混溶于乙醇(8mL)中,加入37%甲醛水溶液(2.0mmol,0.15mL)后,加热至60℃反应3小时。将反应液减压浓缩后加入水(100mL),2N盐酸调节pH=7左右,乙酸乙酯萃取三次,合并有机相,无水硫酸钠干燥,过滤并将滤液减压浓缩,浓缩物经制备高效液相色谱仪纯化得到本步的标题化合物(500mg,收率:95.8%)。
MS m/z(ESI):285.0[M+H]+。
第三步:7-(3-(二氟甲氧基)-5-氟苯基)-3-(2-甲氧基乙基)-2,3-二氢喹唑啉-4(1H)-酮的制备
将7-溴-3-(2-甲氧基乙基)-2,3-二氢喹唑啉-4(1H)-酮(500mg,1.8mmol)和2-(3-(二氟甲氧基)-5-氟苯基)-4,4,5,5-四甲基-1,3,2-二氧杂硼杂环戊烷(1.01g,3.51mmol)溶于1,4-二氧六环(16mL)和水(4mL)的混合溶剂中,加入[1,1'-双(二苯基膦)二茂铁]二氯化钯二氯甲烷络合物(215mg,0.26mmol)和碳酸钾(730mg,5.3mmol),氮气置换后,加热至80℃反应4小时。将反应液倾入水(100mL)中,乙酸乙酯萃取三次,合并有机相,无水硫酸钠干燥,过滤并将滤液减压浓缩,得到本步的标题化合物(600mg,收率:93.4%)。
MS m/z(ESI):367.1[M+H]+。
第四步:7-(3-(二氟甲氧基)-5-氟苯基)-3-(2-甲氧基乙基)-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物5)的制备
将7-(3-(二氟甲氧基)-5-氟苯基)-3-(2-甲氧基乙基)-2,3-二氢喹唑啉-4(1H)-酮(300mg,0.82mmol)完全溶于吡啶(5mL)中,加入3-三氟甲基苯磺酰氯(300mg,1.23mmol),加热至60℃反应4小时。冷却至室温后,减压浓缩,浓缩物经制备高效液相色谱仪纯化得到标题化合物(98mg,收率:20.8%)。
MS m/z(ESI):575.1[M+H]+
1H-NMR(400MHz,DMSO-d6)δ:8.07-8.05(m,1H),7.98-7.96(m,1H),7.88-7.81(m,3H),7.81-7.72(m,2H),7.59-7.56(m,1H),7.47(t,J=72.8Hz,1H),7.46-7.44(m,1H),7.29-7.26(m,1H),5.31(s,2H),3.39-3.36(m,4H),3.25(s,3H)。
实施例6:(S)-7-(3-(二氟甲氧基)-5-氟苯基)-3-(2-甲氧基丙基)-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物6)的制备
采用实施例5合成路线,将第一步原料2-甲氧基乙胺替换为(S)-2-甲氧基丙-1-胺盐酸盐,得到标题化合物(74mg,收率:29.8%)。
MS m/z(ESI):589.1[M+H]+
1H-NMR(400MHz,DMSO-d6)δ:8.07-8.05(m,1H),7.98-7.96(m,1H),7.89-7.86(m,1H),7.84-7.82(m,1H),7.79-7.76(m,1H),7.74-7.70(m,2H),7.58-7.56(m,1H),7.47(t,J=72.8Hz,1H),7.46-7.44(m,1H),7.29-7.26(m,1H),5.32(s,2H),3.43-3.40(m,2H),3.26-3.23(m,4H),0.98-0.96(m,3H)。
实施例7:(R)-7-(3-(二氟甲氧基)-5-氟苯基)-3-(2-甲氧基丙基)-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物7)的制备
采用实施例5合成路线,将第一步原料2-甲氧基乙胺替换为(R)-2-甲氧基丙-1-胺盐酸盐,得到标题化合物(77mg,收率:26.3%)。
MS m/z(ESI):589.1[M+H]+
1H-NMR(400MHz,DMSO-d6)δ:8.07-8.05(m,1H),7.98-7.95(m,1H),7.89-7.86(m,1H),7.84-7.82(m,1H),7.80-7.76(m,1H),7.74-7.70(m,2H),7.58-7.55(m,1H),7.47(t,J=72.8Hz,1H),7.46-7.44(m,1H),7.29-7.27(m,1H),5.32(s,2H),3.43-3.40(m,2H),3.26-3.23(m,4H),0.98-0.96(m,3H)。
实施例8:7-(3-(二氟甲氧基)-5-氟苯基)-3-(3-甲氧基丙基)-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物8)的制备
采用实施例5合成路线,将第一步原料2-甲氧基乙胺替换为3-甲氧基丙胺,得到标题化合物(56mg,收率:26.9%)。
MS m/z(ESI):589.1[M+H]+
1H-NMR(400MHz,DMSO-d6)δ:8.08-8.06(m,1H),7.98-7.96(m,1H),7.89-7.83(m,2H),7.56-7.69(m,3H),7.58-7.56(m,1H),7.47(t,J=72.8Hz,1H),7.46-7.44(m,1H),7.28-7.26(m,1H),5.30(s,2H),3.28-3.25(m,2H),3.24-3.20(m,5H),1.65-1.59(m,2H)。
实施例9:7-(3-(二氟甲氧基)-5-氟苯基)-3-(2-乙氧基乙基)-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物9)的制备
采用实施例5合成路线,将第一步原料2-甲氧基乙胺替换为2-乙氧基乙胺,得到标题化合物(74mg,收率:26.8%)。
MS m/z(ESI):589.1[M+H]+
1H-NMR(400MHz,DMSO-d6)δ:8.07-8.05(m,1H),7.98-7.96(m,1H),7.88-7.81(m,3H),7.76-7.70(m,2H),7.58-7.56(m,1H),7.47(t,J=72.8Hz,1H),7.45-7.44(m,1H),7.28-7.26(m,1H),5.32(s,2H),3.46-3.33(m,6H),1.12-1.09(m,3H)。
实施例10:(R)-7-(3-(二氟甲氧基)-5-氟苯基)-3-(1-甲氧基丙-2-基)-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物10)的制备
采用实施例5合成路线,将第一步原料2-甲氧基乙胺替换为(R)-1-甲氧基-2-丙胺盐酸盐,得到标题化合物(69mg,收率:25.6%)。
MS m/z(ESI):589.1[M+H]+
1H-NMR(400MHz,DMSO-d6)δ:8.07-8.05(m,1H),7.93-7.89(m,2H),7.87-7.81(m,3H),7.77-7.73(m,1H),7.54-7.51(m,1H),7.47(t,J=72.8Hz,1H),7.42-7.39(m,1H),7.28-7.26(m,1H),5.31-5.18(m,2H),4.48-4.43(m,1H),3.48-3.45(m,1H),3.36-3.32(m,1H),3.25(s,3H),1.05(d,J=8.0Hz,3H)。
实施例11:7-(3-(二氟甲氧基)-5-氟苯基)-3-(1-甲氧基丙-2-基)-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物11)的制备
采用实施例5合成路线,将第一步原料2-甲氧基乙胺替换为1-甲氧基-2-丙胺盐酸盐,得到标题化合物(69mg,收率:25.6%)。
MS m/z(ESI):589.1[M+H]+
1H-NMR(400MHz,DMSO-d6)δ:8.07-8.05(m,1H),7.93-7.90(m,2H),7.87-7.81(m,3H),7.77-7.73(m,1H),7.54-7.50(m,1H),7.47(t,J=72.8Hz,1H),7.42-7.39(m,1H),7.28-7.26(m,1H),5.31-5.19(m,2H),4.48-4.43(m,1H),3.48-3.45(m,1H),3.36-3.32(m,1H),3.25(s,3H),1.05(d,J=8.0Hz,3H)。
实施例12:7-(3-(二氟甲氧基)-5-氟苯基)-3-甲基-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物12)的制备
采用实施例5合成路线,将第一步原料2-甲氧基乙胺替换为甲胺,得到标题化合物(72mg,收率:24.8%)。
MS m/z(ESI):531.1[M+H]+
1H-NMR(400MHz,DMSO-d6)δ:8.08-8.06(m,1H),7.98-7.96(m,1H),7.88-7.80(m,3H),7.75-7.67(m,2H),7.59-7.56(m,1H),7.47(t,J=72.8Hz,1H),7.45-7.44(m,1H),7.28-7.26(m,1H),5.30(s,2H),2.71(s,3H)。
实施例13:7-(3-(二氟甲氧基)-5-氟苯基)-3-乙基-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物13)的制备
采用实施例5合成路线,将第一步原料2-甲氧基乙胺替换为乙胺,得到标题化合物(73mg,收率:25.7%)。
MS m/z(ESI):545.1[M+H]+
1H-NMR(400MHz,DMSO-d6)δ:8.08-8.06(m,1H),7.98-7.97(m,1H),7.89-7.82(m,2H),7.77-7.75(m,1H),7.74-7.66(m,2H),7.60-7.56(m,1H),7.47(t,J=72.8Hz,1H),7.45-7.44(m,1H),7.29-7.26(m,1H),5.32(s,2H),3.22-3.20(m,2H),0.98-0.94(m,3H)。
实施例14:7-(3-(二氟甲氧基)-5-氟苯基)-3-异丙基-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物14)的制备
采用实施例5合成路线,将第一步原料2-甲氧基乙胺替换为异丙胺,得到标题化合物(64mg,收率:23.9%)。
MS m/z(ESI):559.1[M+H]+
1H-NMR(400MHz,DMSO-d6)δ:8.08-8.06(m,1H),7.97-7.95(m,1H),7.91-7.84(m,2H),7.78-7.71(m,3H),7.56-7.53(m,1H),7.47(t,J=72.8Hz,1H),7.42-7.40(m,1H),7.28-7.26(m,1H),5.23(s,2H),4.41-4.34(m,1H),1.08(d,J=8.0Hz,6H)。
实施例15:3-(7-(3-(二氟甲氧基)-5-氟苯基)-4-氧代-1-((3-(三氟甲基)苯基)磺酰基)-1,2-二氢喹唑啉-3(4H)-基)丙腈(化合物15)的制备
采用实施例5合成路线,将第一步原料2-甲氧基乙胺替换为3-氨基丙腈,得到标题化合物(62mg,收率:25.9%)。
MS m/z(ESI):570.1[M+H]+
1H-NMR(400MHz,CDCl3)δ:7.98-7.95(m,2H),7.83-7.80(m,2H),7.64-7.62(m,1H),7.54-7.51(m,2H),7.25-7.21(m,2H),6.99-6.96(m,1H),6.61(t,J=72.8Hz,1H),5.39(s,2H),3.49(t,J=6.4Hz,2H),2.65(t,J=6.4Hz,2H)。
实施例16:7-(3-(二氟甲氧基)-5-氟苯基)-3-(2-(甲基磺酰基)乙基)-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物16)的制备
采用实施例5合成路线,将第一步原料2-甲氧基乙胺替换为2-(甲磺酰基)乙胺,得到标题化合物(63mg,收率:25.4%)。
MS m/z(ESI):623.1[M+H]+
1H-NMR(400MHz,DMSO-d6)δ:8.10-8.07(m,1H),7.99-7.97(m,1H),7.90-7.88(m,1H),7.84-7.82(m,2H),7.75-7.73(m,2H),7.61-7.58(m,1H),7.47(t,J=72.8Hz,1H),7.48-7.46(m,1H),7.30-7.26(m,1H),5.36(s,2H),3.59(t,J=8.0Hz,2H),3.29(t,J=8.0Hz,2H),3.03(s,3H)。
实施例17:7-(3-(二氟甲氧基)-5-氟苯基)-3-(2-羟基-2-甲基丙基)-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物17)的制备
采用实施例5合成路线,将第一步原料2-甲氧基乙胺替换为1-氨基-2-甲基-2-丙醇,得到标题化合物(87mg,收率:27.5%)。
MS m/z(ESI):589.1[M+H]+
1H-NMR(400MHz,DMSO-d6)δ:8.07-8.06(m,1H),7.99-7.98(m,1H),7.90-7.83(m,2H),7.73-7.71(m,3H),7.59-7.57(m,1H),7.47(t,J=72.8Hz,1H),7.46-7.44(m,1H),7.29-7.26(m,1H),5.36(s,2H),4.63(s,1H),3.11(s,2H),0.99(s,6H)。
实施例18:2-(7-(3-(二氟甲氧基)-5-氟苯基)-4-氧代-1-((3-(三氟甲基)苯基)磺酰基)-1,2-二氢喹唑啉-3(4H)-基)-N,N-二甲基乙酰胺(化合物18)的制备
采用实施例5合成路线,将第一步原料2-甲氧基乙胺替换为N,N-二甲基甘氨酰胺,得到标题化合物(64mg,收率:26.4%)。
MS m/z(ESI):602.1[M+H]+
1H-NMR(400MHz,DMSO-d6)δ:8.08-8.06(m,1H),8.03-7.99(m,2H),7.89-7.85(m,1H),7.82-7.79(m,1H),7.73-7.66(m,2H),7.60-7.57(m,1H),7.47(t,J=72.8Hz,1H),7.46-7.45(m,1H),7.30-7.26(m,1H),5.33(s,2H),4.14(s,2H),2.93(s,3H),2.81(s,3H)。
实施例19:3-(7-(3-(二氟甲氧基)-5-氟苯基)-4-氧代-1-((3-(三氟甲基)苯基)磺酰基)-1,2-二氢喹唑啉-3(4H)-基)-N,N-二甲基丙酰胺(化合物19)的制备
采用实施例5合成路线,将第一步原料2-甲氧基乙胺替换为3-氨基-N,N-二甲基丙酰胺,得到标题化合物(58mg,收率:26.8%)。
MS m/z(ESI):616.1[M+H]+
1H-NMR(400MHz,DMSO-d6)δ:8.09-8.07(m,1H),7.99-7.96(m,1H),7.89-7.86(m,1H),7.83-7.81(m,1H),7.76-7.71(m,3H),7.60-7.57(m,1H),7.47(t,J=72.8Hz,1H),7.46-7.45(m,1H),7.29-7.26(m,1H),5.32(s,2H),3.34-3.31(m,2H),2.90(s,3H),2.81(s,3H),2.51-2.47(m,2H)。
实施例20:4-(7-(3-(二氟甲氧基)-5-氟苯基)-4-氧代-1-((3-(三氟甲基)苯基)磺酰基)-1,2-二氢喹唑啉-3(4H)-基)-N,N-二甲基丁酰胺(化合物20)的制备
采用实施例5合成路线,将第一步原料2-甲氧基乙胺替换为4-氨基-N,N-二甲基丁酰胺盐酸盐,得到标题化合物(58mg,收率:26.4%)。
MS m/z(ESI):630.1[M+H]+
1H-NMR(400MHz,DMSO-d6)δ:8.08-8.06(m,1H),7.99-7.97(m,1H),7.89-7.82(m,2H),7.75-7.69(m,3H),7.59-7.57(m,1H),7.47(t,J=72.8Hz,1H),7.45-7.43(m,1H),7.29-7.26(m,1H),5.33(s,2H),3.20-3.16(m,2H),2.90(s,3H),2.77(s,3H),3.23-3.19(m,2H),1.66-1.59(m,2H)。
实施例21:2-(7-(3-(二氟甲氧基)-5-氟苯基)-4-氧代-1-((3-(三氟甲基)苯基)磺酰基)-1,2-二氢喹唑啉-3(4H)-乙酸甲酯(化合物21)的制备
采用实施例5合成路线,将第一步原料2-甲氧基乙胺替换为甘氨酸甲酯盐酸盐,得到标题化合物(82mg,收率:29.3%)。
MS m/z(ESI):589.1[M+H]+
1H-NMR(400MHz,DMSO-d6)δ:8.08-8.06(m,1H),8.02-8.00(m,1H),7.92-7.88(m,2H),7.84-7.82(m,1H),7.73-7.70(m,2H),7.60-7.57(m,1H),7.47(t,J=72.8Hz,1H),7.46-7.45(m,1H),7.30-7.27(m,1H),5.44(s,2H),4.06(s,2H),3.64(s,3H)。
实施例22:2-(7-(3-(二氟甲氧基)-5-氟苯基)-4-氧代-1-((3-(三氟甲基)苯基)磺酰基)-1,2-二氢喹唑啉-3(4H)-乙酸(化合物22)的制备
/>
采用实施例2合成路线,将原料3-(7-(3-(二氟甲氧基)-5-氟苯基)-4-氧代-1-((3-(三氟甲基)苯基)磺酰基)-1,2-二氢喹唑啉-3(4H)-基)丙酸甲酯替换为2-(7-(3-(二氟甲氧基)-5-氟苯基)-4-氧代-1-((3-(三氟甲基)苯基)磺酰基)-1,2-二氢喹唑啉-3(4H)-乙酸甲酯,得到标题化合物(72mg,收率:36.2%)。
MS m/z(ESI):575.1[M+H]+
1H-NMR(400MHz,DMSO-d6)δ:8.06-8.05(m,1H),7.99-7.97(m,1H),7.89-7.86(m,2H),7.83-7.81(m,1H),7.75-7.69(m,2H),7.59-7.57(m,1H),7.47(t,J=72.8Hz,1H),7.46-7.45(m,1H),7.29-7.26(m,1H),5.36(s,2H),3.82(s,2H)。
实施例23:N-(2-(7-(3-(二氟甲氧基)-5-氟苯基)-4-氧代-1-((3-(三氟甲基)苯基)磺酰基)-1,2-二氢喹唑啉-3(4H)-乙基)甲基磺酰胺(化合物23)的制备
采用实施例5合成路线,将第一步原料2-甲氧基乙胺替换为N-(2-氨基乙基)甲磺酰胺盐酸盐,得到标题化合物(47mg,收率:24.3%)。
MS m/z(ESI):638.1[M+H]+
1H-NMR(400MHz,DMSO-d6)δ:8.08-8.07(m,1H),7.99-7.97(m,1H),7.90-7.82(m,2H),7.76-7.75(m,2H),7.60-7.58(m,1H),7.48-7.46(m,1H),7.47(t,J=72.8Hz,1H),7.29-7.27(m,1H),7.14-7.11(m,1H),5.36(s,2H),3.29-3.26(m,2H),3.05-3.03(m,2H),2.90(s,3H)。
实施例24:2-(7-(3-(二氟甲氧基)-5-氟苯基)-4-氧代-1-((3-(三氟甲基)苯基)磺酰基)-1,2-二氢喹唑啉-3(4H)-基)-N-甲基乙基磺酰胺(化合物24)的制备
采用实施例5合成路线,将第一步原料2-甲氧基乙胺替换为2-氨基-N-甲基乙烷磺酰胺盐酸盐,得到标题化合物(72mg,收率:26.8%)。
MS m/z(ESI):638.1[M+H]+
1H-NMR(400MHz,DMSO-d6)δ:8.10-8.08(m,1H),7.99-7.98(m,1H),7.90-7.83(m,2H),7.76-7.73(m,2H),7.60-7.58(m,1H),7.47(t,J=72.8Hz,1H),7.46-7.45(m,1H),7.29-7.26(m,1H),7.08-7.04(m,1H),5.36(s,2H),3.51-3.47(m,2H),3.19-3.17(m,2H),2.58-2.56(m,3H)。
实施例25:2-(7-(3-(二氟甲氧基)-5-氟苯基)-4-氧代-1-((3-(三氟甲基)苯基)磺酰基)-1,2-二氢喹唑啉-3(4H)-基)-N,N-二甲基乙基磺酰胺(化合物25)的制备
采用实施例5合成路线,将第一步原料2-甲氧基乙胺替换为2-氨基-N,N-二甲基乙基磺酰胺,得到标题化合物(61mg,收率:26.4%)。
MS m/z(ESI):652.1[M+H]+
1H-NMR(400MHz,CDCl3)δ:7.96-7.94(m,2H),7.82-7.79(m,2H),7.62-7.59(m,1H),7.54-7.50(m,2H),7.25-7.21(m,2H),7.00-6.96(m,1H),6.61(t,J=72.8Hz,1H),5.34(s,2H),3.60(t,J=5.6Hz,2H),3.11(t,J=5.6Hz,2H),2.85(s,6H)。
实施例26:7-(3-(二氟甲氧基)-5-氟苯基)-3-(氧杂环丁烷-3-基)-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物26)的制备
采用实施例5合成路线,将第一步原料2-甲氧基乙胺替换为3-氧杂环丁胺,得到标题化合物(65mg,收率:27.3%)。
MS m/z(ESI):573.1[M+H]+
1H-NMR(400MHz,DMSO-d6)δ:8.09-8.07(m,1H),8.00-7.98(m,1H),7.91-7.85(m,2H),7.78-7.76(m,2H),7.59-7.56(m,2H),7.47(t,J=72.8Hz,1H),7.46-7.44(m,1H),7.29-7.26(m,1H),5.39(s,2H),4.97-4.90(m,1H),4.66-4.59(m,4H)。
实施例27:(R)-7-(3-(二氟甲氧基)-5-氟苯基)-3-(四氢呋喃-3-基)-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物27)的制备
采用实施例5合成路线,将第一步原料2-甲氧基乙胺替换为(R)-3-氨基四氢呋喃,得到标题化合物(61mg,收率:27.3%)。
MS m/z(ESI):587.1[M+H]+
1H-NMR(400MHz,DMSO-d6)δ:8.08-8.07(m,1H),7.95-7.87(m,3H),7.76-7.73(m,2H),7.68-7.65(m,1H),7.57-7.54(m,1H),7.46(t,J=72.8Hz,1H),7.45-7.43(m,1H),7.29-7.26(m,1H),5.27(s,2H),4.68-4.66(m,1H),4.00-3.94(m,1H),3.68-3.62(m,3H),2.17-2.10(m,1H),1.93-1.85(m,1H)。
实施例28:(S)-7-(3-(二氟甲氧基)-5-氟苯基)-3-(四氢呋喃-3-基)-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物28)的制备
采用实施例5合成路线,将第一步原料2-甲氧基乙胺替换为(S)-3-氨基四氢呋喃,得到标题化合物(65mg,收率:28.7%)。
MS m/z(ESI):587.1[M+H]+
1H-NMR(400MHz,DMSO-d6)δ:8.09-8.07(m,1H),7.96-7.87(m,3H),7.76-7.73(m,2H),7.68-7.65(m,1H),7.57-7.54(m,1H),7.47(t,J=72.8Hz,1H),7.45-7.43(m,1H),7.29-7.26(m,1H),5.27(s,2H),4.68-4.65(m,1H),4.00-3.94(m,1H),3.68-3.63(m,3H),2.17-2.10(m,1H),1.93-1.86(m,1H)。
实施例29:7-(3-(二氟甲氧基)-5-氟苯基)-3-(四氢-2H-吡喃-4-基)-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物29)的制备
采用实施例5合成路线,将第一步原料2-甲氧基乙胺替换为4-氨基四氢吡喃,得到标题化合物(69mg,收率:28.7%)。
MS m/z(ESI):601.1[M+H]+
1H-NMR(400MHz,DMSO-d6)δ:8.08-8.06(m,1H),7.94-7.85(m,3H),7.79-7.74(m,2H),7.72-7.70(m,1H),7.55-7.53(m,1H),7.46(t,J=72.8Hz,1H),7.43-7.41(m,1H),7.29-7.26(m,1H),5.26(s,2H),4.26-4.19(m,1H),3.93-3.90(m,2H),3.37-3.32(m,2H),1.84-1.76(m,2H),1.39-1.36(m,2H)。
实施例30:7-(3-(二氟甲氧基)-5-氟苯基)-3-(氧杂环丁烷-2-基甲基)-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物30)的制备
采用实施例5合成路线,将第一步原料2-甲氧基乙胺替换为2-氨甲基氧杂环丁烷,得到标题化合物(86mg,收率:28.4%)。
MS m/z(ESI):587.1[M+H]+
1H-NMR(400MHz,DMSO-d6)δ:8.08-8.06(m,1H),8.01-7.97(m,1H),7.90-7.84(m,3H),7.74-7.70(m,2H),7.59-7.57(m,1H),7.47(t,J=72.8Hz,1H),7.48-7.46(m,1H),7.29-7.26(m,1H),5.44-5.34(m,2H),4.74-4.72(m,1H),4.53-4.43(m,2H),3.51-3.41(m,2H),2.54-2.51(m,1H),2.35-2.26(m,1H)。
实施例31:(R)-7-(3-(二氟甲氧基)-5-氟苯基)-3-((四氢呋喃-2-基)甲基)-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物31)的制备
采用实施例5合成路线,将第一步原料2-甲氧基乙胺替换为(R)-(+)-四氢糠胺,得到标题化合物(75mg,收率:28.9%)。
MS m/z(ESI):601.1[M+H]+
1H-NMR(400MHz,DMSO-d6)δ:8.06-8.04(m,1H),7.98-7.96(m,1H),7.89-7.82(m,3H),7.75-7.72(m,2H),7.58-7.56(m,1H),7.47(t,J=72.8Hz,1H),7.45-7.42(m,1H),7.28-7.26(m,1H),5.37-5.29(m,2H),3.86-3.77(m,3H),3.39-3.36(m,1H),3.13-3.08(m,1H),1.88-1.73(m,3H),1.46-1.41(m,1H)。
实施例32:(S)-7-(3-(二氟甲氧基)-5-氟苯基)-3-((四氢呋喃-2-基)甲基)-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物32)的制备
采用实施例5合成路线,将第一步原料2-甲氧基乙胺替换为(S)-(+)-四氢糠胺,得到标题化合物(75mg,收率:28.9%)。
MS m/z(ESI):601.1[M+H]+
1H-NMR(400MHz,DMSO-d6)δ:8.06-8.05(m,1H),7.98-7.96(m,1H),7.89-7.82(m,3H),7.75-7.71(m,2H),7.58-7.56(m,1H),7.47(t,J=72.8Hz,1H),7.45-7.43(m,1H),7.28-7.26(m,1H),5.37-5.28(m,2H),3.86-3.77(m,3H),3.39-3.37(m,1H),3.14-3.07(m,1H),1.88-1.73(m,3H),1.46-1.40(m,1H)。
实施例33:7-(3-(二氟甲氧基)-5-氟苯基)-3-((四氢-2H-吡喃-2-基)甲基)-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物33)的制备
采用实施例5合成路线,将第一步原料2-甲氧基乙胺替换为2-氨基甲基四氢吡喃,得到标题化合物(69mg,收率:27.6%)。
MS m/z(ESI):615.1[M+H]+
1H-NMR(400MHz,DMSO-d6)δ:8.06-8.04(m,1H),7.98-7.96(m,1H),7.88-7.71(m,5H),7.58-7.55(m,1H),7.47(t,J=72.8Hz,1H),7.47-7.45(m,1H),7.29-7.26(m,1H),5.29(s,2H),3.88-3.85(m,1H),3.30-3.10(m,4H),1.75-1.73(m,1H),1.48-1.43(m,4H),1.14-1.11(m,1H)。
实施例34:7-(2-氟苯基)-3-(2-甲氧乙基)-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物34)的制备
采用实施例5合成路线,将第三步原料2-(3-(二氟甲氧基)-5-氟苯基)-4,4,5,5-四甲基-1,3,2-二氧杂硼杂环戊烷替换为2-氟苯硼酸,得到标题化合物(72mg,收率:28.9%)。
MS m/z(ESI):509.1[M+H]+
1H-NMR(400MHz,CDCl3)δ:7.98-7.93(m,2H),7.86-7.84(m,1H),7.78-7.76(m,1H),7.60-7.39(m,5H),7.31-7.28(m,1H),7.26-7.20(m,1H),5.28(s,2H),3.50-3.43(m,4H),3.33(s,3H)。
实施例35:7-(3-氟苯基)-3-(2-甲氧乙基)-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物35)的制备
采用实施例5合成路线,将第三步原料2-(3-(二氟甲氧基)-5-氟苯基)-4,4,5,5-四甲基-1,3,2-二氧杂硼杂环戊烷替换为3-氟苯硼酸,得到标题化合物(69mg,收率:28.6%)。
MS m/z(ESI):509.1[M+H]+
1H-NMR(400MHz,DMSO-d6)δ:8.07-8.05(m,1H),7.97-7.94(m,1H),7.86-7.80(m,3H),7.77-7.71(m,2H),7.65-7.58(m,3H),7.35-7.31(m,1H),5.31(s,2H),3.40-3.36(m,4H),3.26(s,3H)。
实施例36:7-(2-二氟甲氧基苯基)-3-(2-甲氧乙基)-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物36)的制备
采用实施例5合成路线,将第三步原料2-(3-(二氟甲氧基)-5-氟苯基)-4,4,5,5-四甲基-1,3,2-二氧杂硼杂环戊烷替换为2-二氟甲氧基苯硼酸,得到标题化合物(78mg,收率:25.6%)。
MS m/z(ESI):557.1[M+H]+
1H-NMR(400MHz,DMSO-d6)δ:8.06-8.04(m,1H),7.86-7.80(m,3H),7.76-7.72(m,2H),7.59-7.54(m,3H),7.45-7.39(m,2H),7.25(t,J=72.8Hz,1H),5.32(s,2H),3.44-3.41(m,4H),3.28(s,3H)。
实施例37:7-(3-二氟甲氧基苯基)-3-(2-甲氧乙基)-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物37)的制备
采用实施例5合成路线,将第三步原料2-(3-(二氟甲氧基)-5-氟苯基)-4,4,5,5-四甲基-1,3,2-二氧杂硼杂环戊烷替换为3-二氟甲氧基苯硼酸,得到标题化合物(72mg,收率:26.1%)。
MS m/z(ESI):557.1[M+H]+
1H-NMR(400MHz,DMSO-d6)δ:8.07-8.05(m,1H),7.96-7.94(m,1H),7.84-7.71(m,5H),7.68-7.57(m,3H),7.41(t,J=72.8Hz,1H),7.32-7.30(m,1H),5.32(s,2H),3.44-3.40(m,4H),3.27(s,3H)。
实施例38:7-(4-二氟甲氧基苯基)-3-(2-甲氧乙基)-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物38)的制备
采用实施例5合成路线,将第三步原料2-(3-(二氟甲氧基)-5-氟苯基)-4,4,5,5-四甲基-1,3,2-二氧杂硼杂环戊烷替换为4-二氟甲氧基苯硼酸,得到标题化合物(82mg,收率:28.6%)。
MS m/z(ESI):557.1[M+H]+
1H-NMR(400MHz,CDCl3)δ:7.97-7.94(m,2H),7.83-7.77(m,2H),7.70-7.68(m,2H),7.61-7.59(m,1H),7.52-7.47(m,2H),7.29-7.27(m,2H),6.59(t,J=72.8Hz,1H),5.26(s,2H),3.47-3.40(m,4H),3.33(s,3H)。
实施例39:7-(2-甲氧基苯基)-3-(2-甲氧乙基)-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物39)的制备
采用实施例5合成路线,将第三步原料2-(3-(二氟甲氧基)-5-氟苯基)-4,4,5,5-四甲基-1,3,2-二氧杂硼杂环戊烷替换为2-甲氧基苯硼酸,得到标题化合物(78mg,收率:26.3%)。
MS m/z(ESI):521.1[M+H]+
1H-NMR(400MHz,CDCl3)δ:8.05-8.03(m,1H),7.83-7.81(m,2H),7.77-7.73(m,3H),7.57-7.54(m,1H),7.47-7.43(m,1H),7.40-7.38(m,1H),7.21-7.19(m,1H),7.13-7.10(m,1H),5.31(s,2H),3.84(s,3H),3.43-3.41(m,4H),3.27(s,3H)。
实施例40:7-(3-甲氧基苯基)-3-(2-甲氧乙基)-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物40)的制备
采用实施例5合成路线,将第三步原料2-(3-(二氟甲氧基)-5-氟苯基)-4,4,5,5-四甲基-1,3,2-二氧杂硼杂环戊烷替换为3-甲氧基苯硼酸,得到标题化合物(82mg,收率:27.5%)。
MS m/z(ESI):521.1[M+H]+
1H-NMR(400MHz,CDCl3)δ:8.01-7.99(m,1H),7.94-7.92(m,1H),7.85-7.83(m,1H),7.78-7.76(m,1H),7.64-7.61(m,1H),7.51-7.41(m,3H),7.29-7.27(m,1H),7.21-7.19(m,1H),7.00-6.98(m,1H),5.26(s,2H),3.91(s,3H),3.48-3.40(m,4H),3.33(s,3H)。
实施例41:7-(2-氰基苯基)-3-(2-甲氧乙基)-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物41)的制备
采用实施例5合成路线,将第三步原料2-(3-(二氟甲氧基)-5-氟苯基)-4,4,5,5-四甲基-1,3,2-二氧杂硼杂环戊烷替换为2-氰基苯硼酸,得到标题化合物(75mg,收率:26.3%)。
MS m/z(ESI):516.1[M+H]+
1H-NMR(400MHz,DMSO-d6)δ:8.06-8.04(m,2H),7.91-7.84(m,5H),7.75-7.67(m,4H),5.34(s,2H),3.44-3.41(m,4H),3.27(s,3H)。
实施例42:7-(3-氰基苯基)-3-(2-甲氧乙基)-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物42)的制备
采用实施例5合成路线,将第三步原料2-(3-(二氟甲氧基)-5-氟苯基)-4,4,5,5-四甲基-1,3,2-二氧杂硼杂环戊烷替换为3-氰基苯硼酸,得到标题化合物(64mg,收率:25.6%)。
MS m/z(ESI):516.1[M+H]+
1H-NMR(400MHz,CDCl3)δ:8.01-7.99(m,2H),7.95-7.90(m,2H),7.83-7.74(m,3H),7.66-7.60(m,2H),7.53-7.48(m,2H),5.27(s,2H),3.48-3.39(m,4H),3.33(s,3H)。
实施例43:7-(2,3-二氟苯基)-3-(2-甲氧乙基)-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物43)的制备
采用实施例5合成路线,将第三步原料2-(3-(二氟甲氧基)-5-氟苯基)-4,4,5,5-四甲基-1,3,2-二氧杂硼杂环戊烷替换为2,3-二氟苯硼酸,得到标题化合物(81mg,收率:27.6%)。
MS m/z(ESI):527.1[M+H]+
1H-NMR(400MHz,DMSO-d6)δ:8.07-8.05(m,1H),7.86-7.80(m,3H),7.77-7.73(m,2H),7.70-7.67(m,1H),7.60-7.54(m,1H),7.48-7.39(m,2H),5.33(s,2H),3.44-3.39(m,4H),3.27(s,3H)。
实施例44:7-(2,5-二氟苯基)-3-(2-甲氧乙基)-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物44)的制备
采用实施例5合成路线,将第三步原料2-(3-(二氟甲氧基)-5-氟苯基)-4,4,5,5-四甲基-1,3,2-二氧杂硼杂环戊烷替换为2,5-二氟苯硼酸,得到标题化合物(78mg,收率:28.9%)。
MS m/z(ESI):527.1[M+H]+
1H-NMR(400MHz,DMSO-d6)δ:8.07-8.05(m,1H),7.87-7.68(m,6H),7.56-7.39(m,3H),5.32(s,2H),3.43-3.40(m,4H),3.27(s,3H)。
实施例45:7-(2,6-二氟苯基)-3-(2-甲氧乙基)-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物45)的制备
采用实施例5合成路线,将第三步原料2-(3-(二氟甲氧基)-5-氟苯基)-4,4,5,5-四甲基-1,3,2-二氧杂硼杂环戊烷替换为2,6-二氟苯硼酸,得到标题化合物(89mg,收率:26.8%)。
MS m/z(ESI):527.1[M+H]+
1H-NMR(400MHz,DMSO-d6)δ:8.07-8.05(m,1H),7.87-7.76(m,4H),7.66-7.56(m,3H),7.34-7.30(m,2H),5.34(s,2H),3.43-3.40(m,4H),3.28(s,3H)。
实施例46:7-(3,5-二氟苯基)-3-(2-甲氧乙基)-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物46)的制备
采用实施例5合成路线,将第三步原料2-(3-(二氟甲氧基)-5-氟苯基)-4,4,5,5-四甲基-1,3,2-二氧杂硼杂环戊烷替换为3,5-二氟苯硼酸,得到标题化合物(87mg,收率:28.6%)。
MS m/z(ESI):527.1[M+H]+
1H-NMR(400MHz,DMSO-d6)δ:8.07-8.05(m,1H),7.99-7.97(m,1H),7.89-7.86(m,1H),7.83-7.80(m,2H),7.76-7.70(m,2H),7.60-7.55(m,2H),7.42-7.36(m,1H),5.31(s,2H),3.39-3.36(m,4H),3.25(s,3H)。
实施例47:3-(2-甲氧基乙基)-7-(6-甲氧基吡啶-2-基)-1-(3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物47)的制备
采用实施例5合成路线,将第三步原料2-(3-(二氟甲氧基)-5-氟苯基)-4,4,5,5-四甲基-1,3,2-二氧杂硼杂环戊烷替换为6-甲氧基吡啶-2-硼酸,得到标题化合物(75mg,收率:26.3%)。
MS m/z(ESI):522.1[M+H]+
1H-NMR(400MHz,DMSO-d6)δ:8.42-8.40(m,1H),8.20-8.18(m,1H),8.07-8.05(m,1H),7.90-7.81(m,3H),7.74-7.71(m,3H),6.93-6.91(m,1H),5.32(s,2H),4.00(s,3H),3.40-3.38(m,4H),3.25(s,3H)。
实施例48:3-(2-甲氧基乙基)-7-(2-甲氧基吡啶-3-基)-1-(3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物48)的制备
采用实施例5合成路线,将第三步原料2-(3-(二氟甲氧基)-5-氟苯基)-4,4,5,5-四甲基-1,3,2-二氧杂硼杂环戊烷替换为2-甲氧基吡啶-3-硼酸,得到标题化合物(81mg,收率:27.3%)。
MS m/z(ESI):522.1[M+H]+
1H-NMR(400MHz,DMSO-d6)δ:8.29-8.27(m,1H),8.06-8.04(m,1H),7.91-7.87(m,2H),7.83-7.73(m,4H),7.65-7.63(m,1H),7.20-7.17(m,1H),5.31(s,2H),3.95(s,3H),3.42-3.40(m,4H),3.27(s,3H)。
实施例49:7-(3-(二氟甲氧基)-5-氟苯基)-3-(2-甲氧基乙基)-1-((3-氰基苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物49)的制备
采用实施例5合成路线,将第四步原料3-三氟甲基苯磺酰氯替换为3-氰基苯磺酰氯,得到标题化合物(68mg,收率:27.2%)。
MS m/z(ESI):532.1[M+H]+
1H-NMR(400MHz,DMSO-d6)δ:8.19-8.14(m,2H),7.96-7.94(m,1H),7.89-7.79(m,2H),7.72-7.65(m,2H),7.61-7.57(m,1H),7.47(t,J=72.8Hz,1H),7.46-7.44(m,1H),7.29-7.26(m,1H),5.28(s,2H),3.43-3.40(m,4H),3.28(s,3H)。
实施例50:7-(3-(二氟甲氧基)-5-氟苯基)-3-(2-甲氧基乙基)-1-((3-甲氧基苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物50)的制备
采用实施例5合成路线,将第四步原料3-三氟甲基苯磺酰氯替换为3-甲氧基苯磺酰氯,得到标题化合物(75mg,收率:27.8%)。
MS m/z(ESI):537.1[M+H]+
1H-NMR(400MHz,DMSO-d6)δ:7.96-7.94(m,1H),7.85-7.83(m,2H),7.57-7.55(m,1H),7.47(t,J=72.8Hz,1H),7.46-7.39(m,2H),7.28-7.25(m,1H),7.23-7.20(m,1H),7.09-7.07(m,1H),6.93-6.91(m,1H),5.25(s,2H),3.65(s,3H),3.38-3.35(m,4H),3.28(s,3H)。
实施例51:7-(3-(二氟甲氧基)-5-氟苯基)-3-(2-甲氧基乙基)-2,2-二甲基-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物51)的制备
第一步:7-溴-3-(2-甲氧乙基)-2,2-二甲基-2,3-二氢喹唑啉-4(1H)-酮的制备
将2-氨基-4-溴-N-(2-甲氧乙基)苯甲酰胺(600mg,2.2mmol)、对甲苯磺酸(38mg,0.22mmol)溶于乙腈(8mL)中,加入2-甲氧基丙烯(5mL)后,室温反应12小时。将反应液减压浓缩后加入水(100mL),乙酸乙酯萃取三次,合并有机相,饱和碳酸氢钠溶液返洗,无水硫酸钠干燥有机相,过滤并将滤液减压浓缩,得到本步的标题化合物(650mg,收率:94.5%)。
MS m/z(ESI):313.0[M+H]+。
第二步:7-(3-(二氟甲氧基)-5-氟苯基)-3-(2-甲氧基乙基)-2,2-二甲基-2,3-二氢喹唑啉-4(1H)-酮的制备
将7-溴-3-(2-甲氧乙基)-2,2-二甲基-2,3-二氢喹唑啉-4(1H)-酮(600mg,1.92mmol)、2-(3-(二氟甲氧基)-5-氟苯基)-4,4,5,5-四甲基-1,3,2-二氧杂硼杂环戊烷(993mg,3.45mmol)和碳酸钾(530mg,3.84mmol)溶于1,4-二氧六环(20mL)和水(4mL)的混合溶剂中,加入[1,1'-双(二苯基膦)二茂铁]二氯化钯二氯甲烷络合物(156mg,0.19mmol),氮气置换后,加热至80℃反应4小时。将反应液倾入水(100mL)中,乙酸乙酯萃取三次,合并有机相,无水硫酸钠干燥,过滤并将滤液减压浓缩,浓缩物经制备高效液相色谱仪纯化得到本步的标题化合物(478mg,收率:63.2%)。
MS m/z(ESI):395.2[M+H]+。
第三步:7-(3-(二氟甲氧基)-5-氟苯基)-3-(2-甲氧基乙基)-2,2-二甲基-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物51)的制备
将7-(3-(二氟甲氧基)-5-氟苯基)-3-(2-甲氧基乙基)-2,2-二甲基-2,3-二氢喹唑啉-4(1H)-酮(400mg,1.01mmol)完全溶于吡啶(5mL)中,加入分子筛(200mg),3-三氟甲基苯磺酰氯(1.24g,5.05mmol),微波加热至100℃反应1小时。冷却至室温后,过滤并将滤液减压浓缩,浓缩物经制备高效液相色谱仪纯化得到标题化合物(37mg,收率:6.1%)。
MS m/z(ESI):603.1[M+H]+
1H-NMR(400MHz,DMSO-d6)δ:8.09-8.07(m,1H),7.98-7.94(m,2H),7.83-7.78(m,3H),7.62-7.60(m,1H),7.50-7.49(m,1H),7.48(t,J=72.8Hz,1H),7.39-7.38(m,1H),7.28-7.25(m,1H),3.20-3.17(m,7H),2.11-2.07(m,3H),1.40-1.36(m,3H)。
实施例52:3-(7-(3-(二氟甲氧基)-5-氟苯基)-4-氧代-1-((3-(三氟甲基)苯基)磺酰基)-1,2-二氢喹唑啉-3(4H)-基)-2,2-二甲基丙酸(化合物52)的制备
第一步:3-(2-氨基-4-溴苯基甲酰基氨基)-2,2-二甲基丙酸乙酯的制备
将2-氨基-4-溴苯甲酸(5.0g,23.1mmol)、2,2-二甲基-3-氨基丙酸乙酯盐酸盐(4.7g,27.8mmol)和HATU(9.7g,25.5mmol)加入四氢呋喃(50mL)中,室温搅拌下缓慢加入DIPEA(15.0g,115.7mmol)后维持室温反应4小时。将反应液倾入水(250mL)中,乙酸乙酯萃取三次,合并有机相,无水硫酸钠干燥,过滤并将滤液减压浓缩,得到本步的标题化合物(7.23g,收率:94.9%)。
MS m/z(ESI):343.1[M+H]+。
第二步:3-(7-溴-4-氧代-1,2-二氢喹唑啉-3(4H)-基)-2,2-二甲基丙酸乙酯的制备
将3-(2-氨基-4-溴苯甲酰胺)-2,2-二甲基丙酸乙酯(3.35g,10.2mmol)和37%甲醛水溶液(826mg,10.2mmol)混溶于乙醇(30mL)中,加入氢氧化钠(570mg,14.3mmol)后,加热至60℃反应3小时。将反应液减压浓缩后加入水(150mL),乙酸乙酯萃取三次,合并有机相,无水硫酸钠干燥,过滤并将滤液减压浓缩,浓缩物经过硅胶柱层析纯化(洗脱剂:石油醚/乙酸乙酯=5/1)得到本步的标题化合物(3.2g,收率:85.8%)。
MS m/z(ESI):355.1[M+H]+。
第三步:3-(7-(3-(二氟甲氧基)-5-氟苯基)-4-氧代-1,2-二氢喹唑啉-3(4H)-基)-2,2-二甲基丙酸乙酯的制备
将3-(7-溴-4-氧代-1,2-二氢喹唑啉-3(4H)-基)-2,2-二甲基丙酸乙酯(350mg,0.99mmol)和2-(3-(二氟甲氧基)-5-氟苯基)-4,4,5,5-四甲基-1,3,2-二氧杂硼杂环戊烷(369mg,1.28mmol)溶于1,4-二氧六环(4mL)和水(1mL)的混合溶剂中,加入碳酸钾(272mg,1.97mmol)和[1,1'-双(二苯基膦)二茂铁]二氯化钯二氯甲烷络合物(81mg,98μmol),氮气置换后加热至80℃反应4小时。将反应液倾入水(150mL)中,乙酸乙酯萃取三次,合并有机相,无水硫酸钠干燥,过滤并将滤液减压浓缩,得到本步的标题化合物(350mg,收率:81.4%)。
MS m/z(ESI):437.2[M+H]+
第四步:3-(7-(3-(二氟甲氧基)-5-氟苯基)-4-氧代-1-((3-(三氟甲基)苯基)磺酰基)-1,2-二氢喹唑啉-3(4H)-基)-2,2-二甲基丙酸乙酯的制备
将3-(7-(3-(二氟甲氧基)-5-氟苯基)-4-氧代-1,2-二氢喹唑啉-3(4H)-基)-2,2-二甲基丙酸乙酯(350mg,0.80mmol)完全溶于吡啶(4mL)中,加入3-三氟甲基苯磺酰氯(588mg,2.41mmol),加热至80℃反应2小时。冷却至室温后,减压浓缩,剩余物加入水(150mL),乙酸乙酯萃取三次,合并有机相,无水硫酸钠干燥,过滤并将滤液减压浓缩得到本步的标题化合物(420mg,收率:81.2%)。
MS m/z(ESI):645.1[M+H]+。
第五步:3-(7-(3-(二氟甲氧基)-5-氟苯基)-4-氧代-1-((3-(三氟甲基)苯基)磺酰基)-1,2-二氢喹唑啉-3(4H)-基)-2,2-二甲基丙酸(化合物52)的制备
将3-(7-(3-(二氟甲氧基)-5-氟苯基)-4-氧代-1-((3-(三氟甲基)苯基)磺酰基)-1,2-二氢喹唑啉-3(4H)-基)-2,2-二甲基丙酸乙酯(200mg,0.31mmol)溶于乙醇(3mL)和水(3mL)的混合溶剂中,加入氢氧化钠(124mg,3.10mmol),升温于80℃搅拌反应1小时。冷却至室温后减压浓缩除去乙醇,剩余物加入水(100mL),用2N盐酸调节pH=2,乙酸乙酯萃取三次,合并有机相,无水硫酸钠干燥,过滤并将滤液减压浓缩,浓缩物经制备高效液相色谱仪纯化得到标题化合物(80mg,收率:41.0%)。
MS m/z(ESI):617.1[M+H]+
1H-NMR(400MHz,DMSO-d6)δ:8.08-8.06(m,1H),7.98-7.97(m,1H),7.90-7.87(m,1H),7.81-7.80(m,1H),7.76-7.72(m,3H),7.58-7.56(m,1H),7.47(t,J=72.8Hz,1H),7.46-7.45(m,1H),7.29-7.26(m,1H),5.33(s,2H),3.33-3.30(m,2H),1.02(s,6H)。
实施例53:3-(4-氧代-7-苯基-1-((3-(三氟甲基)苯基)磺酰基)-1,2-二氢喹唑啉-3(4H)-基)-2,2-二甲基丙酸(化合物53)的制备
采用实施例52合成路线,将第三步原料2-(3-(二氟甲氧基)-5-氟苯基)-4,4,5,5-四甲基-1,3,2-二氧杂硼杂环戊烷替换为苯硼酸,得到标题化合物(87mg,收率:28.9%)。
MS m/z(ESI):533.1[M+H]+
1H-NMR(400MHz,DMSO-d6)δ:12.6(br,1H),8.08-8.06(m,1H),7.92-7.90(m,1H),7.83-7.70(m,7H),7.59-7.51(m,2H),7.51-7.47(m,1H),5.34(s,2H),3.47-3.45(m,2H),1.04(s,6H)。
实施例54:3-(7-(3-氟苯基)-4-氧代-1-((3-(三氟甲基)苯基)磺酰基)-1,2-二氢喹唑啉-3(4H)-基)-2,2-二甲基丙酸(化合物54)的制备
/>
采用实施例52合成路线,将第三步原料2-(3-(二氟甲氧基)-5-氟苯基)-4,4,5,5-四甲基-1,3,2-二氧杂硼杂环戊烷替换为3-氟苯硼酸,得到标题化合物(72mg,收率:27.4%)。
MS m/z(ESI):551.1[M+H]+
1H-NMR(400MHz,DMSO-d6)δ:12.6(br,1H),8.08-8.06(m,1H),7.95-7.93(m,1H),7.87-7.79(m,2H),7.76-7.58(m,6H),7.36-7.31(m,1H),5.33(s,2H),3.35-3.32(m,2H),1.04(s,6H)。
实施例55:3-(7-(3-甲氧基苯基)-4-氧代-1-((3-(三氟甲基)苯基)磺酰基)-1,2-二氢喹唑啉-3(4H)-基)-2,2-二甲基丙酸(化合物55)的制备
采用实施例52合成路线,将第三步原料2-(3-(二氟甲氧基)-5-氟苯基)-4,4,5,5-四甲基-1,3,2-二氧杂硼杂环戊烷替换为3-甲氧基苯硼酸,得到标题化合物(78mg,收率:28.3%)。
MS m/z(ESI):563.1[M+H]+
1H-NMR(400MHz,CDCl3)δ:7.98-7.97(m,1H),7.91-7.89(m,1H),7.80-7.78(m,2H),7.65-7.63(m,1H),7.52-7.40(m,3H),7.25-7.23(m,1H),7.19-7.18(m,1H),7.00-6.98(m,1H),5.27(s,2H),3.89(s,3H),3.41(s,2H),1.21(s,6H)。
实施例56:3-(7-(2-二氟甲氧基苯基)-4-氧代-1-((3-(三氟甲基)苯基)磺酰基)-1,2-二氢喹唑啉-3(4H)-基)-2,2-二甲基丙酸(化合物56)的制备
采用实施例52合成路线,将第三步原料2-(3-(二氟甲氧基)-5-氟苯基)-4,4,5,5-四甲基-1,3,2-二氧杂硼杂环戊烷替换为2-二氟甲氧基苯硼酸,得到标题化合物(82mg,收率:29.3%)。
MS m/z(ESI):599.1[M+H]+
1H-NMR(400MHz,CDCl3)δ:7.90-7.89(m,2H),7.79-7.76(m,2H),7.55-7.42(m,5H),7.36-7.30(m,2H),6.47(t,J=72.8Hz,1H),5.28(s,2H),3.42(s,2H),1.19(s,6H)。
实施例57:3-(7-(2-氯-5-氟苯基)-4-氧代-1-((3-(三氟甲基)苯基)磺酰基)-1,2-二氢喹唑啉-3(4H)-基)-2,2-二甲基丙酸(化合物57)的制备
采用实施例52合成路线,将第三步原料2-(3-(二氟甲氧基)-5-氟苯基)-4,4,5,5-四甲基-1,3,2-二氧杂硼杂环戊烷替换为2-氯-5-氟苯硼酸,得到标题化合物(74mg,收率:26.2%)。
MS m/z(ESI):585.1[M+H]+
1H-NMR(400MHz,DMSO-d6)δ:12.6(br,1H),8.08-8.06(m,1H),7.82-7.69(m,5H),7.66-7.64(m,1H),7.57-7.55(m,1H),7.42-7.38(m,2H),5.35(s,2H),3.38-3.35(m,2H),1.05(s,6H)。
实施例58:3-(7-(2-氯-6-氟苯基)-4-氧代-1-((3-(三氟甲基)苯基)磺酰基)-1,2-二氢喹唑啉-3(4H)-基)-2,2-二甲基丙酸(化合物58)的制备
采用实施例52合成路线,将第三步原料2-(3-(二氟甲氧基)-5-氟苯基)-4,4,5,5-四甲基-1,3,2-二氧杂硼杂环戊烷替换为2-氯-6-氟苯硼酸,得到标题化合物(83mg,收率:27.6%)。
MS m/z(ESI):585.1[M+H]+
1H-NMR(400MHz,DMSO-d6)δ:8.08-8.06(m,1H),7.85-7.80(m,3H),7.67-7.66(m,1H),7.58-7.50(m,4H),7.45-7.42(m,1H),5.37(s,2H),3.39-3.37(m,2H),1.05(s,6H)。
实施例59:3-(7-(3-氯-2-甲氧基苯基)-4-氧代-1-((3-(三氟甲基)苯基)磺酰基)-1,2-二氢喹唑啉-3(4H)-基)-2,2-二甲基丙酸(化合物59)的制备
采用实施例52合成路线,将第三步原料2-(3-(二氟甲氧基)-5-氟苯基)-4,4,5,5-四甲基-1,3,2-二氧杂硼杂环戊烷替换为3-氯-2-甲氧基苯硼酸,得到标题化合物(72mg,收率:27.8%)。
MS m/z(ESI):597.1[M+H]+
1H-NMR(400MHz,DMSO-d6)δ:8.08-8.07(m,1H),7.85-7.84(m,1H),7.81-7.76(m,3H),7.67-7.60(m,3H),7.45-7.43(m,1H),7.34-7.30(m,1H),5.34(s,2H),3.58(s,3H),3.36-3.34(m,2H),1.03(s,6H)。
实施例60:3-(7-(2-氯-3-氟苯基)-4-氧代-1-((3-(三氟甲基)苯基)磺酰基)-1,2-二氢喹唑啉-3(4H)-基)-2,2-二甲基丙酸(化合物60)的制备
采用实施例52合成路线,将第三步原料2-(3-(二氟甲氧基)-5-氟苯基)-4,4,5,5-四甲基-1,3,2-二氧杂硼杂环戊烷替换为2-氯-3-氟苯硼酸,得到标题化合物(87mg,收率:26.3%)。
MS m/z(ESI):585.1[M+H]+
1H-NMR(400MHz,CDCl3)δ:7.94-7.92(m,1H),7.86-7.85(m,1H),7.81-7.77(m,2H),7.58-7.47(m,3H),7.38-7.32(m,1H),7.25-7.22(m,1H),7.19-7.17(m,1H),5.29(s,2H),3.46(s,2H),1.23(s,6H)。
实施例61:3-(7-(2-氟-3-甲基苯基)-4-氧代-1-((3-(三氟甲基)苯基)磺酰基)-1,2-二氢喹唑啉-3(4H)-基)-2,2-二甲基丙酸(化合物61)的制备
采用实施例52合成路线,将第三步原料2-(3-(二氟甲氧基)-5-氟苯基)-4,4,5,5-四甲基-1,3,2-二氧杂硼杂环戊烷替换为2-氟-3-甲基苯硼酸,得到标题化合物(75mg,收率:27.2%)。
MS m/z(ESI):565.1[M+H]+
1H-NMR(400MHz,DMSO-d6)δ:12.6(br,1H),8.08-8.06(m,1H),7.81-7.73(m,4H),7.67-7.64(m,2H),7.43-7.40(m,2H),7.29-7.25(m,1H),5.35(s,2H),3.36-3.35(m,2H),2.35(s,3H),1.05(s,6H)。
实施例62:3-(7-(6-甲基吡啶-2-基)-4-氧代-1-((3-(三氟甲基)苯基)磺酰基)-1,2-二氢喹唑啉-3(4H)-基)-2,2-二甲基丙酸(化合物62)的制备
采用实施例52合成路线,将第三步原料2-(3-(二氟甲氧基)-5-氟苯基)-4,4,5,5-四甲基-1,3,2-二氧杂硼杂环戊烷替换为6-甲基吡啶-2硼酸,得到标题化合物(75mg,收率:27.1%)。
MS m/z(ESI):548.1[M+H]+
1H-NMR(400MHz,DMSO-d6)δ:8.38-8.37(m,1H),8.20-8.18(m,1H),8.08-8.06(m,1H),7.92-7.81(m,3H),7.75-7.66(m,3H),7.35-7.34(m,1H),5.33(s,2H),3.38-3.35(m,2H),2.59(s,3H),1.02(s,6H)。
实施例63:3-(7-(3-氯-5-甲氧基苯基)-4-氧代-1-((3-(三氟甲基)苯基)磺酰基)-1,2-二氢喹唑啉-3(4H)-基)-2,2-二甲基丙酸(化合物63)的制备
第一步:3-(7-(3-氯-5-甲氧基苯基)-4-氧代-1,2-二氢喹唑啉-3(4H)-基)-2,2-二甲基丙酸乙酯的制备
将3-(7-溴-4-氧代-1,2-二氢喹唑啉-3(4H)-基)-2,2-二甲基丙酸乙酯(350mg,0.99mmol)和3-氯-5-甲氧基苯基硼酸(239mg,1.28mmol)溶于1,4-二氧六环(4mL)和水(1mL)的混合溶剂中,加入碳酸钾(272mg,1.97mmol)和[1,1'-双(二苯基膦)二茂铁]二氯化钯二氯甲烷络合物(81mg,98μmol),氮气置换后加热至80℃反应4小时。将反应液倾入水(150mL)中,乙酸乙酯萃取三次,合并有机相,无水硫酸钠干燥,过滤并将滤液减压浓缩,得到本步的标题化合物(362mg,收率:87.7%)。
MS m/z(ESI):417.2[M+H]+。
第二步:3-(7-(3-氯-5-甲氧基苯基)-4-氧代-1-((3-(三氟甲基)苯基)磺酰基)-1,2-二氢喹唑啉-3(4H)-基)-2,2-二甲基丙酸乙酯的制备
将3-(7-(3-氯-5-甲氧基苯基)-4-氧代-1,2-二氢喹唑啉-3(4H)-基)-2,2-二甲基丙酸乙酯(350mg,0.84mmol)完全溶于吡啶(4mL)中,加入3-三氟甲基苯磺酰氯(616mg,2.52mmol),加热至80℃反应2小时。冷却至室温后,减压浓缩,剩余物加入水(150mL),乙酸乙酯萃取三次,合并有机相,无水硫酸钠干燥,过滤并将滤液减压浓缩得到本步的标题化合物(458mg,收率:87.2%)。
MS m/z(ESI):625.1[M+H]+。
第三步:3-(7-(3-氯-5-甲氧基苯基)-4-氧代-1-((3-(三氟甲基)苯基)磺酰基)-1,2-二氢喹唑啉-3(4H)-基)-2,2-二甲基丙酸(化合物63)的制备
将3-(7-(3-氯-5-甲氧基苯基)-4-氧代-1-((3-(三氟甲基)苯基)磺酰基)-1,2-二氢喹唑啉-3(4H)-基)-2,2-二甲基丙酸乙酯(200mg,0.32mmol)溶于乙醇(3mL)和水(3mL)的混合溶剂中,加入氢氧化钠(128mg,3.20mmol),升温于80℃搅拌反应1小时。冷却至室温后减压浓缩除去乙醇,剩余物加入水(100mL),用2N盐酸调节pH=2,乙酸乙酯萃取三次,合并有机相,无水硫酸钠干燥,过滤并将滤液减压浓缩,浓缩物经制备高效液相色谱仪纯化得到标题化合物(75mg,收率:39.3%)。
MS m/z(ESI):597.1[M+H]+
1H-NMR(400MHz,DMSO-d6)δ:8.33-8.31(m,1H),8.08-8.06(m,1H),7.90-7.84(m,2H),7.78-7.65(m,3H),7.39-7.37(m,1H),7.26-7.24(m,1H),7.17-7.15(m,1H),5.30(s,2H),3.89(s,3H),3.30-3.28(m,2H),0.99(s,6H)。
实施例64:7-(3-(二氟甲氧基)-5-氟苯基)-3-(2-吗啉基乙基)-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物64)的制备
采用实施例5合成路线,将第一步原料2-甲氧基乙胺替换为N-(2-氨基乙基)吗啉,得到标题化合物(11mg,收率:20.3%)。
MS m/z(ESI):630.1[M+H]+
1H-NMR(400MHz,DMSO-d6)δ:8.07-8.05(m,1H),7.97-7.96(m,1H),7.88-7.81(m,3H),7.74-7.72(m,2H),7.58-7.56(m,1H),7.47(t,J=72Hz,1H),7.46-7.44(m,1H),7.29-7.26(m,1H),5.34(s,2H),3.54-3.51(m,4H),3.31-3.28(m,2H),2.38-2.32(m,6H)。
生物学评价:
测试例1RORγ-LBD TR-FRET实验
一、实验材料及仪器
1.RORγ-LBD(辉源生物)
2.生物素-SRC1(PerkinElmer)
3.LANCE Eu-抗-6×His抗体(PerkinElmer)
4.SureLight Allophycocyanin-Streptavidin(PerkinElmer)
5.酶标仪(BMG Labtech)
二、实验方法
溶液配制:配制反应缓冲液(25mM HEPES,pH 7.0,100Mm NaCl,0.01%Tween 20,0.2%BSA,5mM DTT)。以反应缓冲液配制含1nM LANCE Eu-抗-6×His抗体的溶液A1,含1nMLANCE Eu-抗-6×His抗体和15nM RORγ-LBD的溶液A2,以及含200nM生物素-SRC1和15nMAllophycocyanin-Streptavidin的溶液B,均置于冰上待用。
以DMSO稀释化合物,5μM起始,4倍稀释,10个浓度点。384孔板中的待测化合物孔加入0.25μl稀释后化合物、15μl溶液A2、以及10μl溶液B;阴性对照孔加入0.25μl DMSO、15μl溶液A1、以及10μl溶液B;溶剂对照孔加入0.25μl DMSO、15μl溶液A2、以及10μl溶液B。封口胶带封板,震荡2分钟混匀反应液。将384孔板置于4℃过夜。第2天取出384孔板至室温平衡1小时,离心1分钟。酶标仪读板(检测波长665nm/615nm)。
数据处理:化合物激活率=(FI比值化合物-FI比值溶剂对照)/(FI比值溶剂对照-FI比值阴性对照)*100%,FI比值表示酶标仪读出荧光值(665nm)与酶标仪读出荧光值(615nm)的比值;由GraphPad Prism软件计算EC50值。最大激活率是指:由上述化合物激活率公式得到的曲线处于上平台期时对应浓度点的激活率;所述最大激活率大于0时,表明待测化合物对RORγ具有激动作用。
本发明的待测化合物对RORγ的激动活性见表1。
表1本发明化合物对RORγ的激动活性
/>
/>
由此可见,本发明化合物对RORγ具有明显的激动作用,具有例如小于100nM、优选小于20nM、更优选小于10nM的EC50,最大激活率均在40%以上。
测试例2RORγ-荧光素酶报告基因实验
一、实验材料及仪器
1.质粒pcDNA3.1(GAL4DBD/RORγLBD),pGL4.35(luc2P/9×GAL4UAS/Hygro)南京科佰生物构建
2.Lipofectamine 3000(Invitrogen)
3.Bright-GloTM(Promega)
4.乌苏酸(Cayman Chemical)
5.酶标仪(BMG Labtech)
6. 293T细胞(购自ATCC)
7.待测化合物(以DMSO配制为10mM储备液)
二、实验方法
293T细胞以DMEM高糖培养基(含10%FBS)培养于T25细胞培养瓶中,生长至融合度80%左右时,按Lipofectamine 3000说明书制备包载质粒的脂质体。将脂质体与一定体积的DMEM高糖培养基(含10%FBS)混合,去除T25培养瓶中原培养基,加入上述脂质体与DMEM高糖培养基的混合液转染293T细胞。转染后24h,消化细胞并计数。以DMEM高糖培养基(含10%FBS,2μM乌苏酸)稀释细胞至一定浓度,均匀铺至96孔培养板,每孔含细胞约105个。以DMEM高糖培养基(含10%FBS,2μM乌苏酸)稀释待测化合物储备液以及溶剂对照(DMSO),100μM起始,3倍稀释,10个浓度点。将稀释后化合物和溶剂对照分别加入96孔细胞培养板的实验孔和溶剂对照孔中。震荡细胞培养板2分钟使化合物与培养基充分混合,于37℃,5%CO2孵箱中继续培养24小时。取出96孔细胞培养板至室温平衡10min,按照说明书加入Bright-GloTM,震荡5分钟充分混匀。快速转移混合液至检测板。酶标仪检测发光强度。
数据处理:激活率=实验孔发光值/溶剂对照孔平均发光值*100%。溶剂对照孔平均发光值定义为100%,使用Graphpad Prism 5软件进行数据分析与作图,以激活率与化合物浓度的对数经四参数拟合曲线计算EC50值;最大激活率为所述拟合曲线处于上平台期时对应浓度点的激活率;所述最大激活率大于100%时,表明待测化合物对RORγ具有激动作用。
本发明化合物在细胞中对RORγ的激动活性见表2。
表2本发明化合物对RORγ的激动活性
/>
由此可见,本发明化合物在细胞中对RORγ具有明显的激动作用,具有例如小于1μM的EC50以及大于300%的最大激活率。
Claims (24)
1.式II-A化合物或其药学上可接受的盐、立体异构体,其中:
环A1选自苯基、吡啶基、吡咯基、咪唑基、吡唑基、嘧啶基、哒嗪基、吡嗪基;
环A2选自苯基;
R1选自C1-6烷基和4-6元杂环基;且可任选地被0、1或2个独立的选自下组的取代基所取代,该组取代基选自:卤素、-CN、-OH、-CO2R5a、-OR6、-S(O)2-R6、-C(O)-N(R5a)(R5b)、-N(R5a)C(O)R6、-S(O)2-N(R5a)(R5b)、-N(R5a)S(O)2R6、4-6元杂环基;所述“4-6元杂环基”是指含有1、2或3个选自N、O、S的杂原子的4-6元饱和杂环基团;
每个R2各自独立地选自卤素、氰基、羟基、C1-6烷基、C1-6卤代烷基、C1-6烷氧基和C1-6卤代烷氧基;
每个R3各自独立地选自卤素、氰基、羟基、C1-6烷基、C1-6卤代烷基、C1-6烷氧基、C1-6卤代烷氧基和-S(O)2-R6;
R5a和R5b各自独立地选自氢和C1-6烷基;
R6选自C1-6烷基;
每个Ra和Rb各自独立地选自氢和C1-6烷基;
m为0、1、2或3;
n为0、1、2或3。
2.根据权利要求1所述的化合物或其药学上可接受的盐、立体异构体,其中:
R1选自C1-4烷基和4-6元杂环基;且可任选地被0、1或2个独立的选自下组的取代基所取代,该组取代基选自:卤素、-CN、-OH、-CO2R5a、-OR6、-S(O)2-R6、-C(O)-N(R5a)(R5b)、-N(R5a)C(O)R6、-S(O)2-N(R5a)(R5b)、-N(R5a)S(O)2R6和4-6元杂环基。
3.根据权利要求2所述的化合物或其药学上可接受的盐、立体异构体,其中:
R1选自C1-4烷基、C1-4卤代烷基、-C1-4亚烷基-CN、-C1-4亚烷基-OH、-C1-4亚烷基-CO2R5a、-C1-4亚烷基-O-R6、-C1-4亚烷基-S(O)2-R6、-C1-4亚烷基-C(O)-N(R5a)(R5b)、-C1-4亚烷基-N(R5a)C(O)R6、-C1-4亚烷基-S(O)2-N(R5a)(R5b)和-C1-4亚烷基-N(R5a)S(O)2R6、氧杂环丁烷基、四氢呋喃基、四氢-2H-吡喃基、-C1-4亚烷基-氧杂环丁烷、-C1-4亚烷基-四氢呋喃、-C1-4亚烷基-四氢吡喃和-C1-4亚烷基-吗啉;
R5a和R5b各自独立地选自氢和C1-4烷基;
R6选自C1-4烷基。
4.根据权利要求3所述的化合物或其药学上可接受的盐、立体异构体,其中:
R1选自C1-4烷基、C1-4卤代烷基、-C1-4亚烷基-CN、-C1-4亚烷基-OH、-C1-4亚烷基-C(O)OH、-C1-4亚烷基-C(O)O-C1-4烷基、-C1-4亚烷基-O-C1-4烷基、-C1-4亚烷基-S(O)2-C1-4烷基、-C1-4亚烷基-C(O)-NH-C1-4烷基、-C1-4亚烷基-C(O)-N(C1-4烷基)(C1-4烷基)、-C1-4亚烷基-NH-C(O)-C1-4烷基、-C1-4亚烷基-S(O)2-N(C1-4烷基)(C1-4烷基)、-C1-4亚烷基-S(O)2-NH-(C1-4烷基)、-C1-4亚烷基-S(O)2-NH2、-C1-4亚烷基-NH-S(O)2-C1-4烷基、氧杂环丁烷基、四氢呋喃基、四氢-2H-吡喃基、-C1-3亚烷基-氧杂环丁烷、-C1-3亚烷基-四氢呋喃、-C1-3亚烷基-四氢吡喃和-C1-3亚烷基-吗啉。
5.根据权利要求1所述的化合物或其药学上可接受的盐、立体异构体,其中:
R1选自-CH3、-CH2CH3、-CH(CH3)2、-CH2CH2CH2F、-CH2CH2-CN、-CH2CH2CH2-CN、-CH2CH2C(CH3)2-CN、-CH2C(CH3)2-OH、-CH2CH2C(CH3)2-OH、-CH2C(O)OH、-CH2CH2C(O)OH、-CH2C(CH3)2C(O)OH、-CH2C(O)O-CH3、-CH2CH2C(O)O-CH3、-CH2C(CH3)2C(O)O-CH3、-CH2CH2-O-CH3、-CH2CH(CH3)-O-CH3、-CH2CH2CH2-O-CH3、-CH2CH2-O-CH2CH3、-CH(CH3)CH2-O-CH3、-CH2CH2-S(O)2-CH3、-CH2CH2-C(O)-NH-CH3、-CH2CH2CH2-C(O)-N(CH3)2、-CH2CH2-C(O)-N(CH3)2、-CH2-C(O)-N(CH3)2、-CH2CH2-NH-C(O)-CH3、-CH2CH2-S(O)2-N(CH3)2、-CH2CH2-S(O)2-NHCH3、-CH2CH2-S(O)2-NH2、-CH2CH2-NH-S(O)2-CH3、
6.根据权利要求1-5任一项所述的化合物或其药学上可接受的盐、立体异构体,其中:
R2选自卤素、氰基、羟基、C1-4烷基、C1-4卤代烷基、C1-4烷氧基和C1-4卤代烷氧基。
7.根据权利要求6所述的化合物或其药学上可接受的盐、立体异构体,其中:
环A1选自苯基、吡啶基和吡唑基;R2选自卤素、氰基、C1-4卤代烷基和C1-4卤代烷氧基。
8.根据权利要求7所述的化合物或其药学上可接受的盐、立体异构体,其中:
环A1选自苯基和吡啶基;R2选自卤素、氰基、C1-4烷基、C1-4烷氧基、C1-4卤代烷基和C1-4卤代烷氧基。
9.根据权利要求8所述的化合物或其药学上可接受的盐、立体异构体,其中:
R2选自氟、氯、氰基、甲基、甲氧基和二氟甲氧基。
10.根据权利要求1-5、7-9任一项所述的化合物或其药学上可接受的盐、立体异构体,其中:
R3选自卤素、氰基、C1-4烷基、C1-4卤代烷基、C1-4烷氧基、C1-4卤代烷氧基和-S(O)2-C1-4烷基。
11.根据权利要求10所述的化合物或其药学上可接受的盐、立体异构体,其中:
R3选自三氟甲基、甲基、氰基、氟和甲磺酰基。
12.根据权利要求1所述的化合物或其药学上可接受的盐、立体异构体,其中:
环A1选自苯基和吡啶基;
Ra和Rb都是氢;
R1选自-CH3、-CH2CH3、-CH(CH3)2、-CH2CH2CH2F、-CH2CH2-CN、-CH2CH2CH2-CN、-CH2CH2C(CH3)2-CN、-CH2C(CH3)2-OH、-CH2CH2C(CH3)2-OH、-CH2C(O)OH、-CH2CH2C(O)OH、-CH2C(CH3)2C(O)OH、-CH2C(O)O-CH3、-CH2CH2C(O)O-CH3、-CH2C(CH3)2C(O)O-CH3、-CH2CH2-O-CH3、-CH2CH(CH3)-O-CH3、-CH2CH2CH2-O-CH3、-CH2CH2-O-CH2CH3、-CH(CH3)CH2-O-CH3、-CH2CH2-S(O)2-CH3、-CH2CH2-C(O)-NH-CH3、-CH2CH2CH2-C(O)-N(CH3)2、-CH2CH2-C(O)-N(CH3)2、-CH2-C(O)-N(CH3)2、-CH2CH2-NH-C(O)-CH3、-CH2CH2-S(O)2-N(CH3)2、-CH2CH2-S(O)2-NHCH3、-CH2CH2-S(O)2-NH2、-CH2CH2-NH-S(O)2-CH3、
每个R2各自独立地选自卤素、氰基、C1-4烷基、C1-4卤代烷基、C1-4烷氧基、C1-4卤代烷氧基;
每个R3各自独立地选自卤素、氰基、C1-4烷基、C1-4卤代烷基和-S(O)2-C1-4烷基;
m为0、1、2或3;
n为0、1、2或3。
13.根据权利要求1所述的化合物或其药学上可接受的盐、立体异构体,其中所述化合物选自:
。
14.药物组合物,其包含预防或治疗有效量的权利要求1-13中任一项的化合物或其药学可接受的盐、立体异构体,以及任选的一种或多种药学上可接受的赋形剂。
15.药物制剂,其包含权利要求1-13中任一项的化合物或其药学可接受的盐、立体异构体,或者权利要求14的药物组合物。
16.权利要求1-13中任一项的化合物或其药学可接受的盐、立体异构体、权利要求14的药物组合物或权利要求15的药物制剂在制备用于预防或治疗RORγ相关疾病的药物中的用途。
17.根据权利要求16所述的用途,其中所述药物为通过口服、静脉内、动脉内、皮下、腹膜内、肌内或经皮途径给药的药物。
18.根据权利要求17所述的用途,其中所述RORγ相关疾病或病症选自肿瘤或癌症。
19.根据权利要求18所述的用途,其中所述肿瘤或癌症选自弥漫大B细胞淋巴瘤、滤泡性淋巴瘤、滑膜肉瘤、乳腺癌、宫颈癌、结肠癌、肺癌、口腔癌、脑癌、胃癌、肝癌、直肠癌、胰腺癌、皮肤癌、前列腺癌、骨癌、肾癌、卵巢癌、膀胱癌、输卵管肿瘤、腹膜肿瘤、黑色素瘤、神经胶质瘤、神经胶母细胞瘤、乳突状恶性瘤、白血病或骨髓瘤。
20.根据权利要求18所述的用途,其中所述肿瘤或癌症选自头颈部肿瘤、淋巴瘤。
21.根据权利要求20所述的用途,其中所述肿瘤或癌症选自非霍奇金淋巴瘤。
22.根据权利要求18所述的用途,其中所述肿瘤或癌症选自实体瘤。
23.根据权利要求16-22任一项所述的用途,其中所述药物还包含其他抗肿瘤剂。
24.制备式(II-A)的化合物的方法,所述方法包括以下步骤:
其中,X表示离去基团,所述的离去基团选自卤素原子、甲磺酰基氧基和对甲基苯磺酰基氧基,R1、R2、R3、Ra、Rb、环A1、环A2、m、n如权利要求1-13中任一项所定义;
(1)使化合物IN-A-1与化合物IN-A-2反应以得到化合物IN-A-3;
(2)使化合物IN-A-3与化合物IN-A-4进行关环反应以得到化合物IN-A-5;或者当化合物IN-A-5中的Ra与Rb均为甲基时,也可以使化合物IN-A-3与2-甲氧基丙烯进行关环反应以得到化合物IN-A-5;
(3)使化合物IN-A-5与化合物IN-A-6反应以得到化合物IN-A-7;
(4)使化合物IN-A-7与化合物IN-A-8反应以得到式(II-A)的化合物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2018107694562 | 2018-07-13 | ||
CN201810769456 | 2018-07-13 | ||
CN201910022463 | 2019-01-10 | ||
CN2019100224630 | 2019-01-10 | ||
PCT/CN2019/094579 WO2020011086A1 (zh) | 2018-07-13 | 2019-07-03 | 苯并二氮杂环类化合物、其制备方法及用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112119065A CN112119065A (zh) | 2020-12-22 |
CN112119065B true CN112119065B (zh) | 2024-01-23 |
Family
ID=69142159
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201980032188.9A Active CN112119065B (zh) | 2018-07-13 | 2019-07-03 | 苯并二氮杂环类化合物、其制备方法及用途 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN112119065B (zh) |
WO (1) | WO2020011086A1 (zh) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA75902C2 (en) * | 2000-12-21 | 2006-06-15 | Newpogen Corp | Benzimidazole , pyridylimidazole derivatives as ligands of gaba receptors, pharmaceutical composition based thereon, a method for the preparation thereof |
CN105085504A (zh) * | 2014-04-16 | 2015-11-25 | 北京大学 | 4-取代苯磺酰胺衍生物及其制备方法和应用 |
CN105705501A (zh) * | 2013-09-09 | 2016-06-22 | 百时美施贵宝公司 | RORγ调节剂 |
WO2016179343A1 (en) * | 2015-05-05 | 2016-11-10 | Lycera Corporation | DIHYDRO-2H-BENZO[b][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE |
WO2017213210A1 (ja) * | 2016-06-10 | 2017-12-14 | 武田薬品工業株式会社 | 複素環化合物 |
CN107980042A (zh) * | 2015-06-11 | 2018-05-01 | 莱斯拉公司 | 用作RORγ激动剂和用于治疗疾病的芳基二氢-2H-苯并[b][1,4]噁嗪磺酰胺和相关化合物 |
CN108689942A (zh) * | 2017-04-11 | 2018-10-23 | 广东东阳光药业有限公司 | 含氮双环化合物及其制备方法和用途 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11201702075QA (en) * | 2014-10-29 | 2017-04-27 | Dong A St Co Ltd | Novel pyridopyrimidinone compounds for modulating the catalytic activity of histone lysine demethylases (kdms) |
AU2016319638B2 (en) * | 2015-09-09 | 2021-02-11 | Jubilant Biosys Limited | Tricyclic fused pyridin-2-one derivatives and their use as BRD4 inhibitors |
-
2019
- 2019-07-03 WO PCT/CN2019/094579 patent/WO2020011086A1/zh active Application Filing
- 2019-07-03 CN CN201980032188.9A patent/CN112119065B/zh active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA75902C2 (en) * | 2000-12-21 | 2006-06-15 | Newpogen Corp | Benzimidazole , pyridylimidazole derivatives as ligands of gaba receptors, pharmaceutical composition based thereon, a method for the preparation thereof |
CN105705501A (zh) * | 2013-09-09 | 2016-06-22 | 百时美施贵宝公司 | RORγ调节剂 |
CN105085504A (zh) * | 2014-04-16 | 2015-11-25 | 北京大学 | 4-取代苯磺酰胺衍生物及其制备方法和应用 |
WO2016179343A1 (en) * | 2015-05-05 | 2016-11-10 | Lycera Corporation | DIHYDRO-2H-BENZO[b][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE |
CN107980042A (zh) * | 2015-06-11 | 2018-05-01 | 莱斯拉公司 | 用作RORγ激动剂和用于治疗疾病的芳基二氢-2H-苯并[b][1,4]噁嗪磺酰胺和相关化合物 |
WO2017213210A1 (ja) * | 2016-06-10 | 2017-12-14 | 武田薬品工業株式会社 | 複素環化合物 |
CN108689942A (zh) * | 2017-04-11 | 2018-10-23 | 广东东阳光药业有限公司 | 含氮双环化合物及其制备方法和用途 |
Also Published As
Publication number | Publication date |
---|---|
WO2020011086A1 (zh) | 2020-01-16 |
CN112119065A (zh) | 2020-12-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7017521B2 (ja) | アクチビン受容体様キナーゼの阻害剤 | |
EP3555070B1 (en) | Amine-substituted heterocyclic compounds as ehmt2 inhibitors and methods of use thereof | |
JP6877407B2 (ja) | Ntrk関連障害の治療に有用な化合物および組成物 | |
JP2022081606A (ja) | Ehmt1およびehmt2阻害剤としてのアミン置換アリールまたはヘテロアリール化合物 | |
JP6403172B2 (ja) | ピリジンのケトン誘導体、それらの製造方法、およびそれらの医薬適用 | |
ES2835331T3 (es) | Piridinonas antifibroticas | |
JP2022506887A (ja) | 窒素含有縮合複素環系shp2阻害剤化合物、製造方法及び使用 | |
WO2019101086A1 (zh) | 卤代烯丙基胺类ssao/vap-1抑制剂及其应用 | |
JP7425724B2 (ja) | Ehmt2阻害剤としてのアミン置換複素環化合物及びその誘導体 | |
BR112015017963A2 (pt) | composto de fenil amino pirimidina deuterado, método para preparar a composição farmacêutica, composição farmacêutica e uso do composto | |
JP2024505732A (ja) | ピリドピリミジノン系誘導体及びその製造方法と使用 | |
CN102803246A (zh) | Hedgehog途径拮抗剂及其治疗应用 | |
TW201422616A (zh) | 作爲Syk抑制劑的取代吡啶並吡嗪類化合物 | |
TW202102505A (zh) | 吡咯并雜環類衍生物、其製備方法及其在醫藥上的應用 | |
WO2017097216A1 (zh) | 五元杂环酰胺类wnt通路抑制剂 | |
JP2023022230A (ja) | Ehmt2阻害剤としての置換された融合二環式または三環式複素環化合物 | |
JP2023522863A (ja) | Egfr阻害剤としての三環式化合物 | |
EP4364798A2 (en) | Compounds and compositions for treating conditions associated with apj receptor activity | |
CN104822658B (zh) | 作为多种激酶抑制剂的稠合三环酰胺类化合物 | |
EP2895166A1 (en) | Aminoisoquinoline derivatives as protein kinase inhibitors | |
CN109641909A (zh) | 雷帕霉素信号通路抑制剂的机理靶标及其治疗应用 | |
CN112119065B (zh) | 苯并二氮杂环类化合物、其制备方法及用途 | |
JP2017525734A (ja) | 癌の治療において有用なイソキノリノン誘導体 | |
WO2022228515A1 (zh) | 甲硫氨酸腺苷转移酶抑制剂、其制备方法及应用 | |
CA3195127A1 (en) | Rev-erb agonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |